WO2014207105A1 - Yeast engineered for the production of 1-alcohols from sugars under anoxic conditions - Google Patents
Yeast engineered for the production of 1-alcohols from sugars under anoxic conditions Download PDFInfo
- Publication number
- WO2014207105A1 WO2014207105A1 PCT/EP2014/063517 EP2014063517W WO2014207105A1 WO 2014207105 A1 WO2014207105 A1 WO 2014207105A1 EP 2014063517 W EP2014063517 W EP 2014063517W WO 2014207105 A1 WO2014207105 A1 WO 2014207105A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- coa
- cell
- amino acid
- acid sequence
- activity
- Prior art date
Links
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims description 141
- 238000004519 manufacturing process Methods 0.000 title claims description 92
- 235000000346 sugar Nutrition 0.000 title description 18
- 150000008163 sugars Chemical class 0.000 title description 11
- 210000004027 cell Anatomy 0.000 claims abstract description 387
- 102000004190 Enzymes Human genes 0.000 claims abstract description 225
- 108090000790 Enzymes Proteins 0.000 claims abstract description 225
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 claims abstract description 182
- 238000000034 method Methods 0.000 claims abstract description 98
- 239000000194 fatty acid Substances 0.000 claims abstract description 79
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 75
- 229930195729 fatty acid Natural products 0.000 claims abstract description 75
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 69
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 67
- 238000006243 chemical reaction Methods 0.000 claims abstract description 57
- 230000008569 process Effects 0.000 claims abstract description 42
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 38
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 35
- 210000000172 cytosol Anatomy 0.000 claims abstract description 27
- 230000000813 microbial effect Effects 0.000 claims abstract description 11
- 230000002503 metabolic effect Effects 0.000 claims abstract description 10
- 230000001851 biosynthetic effect Effects 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 271
- 230000000694 effects Effects 0.000 claims description 236
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 189
- 150000001413 amino acids Chemical group 0.000 claims description 177
- 230000014509 gene expression Effects 0.000 claims description 157
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 145
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 132
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 132
- 238000012239 gene modification Methods 0.000 claims description 90
- 230000005017 genetic modification Effects 0.000 claims description 90
- 235000013617 genetically modified food Nutrition 0.000 claims description 90
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 75
- 230000015572 biosynthetic process Effects 0.000 claims description 67
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims description 67
- 230000001419 dependent effect Effects 0.000 claims description 65
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 64
- 108010011939 Pyruvate Decarboxylase Proteins 0.000 claims description 64
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 claims description 45
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 44
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 claims description 42
- 108010021809 Alcohol dehydrogenase Proteins 0.000 claims description 39
- 102000007698 Alcohol dehydrogenase Human genes 0.000 claims description 37
- 102000002932 Thiolase Human genes 0.000 claims description 37
- 108060008225 Thiolase Proteins 0.000 claims description 37
- 108010008221 formate C-acetyltransferase Proteins 0.000 claims description 37
- 101710088194 Dehydrogenase Proteins 0.000 claims description 35
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 35
- 239000008103 glucose Substances 0.000 claims description 35
- 108010049926 Acetate-CoA ligase Proteins 0.000 claims description 34
- 108010023922 Enoyl-CoA hydratase Proteins 0.000 claims description 33
- 102000011426 Enoyl-CoA hydratase Human genes 0.000 claims description 33
- 239000002028 Biomass Substances 0.000 claims description 32
- 230000001086 cytosolic effect Effects 0.000 claims description 32
- 238000003786 synthesis reaction Methods 0.000 claims description 26
- 230000004048 modification Effects 0.000 claims description 24
- 238000012986 modification Methods 0.000 claims description 24
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 claims description 23
- OJFDKHTZOUZBOS-CITAKDKDSA-N acetoacetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 OJFDKHTZOUZBOS-CITAKDKDSA-N 0.000 claims description 23
- 230000003647 oxidation Effects 0.000 claims description 23
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 claims description 22
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims description 18
- 210000003470 mitochondria Anatomy 0.000 claims description 18
- 108090000698 Formate Dehydrogenases Proteins 0.000 claims description 16
- 101001083553 Homo sapiens Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Proteins 0.000 claims description 16
- 102100030358 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial Human genes 0.000 claims description 16
- 210000005253 yeast cell Anatomy 0.000 claims description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 14
- 102000005970 fatty acyl-CoA reductase Human genes 0.000 claims description 14
- 108010085186 Peroxisomal Targeting Signals Proteins 0.000 claims description 13
- LTYOQGRJFJAKNA-KKIMTKSISA-N Malonyl CoA Natural products S(C(=O)CC(=O)O)CCNC(=O)CCNC(=O)[C@@H](O)C(CO[P@](=O)(O[P@](=O)(OC[C@H]1[C@@H](OP(=O)(O)O)[C@@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C LTYOQGRJFJAKNA-KKIMTKSISA-N 0.000 claims description 12
- 101100082596 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PDC5 gene Proteins 0.000 claims description 12
- 150000001299 aldehydes Chemical class 0.000 claims description 12
- LTYOQGRJFJAKNA-DVVLENMVSA-N malonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-DVVLENMVSA-N 0.000 claims description 12
- FQVLRGLGWNWPSS-BXBUPLCLSA-N (4r,7s,10s,13s,16r)-16-acetamido-13-(1h-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide Chemical compound N1C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]1CC1=CN=CN1 FQVLRGLGWNWPSS-BXBUPLCLSA-N 0.000 claims description 11
- 108030002854 Acetoacetyl-CoA synthases Proteins 0.000 claims description 11
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 claims description 11
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 claims description 11
- 102100034035 Alcohol dehydrogenase 1A Human genes 0.000 claims description 11
- 108010018763 Biotin carboxylase Proteins 0.000 claims description 11
- 101000892220 Geobacillus thermodenitrificans (strain NG80-2) Long-chain-alcohol dehydrogenase 1 Proteins 0.000 claims description 11
- 101000780443 Homo sapiens Alcohol dehydrogenase 1A Proteins 0.000 claims description 11
- 241000235648 Pichia Species 0.000 claims description 11
- 150000002402 hexoses Chemical class 0.000 claims description 11
- 101710081312 Trans-2-enoyl-CoA reductase Proteins 0.000 claims description 10
- CRFNGMNYKDXRTN-CITAKDKDSA-N butyryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CRFNGMNYKDXRTN-CITAKDKDSA-N 0.000 claims description 10
- 108010055682 3-hydroxybutyryl-CoA dehydrogenase Proteins 0.000 claims description 9
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 claims description 9
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 claims description 9
- 230000000858 peroxisomal effect Effects 0.000 claims description 9
- 101150051414 FPS1 gene Proteins 0.000 claims description 8
- 102100039894 Hemoglobin subunit delta Human genes 0.000 claims description 8
- 230000000397 acetylating effect Effects 0.000 claims description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 7
- 241001138401 Kluyveromyces lactis Species 0.000 claims description 7
- 230000002538 fungal effect Effects 0.000 claims description 7
- 238000011084 recovery Methods 0.000 claims description 7
- 101000651958 Crotalus durissus terrificus Snaclec crotocetin-1 Proteins 0.000 claims description 6
- 102100036669 Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic Human genes 0.000 claims description 6
- 241001149669 Hanseniaspora Species 0.000 claims description 6
- 101001009678 Homo sapiens Glycerol-3-phosphate dehydrogenase, mitochondrial Proteins 0.000 claims description 6
- 241000235070 Saccharomyces Species 0.000 claims description 6
- 101100382243 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YAT1 gene Proteins 0.000 claims description 6
- 101100431521 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YAT2 gene Proteins 0.000 claims description 6
- 101100488154 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YEA6 gene Proteins 0.000 claims description 6
- 101100432250 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YIA6 gene Proteins 0.000 claims description 6
- 244000288561 Torulaspora delbrueckii Species 0.000 claims description 6
- 238000009833 condensation Methods 0.000 claims description 6
- 230000005494 condensation Effects 0.000 claims description 6
- 108010060146 pyruvate formate-lyase activating enzyme Proteins 0.000 claims description 6
- 101000796894 Coturnix japonica Alcohol dehydrogenase 1 Proteins 0.000 claims description 5
- 101000802894 Dendroaspis angusticeps Fasciculin-2 Proteins 0.000 claims description 5
- 101000780463 Homo sapiens Alcohol dehydrogenase 1C Proteins 0.000 claims description 5
- 101001072574 Homo sapiens Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic Proteins 0.000 claims description 5
- 101150084262 MDH3 gene Proteins 0.000 claims description 5
- 108050006183 Pyruvate dehydrogenase E1 component Proteins 0.000 claims description 5
- 101100439777 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CIT2 gene Proteins 0.000 claims description 5
- 101100229905 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GPP1 gene Proteins 0.000 claims description 5
- 101100229907 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GPP2 gene Proteins 0.000 claims description 5
- 238000006114 decarboxylation reaction Methods 0.000 claims description 5
- 230000002255 enzymatic effect Effects 0.000 claims description 5
- 101150021180 ALD6 gene Proteins 0.000 claims description 4
- 101100382835 Arabidopsis thaliana CCC1 gene Proteins 0.000 claims description 4
- 101100036901 Arabidopsis thaliana RPL40B gene Proteins 0.000 claims description 4
- 241000222122 Candida albicans Species 0.000 claims description 4
- 101710088566 Flagellar hook-associated protein 2 Proteins 0.000 claims description 4
- 102100030395 Glycerol-3-phosphate dehydrogenase, mitochondrial Human genes 0.000 claims description 4
- 241000235649 Kluyveromyces Species 0.000 claims description 4
- 241000235650 Kluyveromyces marxianus Species 0.000 claims description 4
- 241000481961 Lachancea thermotolerans Species 0.000 claims description 4
- 102100034408 Nuclear transcription factor Y subunit alpha Human genes 0.000 claims description 4
- 241000320412 Ogataea angusta Species 0.000 claims description 4
- 101150003085 Pdcl gene Proteins 0.000 claims description 4
- 241000235072 Saccharomyces bayanus Species 0.000 claims description 4
- 101100123443 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HAP4 gene Proteins 0.000 claims description 4
- 241000582914 Saccharomyces uvarum Species 0.000 claims description 4
- 241000235347 Schizosaccharomyces pombe Species 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 241001495125 Torulaspora pretoriensis Species 0.000 claims description 4
- 239000007806 chemical reaction intermediate Substances 0.000 claims description 4
- 101150020171 hap5 gene Proteins 0.000 claims description 4
- 108090001018 hexadecanal dehydrogenase (acylating) Proteins 0.000 claims description 4
- 229960004793 sucrose Drugs 0.000 claims description 4
- 230000004102 tricarboxylic acid cycle Effects 0.000 claims description 4
- 241000235172 Bullera Species 0.000 claims description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 3
- 244000206911 Candida holmii Species 0.000 claims description 3
- 241000235646 Cyberlindnera jadinii Species 0.000 claims description 3
- 101710088564 Flagellar hook-associated protein 3 Proteins 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- 244000096454 Kluyveromyces marxianus var. marxianus Species 0.000 claims description 3
- 241001099157 Komagataella Species 0.000 claims description 3
- 241000235058 Komagataella pastoris Species 0.000 claims description 3
- 241001304304 Kuraishia Species 0.000 claims description 3
- 241000235087 Lachancea kluyveri Species 0.000 claims description 3
- 241001123674 Metschnikowia Species 0.000 claims description 3
- 241000235042 Millerozyma farinosa Species 0.000 claims description 3
- 241001099335 Nakazawaea Species 0.000 claims description 3
- 102100022201 Nuclear transcription factor Y subunit beta Human genes 0.000 claims description 3
- 241001112159 Ogataea Species 0.000 claims description 3
- 241000235645 Pichia kudriavzevii Species 0.000 claims description 3
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 claims description 3
- 241000223252 Rhodotorula Species 0.000 claims description 3
- 241000877401 Saccharomyces ellipsoideus Species 0.000 claims description 3
- 241001407717 Saccharomyces norbensis Species 0.000 claims description 3
- 241001123228 Saccharomyces paradoxus Species 0.000 claims description 3
- 241001123227 Saccharomyces pastorianus Species 0.000 claims description 3
- 241001489223 Saccharomycodes Species 0.000 claims description 3
- 241001489222 Saccharomycodes ludwigii Species 0.000 claims description 3
- 241000235346 Schizosaccharomyces Species 0.000 claims description 3
- 241000311088 Schwanniomyces Species 0.000 claims description 3
- 241000222068 Sporobolomyces <Sporidiobolaceae> Species 0.000 claims description 3
- 244000057717 Streptococcus lactis Species 0.000 claims description 3
- 241000235006 Torulaspora Species 0.000 claims description 3
- 241000684582 Torulaspora microellipsoides Species 0.000 claims description 3
- 241000193620 Wickerhamia Species 0.000 claims description 3
- 241000235152 Williopsis Species 0.000 claims description 3
- 241000235013 Yarrowia Species 0.000 claims description 3
- 241000235033 Zygosaccharomyces rouxii Species 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 230000004136 fatty acid synthesis Effects 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- 108030004487 Alcohol-forming fatty acyl-CoA reductases Proteins 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 241001123652 Candida versatilis Species 0.000 claims description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 101710165590 Mitochondrial pyruvate carrier 1 Proteins 0.000 claims description 2
- 102100024828 Mitochondrial pyruvate carrier 1 Human genes 0.000 claims description 2
- 101710101695 Probable mitochondrial pyruvate carrier 1 Proteins 0.000 claims description 2
- 241000235015 Yarrowia lipolytica Species 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- 235000013681 dietary sucrose Nutrition 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 102000008146 Acetate-CoA ligase Human genes 0.000 claims 4
- 241001337994 Cryptococcus <scale insect> Species 0.000 claims 1
- 101150089023 FASLG gene Proteins 0.000 claims 1
- 241000587104 Sporobolus montanus Species 0.000 claims 1
- 238000011081 inoculation Methods 0.000 claims 1
- 238000000855 fermentation Methods 0.000 abstract description 66
- 230000004151 fermentation Effects 0.000 abstract description 64
- 239000000543 intermediate Substances 0.000 abstract description 7
- 229940088598 enzyme Drugs 0.000 description 207
- 241000588724 Escherichia coli Species 0.000 description 70
- 102000004169 proteins and genes Human genes 0.000 description 64
- 239000000047 product Substances 0.000 description 61
- 230000002829 reductive effect Effects 0.000 description 59
- 229940076788 pyruvate Drugs 0.000 description 55
- 239000013612 plasmid Substances 0.000 description 49
- 235000018102 proteins Nutrition 0.000 description 41
- 150000007523 nucleic acids Chemical class 0.000 description 38
- 230000009467 reduction Effects 0.000 description 37
- 108091028043 Nucleic acid sequence Proteins 0.000 description 33
- 108091026890 Coding region Proteins 0.000 description 31
- 238000012217 deletion Methods 0.000 description 31
- 239000002773 nucleotide Substances 0.000 description 31
- 125000003729 nucleotide group Chemical group 0.000 description 31
- 230000037430 deletion Effects 0.000 description 30
- 102100035709 Acetyl-coenzyme A synthetase, cytoplasmic Human genes 0.000 description 29
- 102000039446 nucleic acids Human genes 0.000 description 29
- 108020004707 nucleic acids Proteins 0.000 description 29
- 241000894007 species Species 0.000 description 28
- 239000003550 marker Substances 0.000 description 27
- 150000001875 compounds Chemical class 0.000 description 26
- 235000001014 amino acid Nutrition 0.000 description 25
- 230000037361 pathway Effects 0.000 description 25
- 108020004705 Codon Proteins 0.000 description 24
- 150000002085 enols Chemical class 0.000 description 23
- 125000005639 glycero group Chemical group 0.000 description 23
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 22
- 229940024606 amino acid Drugs 0.000 description 22
- 101150024975 mhpF gene Proteins 0.000 description 21
- 238000011144 upstream manufacturing Methods 0.000 description 21
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 20
- 239000002609 medium Substances 0.000 description 20
- 239000001301 oxygen Substances 0.000 description 20
- 229910052760 oxygen Inorganic materials 0.000 description 20
- 241000193401 Clostridium acetobutylicum Species 0.000 description 19
- 239000000758 substrate Substances 0.000 description 18
- 108700026244 Open Reading Frames Proteins 0.000 description 17
- 229910019142 PO4 Inorganic materials 0.000 description 17
- 239000010452 phosphate Substances 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 150000001298 alcohols Chemical class 0.000 description 15
- 239000005516 coenzyme A Substances 0.000 description 15
- 229940093530 coenzyme a Drugs 0.000 description 15
- 230000002438 mitochondrial effect Effects 0.000 description 15
- 230000009466 transformation Effects 0.000 description 15
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 14
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 14
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 14
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 14
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 13
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 13
- 239000006227 byproduct Substances 0.000 description 13
- 238000010276 construction Methods 0.000 description 13
- 101150003679 hsaG gene Proteins 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 230000032258 transport Effects 0.000 description 13
- 102100038187 RNA binding protein fox-1 homolog 2 Human genes 0.000 description 12
- 108020003118 fatty acyl-CoA reductase Proteins 0.000 description 12
- 241000193454 Clostridium beijerinckii Species 0.000 description 11
- 101150064904 FOX2 gene Proteins 0.000 description 11
- 238000002703 mutagenesis Methods 0.000 description 11
- 230000035772 mutation Effects 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 101150007867 rbfox2 gene Proteins 0.000 description 11
- 229940035893 uracil Drugs 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- 231100000350 mutagenesis Toxicity 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 230000010076 replication Effects 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 9
- 101100351264 Candida albicans (strain SC5314 / ATCC MYA-2876) PDC11 gene Proteins 0.000 description 9
- 101150050255 PDC1 gene Proteins 0.000 description 9
- 241000589892 Treponema denticola Species 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 230000002441 reversible effect Effects 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 8
- 101150019065 HBD gene Proteins 0.000 description 8
- 101000741885 Homo sapiens Protection of telomeres protein 1 Proteins 0.000 description 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 8
- 102100038745 Protection of telomeres protein 1 Human genes 0.000 description 8
- 241001138501 Salmonella enterica Species 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 235000014469 Bacillus subtilis Nutrition 0.000 description 7
- 241000193403 Clostridium Species 0.000 description 7
- 101000959452 Homo sapiens Alcohol dehydrogenase class-3 Proteins 0.000 description 7
- 108091007638 Mitochondrial pyruvate carriers Proteins 0.000 description 7
- 102000004316 Oxidoreductases Human genes 0.000 description 7
- 108090000854 Oxidoreductases Proteins 0.000 description 7
- 101100519200 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PDC6 gene Proteins 0.000 description 7
- KFWWCMJSYSSPSK-PAXLJYGASA-N crotonoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)/C=C/C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 KFWWCMJSYSSPSK-PAXLJYGASA-N 0.000 description 7
- 239000000446 fuel Substances 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- -1 1 -alcohols Chemical class 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 108020005199 Dehydrogenases Proteins 0.000 description 6
- 101150051269 ERG10 gene Proteins 0.000 description 6
- 241000233866 Fungi Species 0.000 description 6
- 108010044467 Isoenzymes Proteins 0.000 description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 6
- 108091005461 Nucleic proteins Proteins 0.000 description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- GNGACRATGGDKBX-UHFFFAOYSA-N dihydroxyacetone phosphate Chemical compound OCC(=O)COP(O)(O)=O GNGACRATGGDKBX-UHFFFAOYSA-N 0.000 description 6
- 150000002191 fatty alcohols Chemical class 0.000 description 6
- 230000034659 glycolysis Effects 0.000 description 6
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 6
- 230000002779 inactivation Effects 0.000 description 6
- 230000010354 integration Effects 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 238000012269 metabolic engineering Methods 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 6
- 210000002824 peroxisome Anatomy 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 238000010405 reoxidation reaction Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
- 150000000185 1,3-diols Chemical class 0.000 description 5
- 102100031795 All-trans-retinol dehydrogenase [NAD(+)] ADH4 Human genes 0.000 description 5
- 241001110912 Clostridium beijerinckii NCIMB 8052 Species 0.000 description 5
- 241001470650 Clostridium perfringens str. 13 Species 0.000 description 5
- 241001552623 Clostridium tetani E88 Species 0.000 description 5
- 101000802895 Dendroaspis angusticeps Fasciculin-1 Proteins 0.000 description 5
- 244000025670 Eleusine indica Species 0.000 description 5
- 241000195619 Euglena gracilis Species 0.000 description 5
- 101000775437 Homo sapiens All-trans-retinol dehydrogenase [NAD(+)] ADH4 Proteins 0.000 description 5
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 5
- 101100445407 Neosartorya fumigata (strain ATCC MYA-4609 / Af293 / CBS 101355 / FGSC A1100) erg10B gene Proteins 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 239000000370 acceptor Substances 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 230000006978 adaptation Effects 0.000 description 5
- 150000001336 alkenes Chemical class 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 150000001277 beta hydroxy acids Chemical class 0.000 description 5
- 150000004718 beta keto acids Chemical class 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000003471 mutagenic agent Substances 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
- 102100029103 3-ketoacyl-CoA thiolase Human genes 0.000 description 4
- SEHFUALWMUWDKS-UHFFFAOYSA-N 5-fluoroorotic acid Chemical compound OC(=O)C=1NC(=O)NC(=O)C=1F SEHFUALWMUWDKS-UHFFFAOYSA-N 0.000 description 4
- 108010006229 Acetyl-CoA C-acetyltransferase Proteins 0.000 description 4
- 102000005345 Acetyl-CoA C-acetyltransferase Human genes 0.000 description 4
- 108010003902 Acetyl-CoA C-acyltransferase Proteins 0.000 description 4
- 108010001058 Acyl-CoA Dehydrogenase Proteins 0.000 description 4
- 102100034042 Alcohol dehydrogenase 1C Human genes 0.000 description 4
- 244000063299 Bacillus subtilis Species 0.000 description 4
- 102100028672 C-type lectin domain family 4 member D Human genes 0.000 description 4
- 101150010856 CRT gene Proteins 0.000 description 4
- 108091006146 Channels Proteins 0.000 description 4
- 241000857738 Clostridium perfringens SM101 Species 0.000 description 4
- 108700010070 Codon Usage Proteins 0.000 description 4
- 101710204931 Ferroptosis suppressor protein 1 Proteins 0.000 description 4
- 101000766905 Homo sapiens C-type lectin domain family 4 member D Proteins 0.000 description 4
- 101710122479 Isocitrate lyase 1 Proteins 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 102000003960 Ligases Human genes 0.000 description 4
- 108090000364 Ligases Proteins 0.000 description 4
- 101150110652 PDC2 gene Proteins 0.000 description 4
- 102000012751 Pyruvate Dehydrogenase Complex Human genes 0.000 description 4
- 108010090051 Pyruvate Dehydrogenase Complex Proteins 0.000 description 4
- 108010031852 Pyruvate Synthase Proteins 0.000 description 4
- 108700005075 Regulator Genes Proteins 0.000 description 4
- 101100333438 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ENO1 gene Proteins 0.000 description 4
- 240000000111 Saccharum officinarum Species 0.000 description 4
- 235000007201 Saccharum officinarum Nutrition 0.000 description 4
- 241000193446 Thermoanaerobacterium thermosaccharolyticum Species 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 150000001335 aliphatic alkanes Chemical class 0.000 description 4
- 230000001588 bifunctional effect Effects 0.000 description 4
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000004907 flux Effects 0.000 description 4
- 238000004817 gas chromatography Methods 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 101150032602 mls-1 gene Proteins 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 238000002708 random mutagenesis Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 101150058703 ACC1 gene Proteins 0.000 description 3
- 101150016330 ADH3 gene Proteins 0.000 description 3
- 101150021974 Adh1 gene Proteins 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 3
- 108010068197 Butyryl-CoA Dehydrogenase Proteins 0.000 description 3
- 108010066477 Carnitine O-acetyltransferase Proteins 0.000 description 3
- 102100036357 Carnitine O-acetyltransferase Human genes 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 101000690773 Clostridium acetobutylicum (strain ATCC 824 / DSM 792 / JCM 1419 / LMG 5710 / VKM B-1787) NADH-dependent butanol dehydrogenase A Proteins 0.000 description 3
- 101000796961 Clostridium acetobutylicum (strain ATCC 824 / DSM 792 / JCM 1419 / LMG 5710 / VKM B-1787) NADH-dependent butanol dehydrogenase B Proteins 0.000 description 3
- 241000186570 Clostridium kluyveri Species 0.000 description 3
- 108010051219 Cre recombinase Proteins 0.000 description 3
- 241000252867 Cupriavidus metallidurans Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 3
- 101150034017 FDH1 gene Proteins 0.000 description 3
- 108010057366 Flavodoxin Proteins 0.000 description 3
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 3
- 102000000587 Glycerolphosphate Dehydrogenase Human genes 0.000 description 3
- 108010041921 Glycerolphosphate Dehydrogenase Proteins 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 101000780205 Homo sapiens Long-chain-fatty-acid-CoA ligase 5 Proteins 0.000 description 3
- 101000780202 Homo sapiens Long-chain-fatty-acid-CoA ligase 6 Proteins 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 3
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 3
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 3
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 241000589776 Pseudomonas putida Species 0.000 description 3
- 108091007187 Reductases Proteins 0.000 description 3
- 241000588902 Zymomonas mobilis Species 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- 230000009604 anaerobic growth Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000002551 biofuel Substances 0.000 description 3
- 101150037483 bkdA gene Proteins 0.000 description 3
- 108010057307 butanol dehydrogenase Proteins 0.000 description 3
- 108010089934 carbohydrase Proteins 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 150000002192 fatty aldehydes Chemical class 0.000 description 3
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000008723 osmotic stress Effects 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 101150084945 pdhA gene Proteins 0.000 description 3
- 101150086832 pdhC gene Proteins 0.000 description 3
- 101150049339 pflA gene Proteins 0.000 description 3
- 101150111581 pflB gene Proteins 0.000 description 3
- 239000008057 potassium phosphate buffer Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000005204 segregation Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 108010030844 2-methylcitrate synthase Proteins 0.000 description 2
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- 101150026777 ADH5 gene Proteins 0.000 description 2
- 101150059556 ANB1 gene Proteins 0.000 description 2
- ROWKJAVDOGWPAT-UHFFFAOYSA-N Acetoin Chemical compound CC(O)C(C)=O ROWKJAVDOGWPAT-UHFFFAOYSA-N 0.000 description 2
- 102000002735 Acyl-CoA Dehydrogenase Human genes 0.000 description 2
- 102000002296 Acyl-CoA Dehydrogenases Human genes 0.000 description 2
- 102000016560 Aquaglyceroporins Human genes 0.000 description 2
- 108010092667 Aquaglyceroporins Proteins 0.000 description 2
- 101100378521 Arabidopsis thaliana ADH2 gene Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241000351920 Aspergillus nidulans Species 0.000 description 2
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 241000438254 Caldanaerobacter subterraneus subsp. tengcongensis MB4 Species 0.000 description 2
- 241000222178 Candida tropicalis Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010071536 Citrate (Si)-synthase Proteins 0.000 description 2
- 102000006732 Citrate synthase Human genes 0.000 description 2
- 241001167799 Citrobacter rodentium ICC168 Species 0.000 description 2
- 244000058527 Cleisostoma montanum Species 0.000 description 2
- 241001112695 Clostridiales Species 0.000 description 2
- 241000193163 Clostridioides difficile Species 0.000 description 2
- 241000423301 Clostridioides difficile 630 Species 0.000 description 2
- 241001488665 Clostridioides difficile QCD-32g58 Species 0.000 description 2
- 241000423302 Clostridium acetobutylicum ATCC 824 Species 0.000 description 2
- 241000193469 Clostridium pasteurianum Species 0.000 description 2
- 241001470651 Clostridium perfringens ATCC 13124 Species 0.000 description 2
- 241001527609 Cryptococcus Species 0.000 description 2
- 241000769731 Desulfotomaculum reducens MI-1 Species 0.000 description 2
- 108010073112 Dihydrolipoyllysine-residue acetyltransferase Proteins 0.000 description 2
- 102000009093 Dihydrolipoyllysine-residue acetyltransferase Human genes 0.000 description 2
- 108700035560 EC 1.2.1.10 Proteins 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 241000316328 Escherichia albertii TW07627 Species 0.000 description 2
- 101100269244 Escherichia coli (strain K12) yiaY gene Proteins 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 101150096236 FDH2 gene Proteins 0.000 description 2
- 108010087894 Fatty acid desaturases Proteins 0.000 description 2
- 102000009114 Fatty acid desaturases Human genes 0.000 description 2
- 101100243945 Fusarium vanettenii PDAT9 gene Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 101150009006 HIS3 gene Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 241000226935 Klebsiella pneumoniae subsp. pneumoniae NTUH-K2044 Species 0.000 description 2
- 244000285963 Kluyveromyces fragilis Species 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 240000001929 Lactobacillus brevis Species 0.000 description 2
- 102000052922 Large Neutral Amino Acid-Transporter 1 Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000011364 Major intrinsic proteins Human genes 0.000 description 2
- 108050001696 Major intrinsic proteins Proteins 0.000 description 2
- 241000604448 Megasphaera elsdenii Species 0.000 description 2
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 2
- 102000006746 NADH Dehydrogenase Human genes 0.000 description 2
- 108010086428 NADH Dehydrogenase Proteins 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000012204 PDA1 Diseases 0.000 description 2
- 102000001105 Phosphofructokinases Human genes 0.000 description 2
- 108010069341 Phosphofructokinases Proteins 0.000 description 2
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102000013009 Pyruvate Kinase Human genes 0.000 description 2
- 108020005115 Pyruvate Kinase Proteins 0.000 description 2
- 241000232299 Ralstonia Species 0.000 description 2
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 2
- 241001170740 Ruminiclostridium thermocellum ATCC 27405 Species 0.000 description 2
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 2
- 108091006232 SLC7A5 Proteins 0.000 description 2
- 101150014136 SUC2 gene Proteins 0.000 description 2
- 101100055268 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ALD3 gene Proteins 0.000 description 2
- 101100335392 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) FPS1 gene Proteins 0.000 description 2
- 101100446293 Schizosaccharomyces pombe (strain 972 / ATCC 24843) fbh1 gene Proteins 0.000 description 2
- 241000607766 Shigella boydii Species 0.000 description 2
- 102100024639 Short-chain specific acyl-CoA dehydrogenase, mitochondrial Human genes 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 101100083037 Streptococcus mutans serotype c (strain ATCC 700610 / UA159) act gene Proteins 0.000 description 2
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 2
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 101150006429 atoB gene Proteins 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000010923 batch production Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 101150103637 bkdB gene Proteins 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000029038 carnitine shuttle Effects 0.000 description 2
- 239000012159 carrier gas Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000012786 cultivation procedure Methods 0.000 description 2
- 108010035432 cytochrome C(L) Proteins 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 229940032049 enterococcus faecalis Drugs 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 101150030625 fucO gene Proteins 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 235000003869 genetically modified organism Nutrition 0.000 description 2
- GVVPGTZRZFNKDS-JXMROGBWSA-N geranyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O GVVPGTZRZFNKDS-JXMROGBWSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 108010032776 glycerol-1-phosphatase Proteins 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 239000001307 helium Substances 0.000 description 2
- 229910052734 helium Inorganic materials 0.000 description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 238000009655 industrial fermentation Methods 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 101150102492 pda1 gene Proteins 0.000 description 2
- 101150008465 pdb1 gene Proteins 0.000 description 2
- 101150028177 pdhB gene Proteins 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920001791 ((R)-3-Hydroxybutanoyl)(n-2) Polymers 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- BEJKOYIMCGMNRB-GRHHLOCNSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BEJKOYIMCGMNRB-GRHHLOCNSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- NHNODHRSCRALBF-NQNBQJKNSA-N 2-methylacetoacetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C(C(C)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 NHNODHRSCRALBF-NQNBQJKNSA-N 0.000 description 1
- QHHKKMYHDBRONY-RMNRSTNRSA-N 3-hydroxybutanoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 QHHKKMYHDBRONY-RMNRSTNRSA-N 0.000 description 1
- 108030005660 3-hydroxybutyryl-CoA dehydratases Proteins 0.000 description 1
- 101710161460 3-oxoacyl-[acyl-carrier-protein] synthase Proteins 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- XGYIMTFOTBMPFP-KQYNXXCUSA-N 5'-deoxyadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 XGYIMTFOTBMPFP-KQYNXXCUSA-N 0.000 description 1
- NOEGNKMFWQHSLB-UHFFFAOYSA-N 5-hydroxymethylfurfural Chemical compound OCC1=CC=C(C=O)O1 NOEGNKMFWQHSLB-UHFFFAOYSA-N 0.000 description 1
- 101150089022 ADH4 gene Proteins 0.000 description 1
- 101150022075 ADR1 gene Proteins 0.000 description 1
- 101150076082 ALD5 gene Proteins 0.000 description 1
- 101100235000 Acetobacterium woodii (strain ATCC 29683 / DSM 1030 / JCM 2381 / KCTC 1655 / WB1) lctB gene Proteins 0.000 description 1
- 101100235003 Acetobacterium woodii (strain ATCC 29683 / DSM 1030 / JCM 2381 / KCTC 1655 / WB1) lctC gene Proteins 0.000 description 1
- 101710190443 Acetyl-CoA carboxylase 1 Proteins 0.000 description 1
- 102100039164 Acetyl-CoA carboxylase 1 Human genes 0.000 description 1
- 241000417230 Actinobacillus succinogenes 130Z Species 0.000 description 1
- 101710146995 Acyl carrier protein Proteins 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- 102000006488 Acyl-Carrier Protein S-Malonyltransferase Human genes 0.000 description 1
- 108010058912 Acyl-Carrier Protein S-Malonyltransferase Proteins 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- 241000607516 Aeromonas caviae Species 0.000 description 1
- 241000607528 Aeromonas hydrophila Species 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 102100039702 Alcohol dehydrogenase class-3 Human genes 0.000 description 1
- 102000016912 Aldehyde Reductase Human genes 0.000 description 1
- 102100026608 Aldehyde dehydrogenase family 3 member A2 Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- 241001149240 Alkaliphilus metalliredigens QYMF Species 0.000 description 1
- 102100034044 All-trans-retinol dehydrogenase [NAD(+)] ADH1B Human genes 0.000 description 1
- 101710193111 All-trans-retinol dehydrogenase [NAD(+)] ADH4 Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000590031 Alteromonas Species 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 241000219195 Arabidopsis thaliana Species 0.000 description 1
- 101001013546 Arabidopsis thaliana 5-methyltetrahydropteroyltriglutamate-homocysteine methyltransferase 2 Proteins 0.000 description 1
- 101000917308 Arabidopsis thaliana Fatty acyl-CoA reductase 6, chloroplastic Proteins 0.000 description 1
- 241000205042 Archaeoglobus fulgidus Species 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241000228257 Aspergillus sp. Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 101001074429 Bacillus subtilis (strain 168) Polyketide biosynthesis acyltransferase homolog PksD Proteins 0.000 description 1
- 101000936617 Bacillus velezensis (strain DSM 23117 / BGSC 10A6 / FZB42) Polyketide biosynthesis acyltransferase homolog BaeD Proteins 0.000 description 1
- 241001626895 Bacillus vietnamensis Species 0.000 description 1
- 102000011802 Beta-ketoacyl synthases Human genes 0.000 description 1
- 108050002233 Beta-ketoacyl synthases Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241001148106 Brucella melitensis Species 0.000 description 1
- 241001453380 Burkholderia Species 0.000 description 1
- 241001646647 Burkholderia ambifaria Species 0.000 description 1
- 241000371430 Burkholderia cenocepacia Species 0.000 description 1
- 241000589513 Burkholderia cepacia Species 0.000 description 1
- 241001646389 Burkholderia dolosa Species 0.000 description 1
- 241000020731 Burkholderia multivorans Species 0.000 description 1
- 108030004471 Butanal dehydrogenases Proteins 0.000 description 1
- 241000605900 Butyrivibrio fibrisolvens Species 0.000 description 1
- 101150009126 C4 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000253373 Caldanaerobacter subterraneus subsp. tengcongensis Species 0.000 description 1
- 241000321538 Candidia Species 0.000 description 1
- 241000620137 Carboxydothermus hydrogenoformans Species 0.000 description 1
- 241001025886 Carboxydothermus hydrogenoformans Z-2901 Species 0.000 description 1
- 101710147349 Carnitine transporter Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 241000142757 Chromohalobacter Species 0.000 description 1
- 241000047960 Chromohalobacter salexigens Species 0.000 description 1
- 206010061765 Chromosomal mutation Diseases 0.000 description 1
- 102100034229 Citramalyl-CoA lyase, mitochondrial Human genes 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 101100162137 Clostridium acetobutylicum (strain ATCC 824 / DSM 792 / JCM 1419 / LMG 5710 / VKM B-1787) bdhB gene Proteins 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000429427 Clostridium saccharobutylicum Species 0.000 description 1
- 241000193464 Clostridium sp. Species 0.000 description 1
- 241001135745 Colwellia psychrerythraea Species 0.000 description 1
- 241000865251 Congregibacter Species 0.000 description 1
- 241000201848 Corrigiola litoralis Species 0.000 description 1
- 241001445332 Coxiella <snail> Species 0.000 description 1
- 241000606678 Coxiella burnetii Species 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 241000694959 Cryptococcus sp. Species 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 241000605056 Cytophaga Species 0.000 description 1
- 241000605111 Cytophaga hutchinsonii Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 235000000638 D-biotin Nutrition 0.000 description 1
- 239000011665 D-biotin Substances 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101150050804 DAN1 gene Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101100009781 Danio rerio dmbx1a gene Proteins 0.000 description 1
- 108010028127 Dihydrolipoamide Dehydrogenase Proteins 0.000 description 1
- 102000028526 Dihydrolipoamide Dehydrogenase Human genes 0.000 description 1
- 101710090144 Dihydrolipoyl dehydrogenase Proteins 0.000 description 1
- 108700033425 EC 1.2.1.2 Proteins 0.000 description 1
- 108700033421 EC 1.2.1.4 Proteins 0.000 description 1
- 108700035447 EC 1.2.1.51 Proteins 0.000 description 1
- 101150110799 ETFA gene Proteins 0.000 description 1
- 101150046595 ETFB gene Proteins 0.000 description 1
- 241000147019 Enterobacter sp. Species 0.000 description 1
- 241000195620 Euglena Species 0.000 description 1
- 102100022366 Fatty acyl-CoA reductase 1 Human genes 0.000 description 1
- 102100029595 Fatty acyl-CoA reductase 2 Human genes 0.000 description 1
- 108010074122 Ferredoxins Proteins 0.000 description 1
- 241000589565 Flavobacterium Species 0.000 description 1
- 241000605108 Flavobacterium johnsoniae Species 0.000 description 1
- 102000003983 Flavoproteins Human genes 0.000 description 1
- 108010057573 Flavoproteins Proteins 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- 101150059691 GPP2 gene Proteins 0.000 description 1
- 241000968725 Gammaproteobacteria bacterium Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 241000815071 Glaesserella parasuis 29755 Species 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 108050008938 Glucoamylases Proteins 0.000 description 1
- 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 1
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 241001235200 Haemophilus influenzae Rd KW20 Species 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 101000963424 Homo sapiens Acetyl-CoA carboxylase 1 Proteins 0.000 description 1
- 101000894929 Homo sapiens Bcl-2-related protein A1 Proteins 0.000 description 1
- 101001130401 Homo sapiens E3 ubiquitin-protein ligase RAD18 Proteins 0.000 description 1
- 101000824458 Homo sapiens Fatty acyl-CoA reductase 1 Proteins 0.000 description 1
- 101000917301 Homo sapiens Fatty acyl-CoA reductase 2 Proteins 0.000 description 1
- 101000665452 Homo sapiens RNA binding protein fox-1 homolog 2 Proteins 0.000 description 1
- 101000727462 Homo sapiens Reticulon-3 Proteins 0.000 description 1
- 101001132698 Homo sapiens Retinoic acid receptor beta Proteins 0.000 description 1
- 101100263876 Homo sapiens VPS4B gene Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 102000004867 Hydro-Lyases Human genes 0.000 description 1
- 108090001042 Hydro-Lyases Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 101150017040 I gene Proteins 0.000 description 1
- 241000948243 Idiomarina Species 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 108020003285 Isocitrate lyase Proteins 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 101150028693 LPD1 gene Proteins 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 241000178948 Lactococcus sp. Species 0.000 description 1
- 102100034337 Long-chain-fatty-acid-CoA ligase 6 Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101150028530 MIG1 gene Proteins 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 101150034528 MTH1 gene Proteins 0.000 description 1
- 108020004687 Malate Synthase Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 241001135624 Marinomonas Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000589325 Methylobacillus Species 0.000 description 1
- 241000190905 Microscilla Species 0.000 description 1
- 101001014220 Monascus pilosus Dehydrogenase mokE Proteins 0.000 description 1
- 101100161530 Mus musculus Acsbg1 gene Proteins 0.000 description 1
- 101100381816 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) bkdC gene Proteins 0.000 description 1
- 108700038404 NADPH-dependent butanol dehydrogenases Proteins 0.000 description 1
- 229910017677 NH4H2 Inorganic materials 0.000 description 1
- 241000221961 Neurospora crassa Species 0.000 description 1
- 241000088436 Neurospora sp. Species 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 241000605012 Oceanospirillum Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 101150037263 PIP2 gene Proteins 0.000 description 1
- 101150105372 POX1 gene Proteins 0.000 description 1
- 241000037463 Paraburkholderia phytofirmans Species 0.000 description 1
- 101000573542 Penicillium citrinum Compactin nonaketide synthase, enoyl reductase component Proteins 0.000 description 1
- 102100022587 Peroxisomal multifunctional enzyme type 2 Human genes 0.000 description 1
- 101710125609 Peroxisomal multifunctional enzyme type 2 Proteins 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 241000607568 Photobacterium Species 0.000 description 1
- 241000607602 Photobacterium angustum Species 0.000 description 1
- 241001260361 Photobacterium profundum Species 0.000 description 1
- 241000193632 Piromyces sp. Species 0.000 description 1
- 240000007354 Pistacia atlantica Species 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 241000512254 Polaribacter Species 0.000 description 1
- 241000588868 Polaribacter irgensii Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004146 Propane-1,2-diol Substances 0.000 description 1
- 241001110331 Proteus mirabilis HI4320 Species 0.000 description 1
- 241001496712 Proteus penneri ATCC 35198 Species 0.000 description 1
- 241000519590 Pseudoalteromonas Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589540 Pseudomonas fluorescens Species 0.000 description 1
- 241000589774 Pseudomonas sp. Species 0.000 description 1
- 241000948194 Psychromonas Species 0.000 description 1
- 241001104683 Psychromonas ingrahamii Species 0.000 description 1
- 108091093078 Pyrimidine dimer Proteins 0.000 description 1
- 241000205223 Pyrobaculum islandicum Species 0.000 description 1
- 241000205156 Pyrococcus furiosus Species 0.000 description 1
- 102000001170 RAD18 Human genes 0.000 description 1
- 102000002490 Rad51 Recombinase Human genes 0.000 description 1
- 108010068097 Rad51 Recombinase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000582398 Reinekea Species 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- OINXHIBNZUUIMR-HDRQGHTBSA-N S-[2-[3-[[(2R)-4-[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] hex-2-enethioate Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C=CCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 OINXHIBNZUUIMR-HDRQGHTBSA-N 0.000 description 1
- 101150055709 SNF1 gene Proteins 0.000 description 1
- 101100434411 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ADH1 gene Proteins 0.000 description 1
- 101100055265 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ALD2 gene Proteins 0.000 description 1
- 101100055270 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ALD4 gene Proteins 0.000 description 1
- 101100055273 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ALD5 gene Proteins 0.000 description 1
- 101100055274 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ALD6 gene Proteins 0.000 description 1
- 101100339515 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HO gene Proteins 0.000 description 1
- 101100208020 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) TRP1 gene Proteins 0.000 description 1
- 101100262439 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UBA2 gene Proteins 0.000 description 1
- 241000235088 Saccharomyces sp. Species 0.000 description 1
- 241001303116 Saccharophagus Species 0.000 description 1
- 241001670248 Saccharophagus degradans Species 0.000 description 1
- 241000607149 Salmonella sp. Species 0.000 description 1
- 241000284708 Sarcophaga alpha Species 0.000 description 1
- 241000235060 Scheffersomyces stipitis Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241001135258 Serratia proteamaculans Species 0.000 description 1
- 241000863430 Shewanella Species 0.000 description 1
- 241000865982 Shewanella amazonensis Species 0.000 description 1
- 241000878021 Shewanella baltica Species 0.000 description 1
- 241001441009 Shewanella denitrificans Species 0.000 description 1
- 241000557287 Shewanella frigidimarina Species 0.000 description 1
- 241000868986 Shewanella woodyi Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108010052160 Site-specific recombinase Proteins 0.000 description 1
- 241000122971 Stenotrophomonas Species 0.000 description 1
- 241000122973 Stenotrophomonas maltophilia Species 0.000 description 1
- 241000187432 Streptomyces coelicolor Species 0.000 description 1
- 241000145545 Streptomyces collinus Species 0.000 description 1
- 241000187180 Streptomyces sp. Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 241000371384 Syntrophomonas wolfei subsp. wolfei str. Goettingen G311 Species 0.000 description 1
- 101150044379 TIR1 gene Proteins 0.000 description 1
- 101150079473 TIR3 gene Proteins 0.000 description 1
- 101150020675 TIR4 gene Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 102000005488 Thioesterase Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000223230 Trichosporon Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000743436 Ustilago sp. Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000589634 Xanthomonas Species 0.000 description 1
- 241000311098 Yamadazyma Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 241001095440 Yersinia aldovae ATCC 35236 Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 241000607477 Yersinia pseudotuberculosis Species 0.000 description 1
- 241001095436 Yersinia rohdei ATCC 43380 Species 0.000 description 1
- 101100194320 Zea mays PER1 gene Proteins 0.000 description 1
- 241000222124 [Candida] boidinii Species 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 241000193453 [Clostridium] cellulolyticum Species 0.000 description 1
- ASJWEHCPLGMOJE-LJMGSBPFSA-N ac1l3rvh Chemical class N1C(=O)NC(=O)[C@@]2(C)[C@@]3(C)C(=O)NC(=O)N[C@H]3[C@H]21 ASJWEHCPLGMOJE-LJMGSBPFSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 101150015189 aceE gene Proteins 0.000 description 1
- 101150077561 aceF gene Proteins 0.000 description 1
- 108010065064 acetaldehyde dehydrogenase (acylating) Proteins 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 229940100228 acetyl coenzyme a Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 108091006088 activator proteins Proteins 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 101150014383 adhE gene Proteins 0.000 description 1
- 238000010564 aerobic fermentation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 101150023727 ald2 gene Proteins 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940025131 amylases Drugs 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 101150050729 bdhA gene Proteins 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 229940038698 brucella melitensis Drugs 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 208000032343 candida glabrata infection Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000004464 cereal grain Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000007357 dehydrogenase reaction Methods 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 description 1
- 229940008406 diethyl sulfate Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 230000004149 ethanol metabolism Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 101150069125 fadB gene Proteins 0.000 description 1
- 230000009123 feedback regulation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000003144 genetic modification method Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 101150087371 gpd1 gene Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000006195 histone acetylation Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- GFAZHVHNLUBROE-UHFFFAOYSA-N hydroxymethyl propionaldehyde Natural products CCC(=O)CO GFAZHVHNLUBROE-UHFFFAOYSA-N 0.000 description 1
- RJGBSYZFOCAGQY-UHFFFAOYSA-N hydroxymethylfurfural Natural products COC1=CC=C(C=O)O1 RJGBSYZFOCAGQY-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 101150040445 lpd gene Proteins 0.000 description 1
- 101150003321 lpdA gene Proteins 0.000 description 1
- 101150007808 lpdC gene Proteins 0.000 description 1
- 239000003879 lubricant additive Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- LTYOQGRJFJAKNA-VFLPNFFSSA-N malonyl-coa Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-VFLPNFFSSA-N 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 239000010813 municipal solid waste Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 101150017885 nphT7 gene Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000000065 osmolyte Effects 0.000 description 1
- 230000000426 osmoregulatory effect Effects 0.000 description 1
- 238000005895 oxidative decarboxylation reaction Methods 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000010893 paper waste Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000003614 peroxisome proliferator Substances 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000010908 plant waste Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000307 polymer substrate Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000009290 primary effect Effects 0.000 description 1
- 230000019525 primary metabolic process Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 239000013635 pyrimidine dimer Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 210000004767 rumen Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 235000019265 sodium DL-malate Nutrition 0.000 description 1
- WPUMTJGUQUYPIV-UHFFFAOYSA-L sodium malate Chemical compound [Na+].[Na+].[O-]C(=O)C(O)CC([O-])=O WPUMTJGUQUYPIV-UHFFFAOYSA-L 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000010563 solid-state fermentation Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000028070 sporulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 230000004152 substrate-level phosphorylation Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 108020002982 thioesterase Proteins 0.000 description 1
- 238000007079 thiolysis reaction Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 108091023038 transmembrane transporter activity Proteins 0.000 description 1
- 102000040606 transmembrane transporter activity Human genes 0.000 description 1
- AZDRQVAHHNSJOQ-XCIZNGPVSA-N trideuterioalumane Chemical compound [2H][Al]([2H])[2H] AZDRQVAHHNSJOQ-XCIZNGPVSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000005074 turgor pressure Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 101150013983 yiaY gene Proteins 0.000 description 1
- 101150049562 yqeF gene Proteins 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
- C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
- C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
- C12P7/16—Butanols
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
- C12Y102/04—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with a disulfide as acceptor (1.2.4)
- C12Y102/04001—Pyruvate dehydrogenase (acetyl-transferring) (1.2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y103/00—Oxidoreductases acting on the CH-CH group of donors (1.3)
- C12Y103/01—Oxidoreductases acting on the CH-CH group of donors (1.3) with NAD+ or NADP+ as acceptor (1.3.1)
- C12Y103/01008—Acyl-CoA dehydrogenase (NADP+) (1.3.1.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y103/00—Oxidoreductases acting on the CH-CH group of donors (1.3)
- C12Y103/01—Oxidoreductases acting on the CH-CH group of donors (1.3) with NAD+ or NADP+ as acceptor (1.3.1)
- C12Y103/01038—Trans-2-enoyl-CoA reductase (NADPH) (1.3.1.38)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
- C12Y203/01016—Acetyl-CoA C-acyltransferase (2.3.1.16)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
- C12Y203/01054—Formate C-acetyltransferase (2.3.1.54), i.e. pyruvate formate-lyase or PFL
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/01—Carboxy-lyases (4.1.1)
- C12Y401/01001—Pyruvate decarboxylase (4.1.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y501/00—Racemaces and epimerases (5.1)
- C12Y501/02—Racemaces and epimerases (5.1) acting on hydroxy acids and derivatives (5.1.2)
- C12Y501/02003—3-Hydroxybutyryl-CoA epimerase (5.1.2.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y602/00—Ligases forming carbon-sulfur bonds (6.2)
- C12Y602/01—Acid-Thiol Ligases (6.2.1)
- C12Y602/01013—Acetate--CoA ligase (ADP-forming) (6.2.1.13)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E50/00—Technologies for the production of fuel of non-fossil origin
- Y02E50/10—Biofuels, e.g. bio-diesel
Definitions
- the present invention relates to the fields of fermentation and metabolic engineering of yeasts such as Saccharomyces cerevisiae.
- the invention relates to S. cerevisiae strains that have been engineered to express in the absence of fatty acids several of the enzymes that are required in the degradation of such acids along with certain other enzymes.
- the expression of some of the native yeast enzymes has been prevented or minimized in order to prevent the formation of undesired by- products such as ethanol and glycerol.
- By varying the expression of the various enzymes in yeast it has been possible to obtain a range of metabolically-engineered yeasts that each produces a particular 1 -alcohol from sugars such as glucose, fructose and sucrose.
- the invention further relates to the processes wherein the engineered strains of the invention produce 1 -alcohols from sugars, preferentially in the absence of oxygen.
- Ethanol is currently the dominant bio fuel and its production from sugars basically is via an anoxic process.
- 1-Butanol systematic name butan-l-ol
- ethanol as a fuel
- no economic method seems to be available for its production via a fermentation process from sugars.
- the production of 1-butanol (and the byproduct acetone) was one of the first large-scale industrial fermentation processes in the first half of the previous century with volumes that were comparable to the production of ethanol.
- 1-butanol relied on species of Clostridium that produce a mixture of compounds such as acetone, acetoin and lactic acid along with the desired product 1-butanol.
- the route leading into 1-butanol from acetyl-CoA involves a thiolase that couples two acetyl-CoA's to form acetoacetyl-CoA which is reduced into 3-hydroxybutyric acid by a dehydrogenase. In two subsequent steps this compound is transformed into butyryl-CoA by crotonase and butyryl-CoA dehydrogenase. Two reductive steps then lead to the formation of 1-butanol.
- Berezina et al. (Applied Microbiology Biotechnology 2010, 87:635-646) employed a Lactobacillus brevis strain for expressing the Clostridial pathway.
- the recombinant L. brevis strains were able to synthesize up to 300 mg/L of 1-butanol in a glucose-containing medium.
- Garza et al. (J Ind Microbiol Biotechnol 2012, 39: 1101-1107) also introduced a 1-butanol-producing pathway in E. coli from Clostridium. They produced 1254 mg/L of 1-butanol from glucose under anoxic conditions.
- Bond- Watts et al. (Nature Chemical Biology 2011, 7:222-227) the construction of a chimeric pathway assembled from three different organisms for the high-level production of 1-butanol (4,7 g/L).
- the NADH-dependent enzyme trans-enoyl-coenzyme A reductase (TER) from Treponema denticola was a an enzyme that the authors described as potentially irreversible in vivo into the direction of butyryl-CoA.
- Shen et al. (Applied and Environmental Microbiology 2011 , 77:2905-2915) also constructed 1-butanol pathway in E. coli to provide an irreversible reaction by TER. Attention was furthermore paid to NADH and to acetyl-CoA in obtaining driving forces to direct the flux into product formation. Under anoxic conditions, concentrations of 30 g/L of butanol were obtained with yields of up to 88% of the theoretical yield. Dellomonaco et al, (Nature 2011, 476:355-361; WO 2012/109176) disclose the engineered reversal of the ⁇ -oxidation cycle for the synthesis of fuels and chemicals in E. coli.
- Primary 1 -alcohols (n-alcohols) with a carbon chain length greater than 4 can also be produced by microbes from sugar, either via the reversed biodegradative or via the biosynthetic pathway.
- Machado et al. (Metabolic Engineering 2012, 14:504-511) have been building on the work of Dekishima et al.
- An anaerobic E. coli growth-selection platform (mutant that cannot grow anaerobically if no oxidative outlet for NADH is available) was used that allowed selection or enrichment of enzymes for increased synthesis of C6 and C8 linear alcohols.
- mutant that cannot grow anaerobically if no oxidative outlet for NADH is available
- Further directed evolution by random mutagenesis of a 3-hydroxyl-acyl-CoA dehydrogenase improved 1 -hexanol and 1 -octanol production.
- Dellomonaco et al disclose the engineered reversal of the ⁇ -oxidation cycle for the synthesis of fuels and chemicals in E. coli. Not only for butanol, but also for higher alcohols including hexanol, octanol and dodecanol but product concentrations remained limited to below 200 mg/L.
- Yeasts such as S. cerevisiae are known to be superior hosts in the industrial manufacture of compounds from sugar, especially if large volumes are produced.
- a large number of metabolic routes in the production of a variety of compounds has been investigated in bacteria such as Escherichia coli.
- bacteria will not be applied on industrial scales because of their many inherent drawbacks as compared to yeast. Consequently, bacteria-based processes will not lead to economically sound processes.
- Yeasts on the other hand intrinsically pose technical challenges in constructing the desired production hosts via molecular approaches.
- S. cerevisiae is a preferred host over E. coli but that their central metabolism are distinct from each other calling for novel metabolic engineering strategies in S. cerevisiae as compared to E. coli.
- production of desired compounds from sugars at industrial scale preferably is done under anoxic conditions (no oxygen present). Production processes in the presence of oxygen are difficult to control at large scales because of challenges in homogenous mixing of oxygen from air. Furthermore, input of air at large scale is a technical and economic issue in itself.
- the well-known process of producing ethanol from sugar by the yeast S. cerevisiae is an example of a successful anoxic procedure at industrial scale.
- the invention pertains to a modified eukaryotic microbial host cell.
- the host cell preferably is modified to comprise: a) cytosolic expression of the enzymes of the fatty acid ⁇ -oxidation cycle under anoxic conditions, in the absence of fatty acids and in the presence of a non-fatty acid carbon source; b) a metabolic route for producing under anoxic conditions and preferably in the cytosol, acetyl-CoA from the non-fatty acid carbon source to feed into and drive the ⁇ -oxidation cycle in the biosynthetic direction; and, c) expression of a termination enzyme to convert reaction intermediates of the ⁇ -oxidation cycle into a 1 -alcohol or derivatives thereof.
- the invention pertains to the use of a cell modified according to the invention, for the production of a 1 -alcohol or a derivative thereof.
- the invention relates to processes for producing a 1 -alcohol or a derivative thereof, whereby the process comprises the steps of: a) fermenting a medium with a modified cell according to the invention under anoxic conditions, whereby the medium contains or is fed with a non- fatty acid carbon source and whereby the yeast cell ferments the non- fatty acid carbon source to the 1 -alcohol or derivative; and optionally, b) recovery of the 1 -alcohol or derivative.
- a preferred process according to the invention is a process wherein prior to step a) a cell comprising a genetic modification that reduces or eliminates the production of the 1 -alcohol under oxic condition, is cultured under oxic conditions to produce biomass, whereby the biomass obtained under oxic conditions is used to inoculate the medium in step a).
- Sequence identity is herein defined as a relationship between two or more amino acid (polypeptide or protein) sequences or two or more nucleic acid (polynucleotide) sequences, as determined by comparing the sequences.
- identity also means the degree of sequence relatedness between amino acid or nucleic acid sequences, as the case may be, as determined by the match between strings of such sequences.
- similarity between two amino acid sequences is determined by comparing the amino acid sequence and its conserved amino acid substitutes of one polypeptide to the sequence of a second polypeptide. "Identity” and “similarity” can be readily calculated by known methods.
- sequence identity or “sequence similarity” means that two (poly)peptide or two nucleotide sequences, when optimally aligned, preferably over the entire length (of at least the shortest sequence in the comparison) and maximizing the number of matches and minimizes the number of gaps such as by the programs ClustalW (1.83), GAP or BESTFIT using default parameters, share at least a certain percentage of sequence identity as defined elsewhere herein.
- GAP uses the Needleman and Wunsch global alignment algorithm to align two sequences over their entire length, maximizing the number of matches and minimizes the number of gaps.
- the default scoring matrix used is nwsgapdna and for proteins the default scoring matrix is Blosum62 (Henikoff & Henikoff, 1992, PNAS 89, 915-919).
- a preferred multiple alignment program for aligning protein sequences of the invention is ClustalW (1.83) using a blosum matrix and default settings (Gap opening penalty: 10; Gap extension penalty: 0.05).
- RNA sequences are said to be essentially similar or have a certain degree of sequence identity with DNA sequences, thymine (T) in the DNA sequence is considered equal to uracil (U) in the RNA sequence.
- Sequence alignments and scores for percentage sequence identity may be determined using computer programs, such as the GCG Wisconsin Package, Version 10.3, available from Accelrys Inc., 9685 Scranton Road, San Diego, CA 92121-3752 USA or the open-source software Emboss for Windows (current version 2.7.1- 07).
- percent similarity or identity may be determined by searching against databases such as FASTA, BLAST, etc. Preferred methods to determine identity are designed to give the largest match between the sequences tested.
- Methods to determine identity and similarity are codified in publicly available computer programs.
- Preferred computer program methods to determine identity and similarity between two sequences include e.g. the GCG program package (Devereux, J., et al, Nucleic Acids Research 12 (1):387 (1984)), BestFit, BLASTP, BLASTN, and FASTA (Altschul, S. F. et al, J. Mol. Biol. 215:403-410 (1990).
- the BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S., et al, NCBI NLM NIH Bethesda, MD 20894; Altschul, S., et al, J. Mol. Biol. 215:403-410 (1990).
- the well-known Smith Waterman algorithm may also be used to determine identity.
- Preferred parameters for polypeptide sequence comparison include the following: Algorithm: Needleman and Wunsch, J. Mol. Biol. 48:443-453 (1970); Comparison matrix: BLOSSUM62 from Hentikoff and Hentikoff, Proc. Natl. Acad. Sci. USA. 89: 10915-10919 (1992); Gap Penalty: 12; and Gap Length Penalty: 4.
- a program useful with these parameters is publicly available as the "Ogap" program from Genetics Computer Group, located in Madison, WI.
- the aforementioned parameters are the default parameters for amino acid comparisons (along with no penalty for end gaps).
- Preferred parameters for nucleic acid comparison include the following: Algorithm: Needleman and Wunsch, J. Mol. Biol.
- amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide- containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulphur-containing side chains is cysteine and methionine.
- Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine- valine, and asparagine-glutamine.
- Substitutional variants of the amino acid sequence disclosed herein are those in which at least one residue in the disclosed sequences has been removed and a different residue inserted in its place.
- the amino acid change is conservative.
- Preferred conservative substitutions for each of the naturally occurring amino acids are as follows: Ala to ser; Arg to lys; Asn to gin or his; Asp to glu; Cys to ser or ala; Gin to asn; Glu to asp; Gly to pro; His to asn or gin; He to leu or val; Leu to ile or val; Lys to arg; gin or glu; Met to leu or ile; Phe to met, leu or tyr; Ser to thr; Thr to ser; Trp to tyr; Tyr to trp or phe; and, Val to ile or leu.
- Nucleotide sequences of the invention may also be defined by their capability to hybridize with parts of specific nucleotide sequences disclosed herein, respectively, under moderate, or preferably under stringent hybridization conditions.
- Stringent hybridization conditions are herein defined as conditions that allow a nucleic acid sequence of at least about 25, preferably about 50 nucleotides, 75 or 100 and most preferably of about 200 or more nucleotides, to hybridize at a temperature of about 65 °C in a solution comprising about 1 M salt, preferably 6 x SSC or any other solution having a comparable ionic strength, and washing at 65 °C in a solution comprising about 0.1 M salt, or less, preferably 0.2 x SSC or any other solution having a comparable ionic strength.
- the hybridization is performed overnight, i.e. at least for 10 hours and preferably washing is performed for at least one hour with at least two changes of the washing solution. These conditions will usually allow the specific hybridization of sequences having about 90% or more sequence identity.
- Moderate conditions are herein defined as conditions that allow a nucleic acid sequences of at least 50 nucleotides, preferably of about 200 or more nucleotides, to hybridize at a temperature of about 45 °C in a solution comprising about 1 M salt, preferably 6 x SSC or any other solution having a comparable ionic strength, and washing at room temperature in a solution comprising about 1 M salt, preferably 6 x SSC or any other solution having a comparable ionic strength.
- the hybridization is performed overnight, i.e. at least for 10 hours, and preferably washing is performed for at least one hour with at least two changes of the washing solution.
- These conditions will usually allow the specific hybridization of sequences having up to 50% sequence identity. The person skilled in the art will be able to modify these hybridization conditions in order to specifically identify sequences varying in identity between 50% and 90%.
- nucleic acid construct or “nucleic acid vector” is herein understood to mean a man-made nucleic acid molecule resulting from the use of recombinant DNA technology.
- the term “nucleic acid construct” therefore does not include naturally occurring nucleic acid molecules although a nucleic acid construct may comprise (parts of) naturally occurring nucleic acid molecules.
- expression vector or expression construct” refer to nucleotide sequences that are capable of affecting expression of a gene in host cells or host organisms compatible with such sequences. These expression vectors typically include at least suitable transcription regulatory sequences and optionally, 3' transcription termination signals. Additional factors necessary or helpful in effecting expression may also be present, such as expression enhancer elements.
- the expression vector will be introduced into a suitable host cell and be able to effect expression of the coding sequence in an in vitro cell culture of the host cell.
- the expression vector will be suitable for replication in the host cell or organism of the invention.
- promoter or “transcription regulatory sequence” refers to a nucleic acid fragment that functions to control the transcription of one or more coding sequences, and is located upstream with respect to the direction of transcription of the transcription initiation site of the coding sequence, and is structurally identified by the presence of a binding site for DNA-dependent RNA polymerase, transcription initiation sites and any other DNA sequences, including, but not limited to transcription factor binding sites, repressor and activator protein binding sites, and any other sequences of nucleotides known to one of skill in the art to act directly or indirectly to regulate the amount of transcription from the promoter.
- a “constitutive” promoter is a promoter that is active in most tissues under most physiological and developmental conditions.
- An “inducible” promoter is a promoter that is physiologically or developmentally regulated, e.g. by the application of a chemical inducer.
- selectable marker is a term familiar to one of ordinary skill in the art and is used herein to describe any genetic entity which, when expressed, can be used to select for a cell or cells containing the selectable marker.
- reporter may be used interchangeably with marker, although it is mainly used to refer to visible markers, such as green fluorescent protein (GFP). Selectable markers may be dominant or recessive or bidirectional.
- operably linked refers to a linkage of polynucleotide elements in a functional relationship.
- a nucleic acid is “operably linked” when it is placed into a functional relationship with another nucleic acid sequence.
- a transcription regulatory sequence is operably linked to a coding sequence if it affects the transcription of the coding sequence.
- Operably linked means that the DNA sequences being linked are typically contiguous and, where necessary to join two protein encoding regions, contiguous and in reading frame.
- protein or “polypeptide” are used interchangeably and refer to molecules consisting of a chain of amino acids, without reference to a specific mode of action, size, 3-dimensional structure or origin.
- Fungi (singular fungus) are herein understood as heterotrophic eukaryotic microorganisms that digest their food externally, absorbing nutrient molecules into their cells. Fungi are a separate kingdom of eukaryotic organisms and include yeasts, molds, and mushrooms. The terms fungi, fungus and fungal as used herein thus expressly includes yeasts as well as filamentous fungi.
- gene means a DNA fragment comprising a region (transcribed region), which is transcribed into an RNA molecule (e.g. an mRNA) in a cell, operably linked to suitable regulatory regions (e.g. a promoter).
- a gene will usually comprise several operably linked fragments, such as a promoter, a 5' leader sequence, a coding region and a 3'-nontranslated sequence (3 'end) comprising a polyadenylation site.
- “Expression of a gene” refers to the process wherein a DNA region which is operably linked to appropriate regulatory regions, particularly a promoter, is transcribed into an RNA, which is biologically active, i.e.
- nucleic acid or polypeptide when used to indicate the relation between a given (recombinant) nucleic acid or polypeptide molecule and a given host organism or host cell, is understood to mean that in nature the nucleic acid or polypeptide molecule is produced by a host cell or organisms of the same species, preferably of the same variety or strain. If homologous to a host cell, a nucleic acid sequence encoding a polypeptide will typically (but not necessarily) be operably linked to another (heterologous) promoter sequence and, if applicable, another (heterologous) secretory signal sequence and/or terminator sequence than in its natural environment.
- the regulatory sequences, signal sequences, terminator sequences, etc. may also be homologous to the host cell.
- the use of only “homologous” sequence elements allows the construction of "self-cloned” genetically modified organisms (GMO's) (self-cloning is defined herein as in European Directive 98/81/EC Annex II).
- GMO's genetically modified organisms
- self-cloning is defined herein as in European Directive 98/81/EC Annex II.
- the term "homologous" means that one single- stranded nucleic acid sequence may hybridize to a complementary single-stranded nucleic acid sequence. The degree of hybridization may depend on a number of factors including the amount of identity between the sequences and the hybridization conditions such as temperature and salt concentration as discussed later.
- heterologous and exogenous when used with respect to a nucleic acid (DNA or RNA) or protein refers to a nucleic acid or protein that does not occur naturally as part of the organism, cell, genome or DNA or RNA sequence in which it is present, or that is found in a cell or location or locations in the genome or DNA or RNA sequence that differ from that in which it is found in nature.
- Heterologous and exogenous nucleic acids or proteins are not endogenous to the cell into which it is introduced, but have been obtained from another cell or synthetically or recombinantly produced. Generally, though not necessarily, such nucleic acids encode proteins, i.e.
- heterologous/exogenous nucleic acids and proteins may also be referred to as foreign nucleic acids or proteins. Any nucleic acid or protein that one of skill in the art would recognize as foreign to the cell in which it is expressed is herein encompassed by the term heterologous or exogenous nucleic acid or protein.
- heterologous and exogenous also apply to non-natural combinations of nucleic acid or amino acid sequences, i.e. combinations where at least two of the combined sequences are foreign with respect to each other.
- the "specific activity" of an enzyme is herein understood to mean the amount of activity of a particular enzyme per amount of total host cell protein, usually expressed in units of enzyme activity per mg total host cell protein. In the context of the present invention, the specific activity of a particular enzyme may be increased or decreased as compared to the specific activity of that enzyme in an (otherwise identical) wild type host cell.
- "Aerobic conditions” "Oxic conditions” or an aerobic or oxic fermentation process is herein defined as conditions or a fermentation process run in the presence of oxygen and in which oxygen is consumed, preferably at a rate of at least 0.5, 1, 2, 5, 10, 20 or 50 mmol/L/h, and wherein organic molecules serve as electron donor and oxygen serves as electron acceptor.
- Anaerobic or anoxic conditions or an “anaerobic or anoxic fermentation process” is herein defined as conditions or a fermentation process run in the absence of oxygen or in which substantially no oxygen is consumed, preferably less than 5, 2, 1, or 0.5 mmol/L/h, more preferably 0 mmol/L/h is consumed (i.e. oxygen consumption is not detectable), and wherein organic molecules serve as both electron donor and electron acceptors.
- E. coli has been engineered by constitutively expressing enzymes of the aerobic fatty acid ⁇ -oxidation cycle (the " ⁇ -oxidation cycle") in combination with expressing other relevant enzymes and by also removing certain enzyme activities that would lead to unwanted side products.
- ⁇ -oxidation cycle constitutively expressing enzymes of the aerobic fatty acid ⁇ -oxidation cycle
- Such engineered bacteria have been proposed as production organisms in the manufacturing from sugar of several chemicals (see e.g. Clomburg and Gonzalez, 2010 Biotechnol Bioeng. 108(4): 867-79; Dellomonaco et al. supra; and Gulevich et al. supra).
- the present inventors have found, however, that under relevant industrial conditions the production processes envisaged will be far from optimal due to the properties of the E. coli host. They have now found that it is possible to (constitutively) express all relevant genes for producing compounds via the reverse aerobic fatty acid ⁇ - oxidation cycle in yeasts such as S. cerevisiae. In combination with overexpressing and/or deleting enzymes, the present inventors have demonstrated that the industrially- relevant S. cerevisiae can be successfully employed in producing desired compounds under industrial conditions.
- the invention relates to a eukaryotic microbial host cell, preferably a yeast host cell, that has the desired properties for industrial processes and that will be modified following standard molecular techniques.
- a host cell of the invention preferably comprises the following features, which features may already be present in the host cell or which may be newly introduced and/or modified to be improved:
- the host cell preferably functionally expresses (enzymes of) the fatty acid ⁇ - oxidation cycle, preferably in the cytosol of the host cell.
- the ⁇ -oxidation cycle enzymes are expressed under conditions that include the presence of non-fatty acid carbon sources, i.e. carbohydrates (such as hexoses and disaccharides), including catabolite repressing carbon sources, and preferably also in the absence of oxygen (anoxic/anaerobic conditions).
- the host cell preferably provides acetyl-CoA to feed into and drive the ⁇ - oxidation cycle in the reverse, i.e. biosynthetic direction.
- the acetyl-CoA is preferably provided in the cytosol of the host cell via pyruvate that is obtained from a non-fatty acid carbon source, preferably through at least (the last) part of the glycolytic pathway.
- the host preferably directs as much as possible of the carbon flow as acetyl- Co A into the reversed ⁇ -oxidation cycle. Reactions producing unwanted by-products
- the host cell preferably functionally expresses termination enzymes to convert reaction intermediates of the ⁇ -oxidation cycle into the desired end product, such as fatty acids, 1 -alcohols, ⁇ -ketoacids, ⁇ -ketoalcohols, ⁇ -hydroxyacids, 1,3-diols, trans-A 2 -fatty acids, alkanes, alkenes and/or derivatives thereof, preferably, 1 -alcohols other than methanol and ethanol, such as e.g. butanol, decanol, dodecanol and higher 1- alcohols and/or derivatives thereof.
- termination enzymes to convert reaction intermediates of the ⁇ -oxidation cycle into the desired end product, such as fatty acids, 1 -alcohols, ⁇ -ketoacids, ⁇ -ketoalcohols, ⁇ -hydroxyacids, 1,3-diols, trans-A 2 -fatty acids, alkanes, alkenes and/
- a closed overall redox balance at the level of NAD(H) is achieved by decarboxylation of pyruvate to acetaldehyde, which subsequently acts as the electron acceptor for NADH reoxidation.
- this pathway of ethanol formation is the main mode of fermentative metabolism, but some glycerol is also produced in order to account for the NADH reoxidation as formed in biomass production.
- Bakker et al have summarized many important issues in Saccharomyces cerevisiae in the reduction of NAD to NADH and the reoxidation of NADH.
- oxidation/reduction levels of sugars employed as substrate In most cases the gross formula (CH 2 0)n can be given in describing the oxidation/reduction level of monomeric sugars.
- oxidation/reduction level of any other compound in the medium that is metabolized by yeast In particular the presence of furans and/or of acetic acid is very relevant in fermenting hydro ly sates.
- S. cerevisiae contains 3 structural genes (PDC1, PDC5 and PDC6) that encode for the respective enzymes (Eberhardt et al., Eur. J. Biochem. 1999, 262: 191-201).
- Pdclp and Pdc5p are 88% identical and they are closely related pyruvate decarboxylases from other organisms.
- Pdc6p is an active pyruvate decarboxylase, it apparently is not involved in glucose fermentation. In actively fermenting yeast cells, PDC1 is strongly expressed, whereas expression of PDC5 is hardly detectable. Accordingly, deletion of just PDC5 does not noticeably reduce the pyruvate decarboxylase activity.
- glycerol In yeast, glycerol is of crucial interest as by-product under anoxic conditions. It is a major product in ethanol fermentation and allows S. cerevisiae to balance any excess of NADH in the absence of oxygen. Under osmotic stress conditions, glycerol is accumulated within the cell and acts as an osmolyte. For the production and excretion of glycerol, at least three features are important:
- the first step in the branch of the glycolytic pathway involves the catalysis of dihydroxyacetone phosphate to glycero 1-3 -phosphate by cytosolic NADH-dependent glycero 1-3 -phosphate dehydrogenases by two isoenzymes (Gpdlp and Gpd2p).
- Gpdlp and Gpd2p two isoenzymes
- Jain et al., (Applied Microbiology and Biotechnology 2012, 93: 131-141) describe that glycerol is a major product of ethanol fermentation by S. cerevisiae.
- a gpdlAgpd2A double mutant was unable to grow under strict anoxic conditions because NAD regeneration through glycerol production was no longer possible and intracellular NADH did accumulated, resulting in a redox imbalance.
- the second step involves dephosphorylation of glycero 1-3 -phosphate to yield glycerol.
- S. cerevisiae contains 2 glycerol 3 -phosphatases (Gpplp and Gpp2p) that can convert 3-phosphoglycerol formed by Gpdlp or Gpd2p into glycerol.
- Gpplp and Gpp2p glycerol 3 -phosphatases
- glycerol can be exported to the external environment by passive diffusion via the Fpslp plasma membrane glycerol channel which allows S. cerevisiae in part to regulate its internal glycerol levels (Luyten et al., The EMBO Journal 1995, 14: 1360-1371). Under conditions of high osmolarity stress, S. cerevisiae will retain high concentrations of glycerol as a compatible solute (Beese-Sims et al., Yeast 2001, 28:815-819).
- Increased external osmolarity induces Fpslp closure, whereas decreased osmolarity causes channel opening, both within seconds of the change in external osmolarity (Tamas et al., Mol Microbiol. 1999, 31 : 1087-104). This channel is required for survival of a hypo-osmotic shock when yeast cells have to export glycerol rapidly to prevent bursting and is required for controlling turgor pressure.
- the three above mechanisms allow the construction of hosts that are fine-tuned with respect to glycerol production.
- the natural glycerol-based osmoregulatory system in S. cerevisiae is particularly well understood and it is controlled by the high osmolarity glycerol (HOG) signaling system (Hohmann et al., Methods Enzymol. 2007, 428:29-45).
- HOG high osmolarity glycerol
- the parent host cell The present invention concerns the genetic modification of a host cell so as to enable the host cell to produce desired compounds via the reversal of the fatty acid ⁇ - oxidation pathway.
- a number of genetic modifications will be introduced in a parent host cell in accordance with the invention. These modifications include the introduction of expression of a number of heterologous genes, as well as, the modification of the expression of a number of endogenous genes already present in the parent host cell, by reducing or inactivating the expression of some endogenous genes and/or by increasing, i.e. overexpressing, other endogenous genes.
- a parent host cell is thus understood to be a host cell prior to that any of the genetic modifications in accordance with the invention have been introduced in the host cell.
- a parent host cell of the invention preferably is a eukaryotic host cell, more preferably, the host cell is a eukaryotic microorganism such as e.g. a fungal host cell.
- a most preferred parent host cell to be modified in accordance with the invention is a yeast host cell.
- Yeasts are herein defined as eukaryotic microorganisms and include all species of the subdivision Eumycotina (Yeasts: characteristics and identification, J.A. Barnett, R.W. Payne, D. Yarrow, 2000, 3rd ed., Cambridge University Press, Cambridge UK; and, The yeasts, a taxonomic study, CP. Kurtzman and J.W. Fell (eds) 1998, 4th ed., Elsevier Science Publ. B.V., Amsterdam, The Netherlands) that predominantly grow in unicellular form. Yeasts may either grow by budding of a unicellular thallus or may grow by fission of the organism.
- Preferred yeasts cells for use in the present invention belong to the genera Saccharomyces, Kluyveromyces, Candida, Pichia, Schizosaccharomyces, Hansenula, Kloeckera, Schwanniomyces, Yarrowia, Cryptococcus, Debaromyces, Saccharomycecopsis, Saccharomycodes, Wickerhamia, Debayomyces, Hanseniaspora, Ogataea, Kuraishia, Komagataella, Metschnikowia, Williopsis, Nakazawaea, Torulaspora, Bullera, Rhodotorula, and Sporobolomyces.
- the parental yeast host cell is naturally capable of anaerobic fermentation, more preferably alcoholic fermentation and most preferably anaerobic alcoholic fermentation.
- the host cell is modified to avoid or reduce the synthesis of ethanol.
- yeasts such as Saccharomyces species
- yeasts have many attractive features for industrial processes, including e.g. their high tolerance to acids, ethanol and other harmful compounds, their high osmo-tolerance and their capability of anaerobic growth, and of course their high fermentative capacity.
- Preferred yeast species as parent host cells for the invention include e.g.
- Saccharomyces cerevisiae S. exiguus, S. bayanus, S. delbriickii, S. italicus, S. ellipsoideus, S. fermentati, S. kluyveri, S. krusei, S. lactis, S. marxianus, S. microellipsoides, S. montanus, S. norbensis, S. oleaceus, S. paradoxus, S. pastorianus,
- the parent host cell of the invention preferably contains active glycolysis.
- the host cell further preferably has a high tolerance to ethanol, a high tolerance to low pH (i.e. capable of growth at a pH lower than 5, 4, or 3) and towards organic acids like lactic acid, acetic acid or formic acid and sugar degradation products such as furfural and hydroxy-methylfurfural, and a high tolerance to elevated temperatures.
- any of these characteristics or activities of the host cell may be naturally present in the host cell or may be introduced or modified by genetic modification, preferably by self cloning or by the methods of the invention described below.
- a suitable cell is a cultured cell, a cell that may be cultured in fermentation process e.g. in submerged or solid state fermentation.
- genetically modified (yeast) host strains may be carried out by genetic crosses, sporulation of the resulting diploids, tetrad dissection of the haploid spores containing the desired auxotrophic markers, and colony purification of such haploid host cells in the appropriate selection medium. All of these methods are standard fungal and yeast genetic methods known to those in the art. See, for example, Sherman et al, Methods Yeast Genetics, Cold Spring Harbor Laboratory, NY (1978) and Guthrie et al. (Eds.) Guide To Yeast Genetics and Molecular Biology Vol. 194, Academic Press, San Diego (1991).
- suitable promoters for the expression of the heterologous nucleotide sequence coding for desired enzyme activities and/or for overexpression of endogenous genes in the context of the invention include promoters that are preferably insensitive to catabolite (glucose) repression, that are active under oxic (aerobic) and under anoxic (anaerobic) conditions and/or that preferably do not require specific carbon sources for induction. Promoters having these characteristics are widely available and known to the skilled person. Suitable examples of such promoters include e.g.
- promoters from glycolytic genes such as the phosphofructokinase (PPK), triose phosphate isomerase (TPI), glyceraldehyde-3 -phosphate dehydrogenase (GPD, TDH3 or GAPDH), pyruvate kinase (PYK), phosphoglycerate kinase (PGK), glucose-6-phosphate isomerase promoter (PGIl) promoters from yeasts. More details about such promoters from yeast may be found in (WO 93/03159).
- PPK phosphofructokinase
- TPI triose phosphate isomerase
- GPD glyceraldehyde-3 -phosphate dehydrogenase
- PYK pyruvate kinase
- PGK phosphoglycerate kinase
- PGIl glucose-6-phosphate isomerase promoter
- ribosomal protein encoding gene promoters TEFI
- lactase gene promoter LAC4
- alcohol dehydrogenase promoters ADHl, preferably a modified (constitutive) version of the ADHl promoter (SEQ ID NO: 77), ADH4, and the like
- ENO enolase promoter
- HXT7 hexose(glucose) transporter promoter
- a suitable promoter for these purposes is a promoter that allows (over)expression under anaerobic conditions.
- a preferred example of such an anoxic promoter is e.g. the S. cerevisiae ANB1 promoter (SEQ ID NO: 73).
- promoters both constitutive and inducible, and enhancers or upstream activating sequences will be known to those of skill in the art.
- the promoter that is operably linked to nucleotide sequence as defined above is homologous to the host cell.
- Suitable terminator sequences are e.g. obtainable from the cytochrome cl (CYC1) gene or an alcohol dehydrogenase gene (e.g. ADHl).
- the nucleotide sequence encoding of enzymes of the invention are preferably adapted to optimize their codon usage to that of the host cell in question.
- the adaptiveness of a nucleotide sequence encoding an enzyme to the codon usage of a host cell may be expressed as codon adaptation index (CAI).
- CAI codon adaptation index
- the codon adaptation index is herein defined as a measurement of the relative adaptiveness of the codon usage of a gene towards the codon usage of highly expressed genes in a particular host cell or organism.
- the relative adaptiveness (w) of each codon is the ratio of the usage of each codon, to that of the most abundant codon for the same amino acid.
- CAI index is defined as the geometric mean of these relative adaptiveness values. Non-synonymous codons and termination codons (dependent on genetic code) are excluded. CAI values range from 0 to 1, with higher values indicating a higher proportion of the most abundant codons (see Sharp and Li , 1987, Nucleic Acids Research 15: 1281-1295; also see: Jansen et al, 2003, Nucleic Acids Res. 3J_(8):2242-51).
- An adapted nucleotide sequence preferably has a CAI of at least 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8 or 0.9. Most preferred are the sequences which have been codon optimized for expression in the fungal host cell in question such as e.g. S. cerevisiae cells.
- the host cells of the invention are genetically modified so as to reduce or inactivate unwanted side reactions.
- the endogenous pyruvate decarboxylase activity in the host cell is reduced or eliminated as a means to prevent the formation of at least one acetaldehyde, acetate and ethanol.
- Endogenous pyruvate decarboxylase activity in yeast converts pyruvate to acetaldehyde, which is then converted to ethanol, or to acetyl-CoA via acetate (see Figure 1).
- Yeasts may have one or more genes encoding pyruvate decarboxylase.
- there is one gene encoding pyruvate decarboxylase in Kluyveromyces lactis while there are three isozymes of pyruvate decarboxylase encoded by the PDC1, PCD 5, and PDC6 (EC 4.1.1.1) genes in Saccharomyces cerevisiae, as well as a pyruvate decarboxylase regulatory gene PDC2.
- the specific pyruvate decarboxylase activity is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in activity, at least under anaerobic conditions.
- the pyruvate decarboxylase activity can be reduced by modifying at least one gene encoding a pyruvate decarboxylase, or by modifying a gene regulating the expression of pyruvate decarboxylase gene(s). For example, in S.
- the PDC1 and PDC5 genes, or all three genes, can be modified to reduce or eliminate their expression e.g. by disruption.
- pyruvate decarboxylase activity may be reduced by modification, e.g. disruption, of the PDC2 regulatory gene in S. cerevisiae.
- genes to be modified for reducing the specific pyruvate decarboxylase activity in the cell of the invention are one or more or all of the S. cerevisiae PDC1, PDC5, PDC6 and PDC2 genes, encoding the amino acid sequences of SEQ ID NO's: 1, 2, 3 and 4, respectively, or orthologues thereof in other species. Therefore genes to be modified for reducing the specific pyruvate decarboxylase activity in the cell of the invention, preferably are one or more or all of the genes encoding an amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to one or more of SEQ ID NO's: 1, 2, 3 and 4, respectively.
- yeast strains with reduced pyruvate decarboxylase activity due to disruption of pyruvate decarboxylase encoding genes have been reported for Saccharomyces in Flikweert et al. (Yeast (1996) 12:247-257), and disruption of the regulatory gene in Hohmann, (Mol Gen Genet. (1993) 241 :657-666). Saccharomyces strains having no pyruvate decarboxylase activity are available from the ATCC with accession no.'s #200027 and #200028.
- Genes encoding pyruvate decarboxylases and/or PDC regulatory genes may be modified so as to reduce pyruvate decarboxylase specific activity in host cells of the invention using a variety of methods for genetic modification. Many methods for modifying endogenous target genes in host cells so as to reduce or eliminate the activity of the encoded target proteins are known to one skilled in the art and may be used for modifying the host cells of the invention. Modifications that may be used to reduce or eliminate expression of a target protein are disruptions that include, but are not limited to, deletion of the entire gene or a portion of the gene encoding the target protein (e.g.
- a pyruvate decarboxylase inserting a DNA fragment into the target gene (in either the promoter or coding region) so that the protein is not expressed or expressed at lower levels, introducing a mutation into the target coding region which adds a stop codon or frame shift such that a functional protein is not expressed, and introducing one or more mutations into a target coding region to alter amino acids so that a non-functional target protein, or a target protein with reduced enzymatic activity is expressed.
- expression of the target gene may be blocked by expression of an antisense R A or an interfering RNA, and constructs may be introduced that result in co-suppression.
- a target coding sequence may be synthesized whose expression will be low because rare codons are substituted for plentiful ones, when this suboptimal coding sequence is substituted for the corresponding endogenous target coding sequence.
- a suboptimal coding sequence will have a codon adaptation index (see above) of less than 0.5, 0.4, 0.3 0.2, or 0.1.
- Such a suboptimal coding sequence will produce the same polypeptide but at a lower rate due to inefficient translation.
- the synthesis or stability of the transcript may be reduced by mutation.
- the efficiency by which a protein is translated from mRNA may be modulated by mutation, e.g. by using suboptimal translation initiation codons. All of these methods may be readily practiced by one skilled in the art making use of the known or identified sequences encoding target proteins such as the pyruvate decarboxylase proteins.
- DNA sequences flanking a target coding sequence such as the pyruvate decarboxylase coding sequences are also useful in some modification procedures and are available for yeasts such as for Saccharomyces cerevisiae in the complete genome sequence coordinated by Genome Project ID9518 of Genome Projects coordinated by NCBI (National Center for Biotechnology Information) with identification GOPID #13838.
- DNA sequences surrounding a target coding sequence are useful for modification methods using homologous recombination.
- sequences flanking the target gene are placed on either site of a selectable marker gene to mediate homologous recombination whereby the marker gene replaces the target gene.
- partial target gene sequences and target gene flanking sequences bounding a selectable marker gene may be used to mediate homologous recombination whereby the marker gene replaces a portion of the target gene, e.g. a pyruvate decarboxylase gene.
- the selectable marker may be flanked by site-specific recombination sites, so that following expression of the corresponding site-specific recombinase, the resistance gene is excised from the genomic locus where the target gene was present without reactivating the latter.
- the site-specific recombination leaves behind a recombination site which disrupts expression of the target protein.
- the homologous recombination vector may be constructed to also leave a deletion in the target gene following excision of the selectable marker, as is well known to one skilled in the art.
- Deletions may be made using mitotic recombination as described in Wach et al. ((1994) Yeast 10: 1793-1808).
- This method involves preparing a DNA fragment that contains a selectable marker between genomic regions that may be as short as 20 bp, and which bound, i.e. flank the target DNA sequence.
- This DNA fragment can be prepared by PCR amplification of the selectable marker gene using as primers oligonucleotides that hybridize to the ends of the marker gene and that include the genomic regions that can recombine with the yeast genome.
- the linear DNA fragment can be efficiently transformed into yeast and recombined into the genome resulting in gene replacement including with deletion of the target DNA sequence (as described in Methods in Enzymology, v 194, pp 281-301 (1991)).
- promoter replacement methods may be used to exchange the endogenous transcriptional control elements allowing another means to modulate expression such as described in Mnaimneh et al. ((2004) Cell 118(1):31-44) and in the Examples herein.
- the activity of target proteins in any yeast cell may be disrupted using random mutagenesis, which is followed by screening to identify strains with reduced activity of the target proteins such as e.g. a pyruvate decarboxylase.
- the DNA sequence coding for the target proteins e.g. the pyruvate decarboxylase encoding region
- any other region of the genome affecting expression of pyruvate decarboxylase activity need not even be known.
- Methods for creating genetic mutations are common and well known in the art and may be applied to the exercise of creating mutants.
- Commonly used random genetic modification methods include spontaneous mutagenesis, mutagenesis caused by mutator genes, chemical mutagenesis, irradiation with UV or X-rays, or transposon mutagenesis.
- Chemical mutagenesis of yeast commonly involves treatment of yeast cells with one of the following DNA mutagens: ethyl methanesulfonate (EMS), nitrous acid, diethyl sulfate, or N-methyl-N'-nitro-N-nitroso-guanidine (MNNG).
- EMS ethyl methanesulfonate
- MNNG N-methyl-N'-nitro-N-nitroso-guanidine
- Irradiation with ultraviolet (UV) light or X-rays can also be used to produce random mutagenesis in yeast cells.
- the primary effect of mutagenesis by UV irradiation is the formation of pyrimidine dimers which disrupt the fidelity of DNA replication.
- Protocols for UV-mutagenesis of yeast can be found in Spencer et al (Mutagenesis in Yeast, 1996, Yeast Protocols: Methods in Cell and Molecular Biology. Humana Press, Totowa, N.J.).
- Introduction of a mutator phenotype can also be used to generate random chromosomal mutations in yeast.
- Common mutator phenotypes can be obtained through disruption of one or more of the following genes: PMSI, MAGI, RAD18 or RAD51. Restoration of the non-mutator phenotype can be easily obtained by insertion of the wild type allele. Collections of modified cells produced from any of these or other known random mutagenesis processes may be screened for reduced activity of the target protein
- the host comprises a further genetic modification of at least one copy of a transcriptional regulator involved in glucose sensing.
- S. cerevisiae strains in which the structural genes encoding pyruvate decarboxylase (PDC1, PDC5 and PDC6) are deleted are unable to grow in the presence of high glucose concentrations or under glucose-limited conditions without additional C 2 carbon sources such as ethanol or acetate - due to their inability to form cytosolic acetyl-CoA for e.g. fatty acid synthesis.
- C 2 carbon sources is however preferably avoided for processes at industrial scale.
- the transcriptional regulator is preferably encoded by the MTH1 gene or an orthologue thereof.
- the genetic modification preferably is a genetic modification that increases the steady state level of the THi-encoded protein, by at least one of overexpressing the protein and inactivation of a phosphorylation site required for degradation of the transcriptional regulator.
- the transcriptional regulator to be modified preferably has an amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to SEQ ID NO: 5.
- the genetic modification that inactivates the phosphorylation site preferably is an internal in- frame deletion of a segment comprising amino acid positions 57 - 131 of SEQ ID NO: 5, or a corresponding segment in an orthologue of SEQ ID NO: 5.
- the endogenous cytosolic acetaldehyde dehydrogenase activity in the host cell is reduced or eliminated so as to avoid or reduce the synthesis of acetate from acetaldehyde.
- Ald2p and Ald3p are cytosolic enzymes which use only NAD + as cofactor (EC 1.2.1.3). Both genes are induced in response to ethanol or stress and repressed by glucose.
- Ald4p and Ald5p are mitochondrial, use NAD and NADP as co factors, and are K + dependent.
- Ald4p, the major isoform is glucose repressed and ald4 mutants do not grow on ethanol, while Ald5p, the minor isoform, is constitutively expressed.
- ALD6 encodes the Mg 2+ activated cytosolic enzyme, which uses NADP + as cofactor and is constitutively expressed (EC 1.2.1.4).
- the cytosolic ALD6 gene product is the major enzyme responsible for catalyzing the oxidation of acetaldehyde to acetate in yeast.
- the gene to be modified for reducing or eliminating the specific cytosolic acetaldehyde dehydrogenase activity in the cell of the invention is at least the S. cerevisiae ALD6 gene, encoding the amino acid sequence of SEQ ID NO: 6, or an orthologue thereof in another species. Therefore a gene to be modified for reducing or eliminating the specific cytosolic acetaldehyde dehydrogenase activity in the cell of the invention, preferably is a gene encoding a amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to SEQ ID NO: 6. However, in other preferred cells the expression of one or more or all of the ALDl, ALD2, ALD3, ALD4, ALD5 and ALD6 genes or their corresponding orthologues is reduced or eliminated.
- the specific cytosolic acetaldehyde dehydrogenase activity is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in activity, at least under anaerobic conditions.
- Methods for reducing or eliminating the specific cytosolic acetaldehyde dehydrogenase activity in the cell of the invention are as described above in 2.1 for pyruvate decarboxylase as target protein.
- the endogenous alcohol dehydrogenase activity in the host cell is reduced or eliminated so as to avoid or reduce the synthesis of ethanol from acetaldehyde.
- ADH1 to ADH5 there are five genes that encode alcohol dehydrogenases involved in ethanol metabolism, ADH1 to ADH5.
- Adhlp, Adh3p, Adh4p, and Adh5p reduce acetaldehyde to ethanol during glucose fermentation, while Adh2p catalyzes the reverse reaction of oxidizing ethanol to acetaldehyde.
- Adh2p catalyzes the reverse reaction of oxidizing ethanol to acetaldehyde.
- the cytosolic ADH1 gene product is the major enzyme responsible for catalyzing the reduction of acetaldehyde to ethanol with the concomitant regeneration o f NAD + (EC 1.1.1.1).
- a preferred gene to be modified for reducing or eliminating the specific ADH1 -encoded alcohol dehydrogenase activity in the cell of the invention is the S. cerevisiae ADH1 gene, encoding the amino acid sequence of SEQ ID NO: 7, or an orthologue thereof in another species. Therefore a gene to be modified for reducing or eliminating the specific ADH1 -encoded alcohol dehydrogenase activity in the cell of the invention, preferably is a gene encoding an amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to SEQ ID NO: 7.
- preferred genes to be modified for reducing or eliminating the specific alcohol dehydrogenase activity in the cell of the invention are one or more of the S. cerevisiae ADH3, ADH4 and ADH5 genes or orthologues thereof in another species.
- the S. cerevisiae ADH3, ADH4 and ADH5 genes or their orthologues may be modified as such, or in combination with the above modification of the ADH1 gene or its orthologue.
- at least the S. cerevisiae ADH3 gene or its orthologue is modified for reducing or eliminating its specific activity in the cell of the invention, more preferably, in combination with the modification of at least one of the S. cerevisiae ADH1, ADH4 and ADH5 genes or their orthologues.
- genes to be modified for reducing or eliminating the specific alcohol dehydrogenase activity in the cell of the invention preferably are genes encoding an amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to the amino acid sequences of the S. cerevisiae ADH3, ADH4 and ADH5 genes (with respectively Genbank accession no.'s CAA89229.1, CAA64131.1 and CAA85103.1 and SEQ ID NO's 78 - 80).
- the specific (ADH1 -encoded or overall) alcohol dehydrogenase activity is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in activity, at least under anaerobic conditions.
- the specific ( ⁇ DHJ-encoded) alcohol dehydrogenase activity is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in activity, at least under anaerobic conditions.
- the specific ( ⁇ 4ZXH ⁇ -encoded) alcohol dehydrogenase activity is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in activity, at least under anaerobic conditions.
- the specific ( ⁇ 4DH5-encoded) alcohol dehydrogenase activity is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in activity, at least under anaerobic conditions.
- Methods for reducing or eliminating the endogenous alcohol dehydrogenase activity in the cell of the invention are as described above in 2.1 for pyruvate decarboxylase as target protein.
- the endogenous acetyl-CoA synthetase activity in the host cell is reduced or eliminated so as to avoid or reduce the synthesis of acetyl-CoA from acetate.
- whether or not one or all of the endogenous acetyl-CoA synthetase genes are inactivated depends on the introduction of heterologous genes for the production of cytosolic acetyl-CoA; see 3.1, 3.2 and 3.3 below).
- acetyl-CoA synthetase or acetate-CoA ligase (EC 6.2.1.1) is herein understood as an enzyme that catalyzes the formation of a new chemical bond between acetate and coenzyme A (CoA).
- the acetyl- CoA synthetase activity can be reduced by modifying at least one gene encoding a acetyl-CoA synthetase.
- one or both (all) of the ACS1 and ACS2 genes can be modified to reduce or eliminate their expression e.g. by disruption.
- preferred genes to be modified for reducing or eliminating the specific acetyl-CoA synthetase activity in the cell of the invention are at least one of the S. cerevisiae ACS1 and ACS2 genes, encoding the amino acid sequence of SEQ ID NO's: 8 and 9, respectively, or orthologues thereof in another species.
- genes to be modified for reducing the specific acetyl-CoA synthetase activity in the cell of the invention preferably are one or both of the genes encoding an amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to one or more of SEQ ID NO's: 8 and 9, respectively.
- the specific acetyl-CoA synthetase activity is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in activity, at least under anaerobic conditions.
- Methods for reducing or eliminating the specific acetyl-CoA synthetase activity in the cell of the invention are as described above in 2.1 for pyruvate decarboxylase as target protein.
- the activity of the product of the ACC1 gene or an orthologue thereof is reduced in the host cell by genetically modifying the gene so as to avoid or reduce the formation of fatty acids, via the yeast native fatty acid forming pathway because this pathway would compete with the reversed ⁇ -oxidation pathway introduced in the host cell of the invention.
- the S. cerevisiae ACC1 gene encodes the acetyl-CoA carboxylase (EC 6.4.1.2) which catalyzes the carboxylation of cytosolic acetyl-CoA to form malonyl-CoA and regulates histone acetylation by regulating the availability of acetyl-CoA; required for de novo biosynthesis of long-chain fatty acids.
- the S. cerevisiae ACCI gene or an orthologue thereof in another species is modified to reduce or eliminate activity of its gene product.
- the S. cerevisiae ACCI gene encodes the amino acid sequence of SEQ ID NO: 10.
- a gene to be modified for reducing or eliminating the activity of the ACCI gene product or that of its orthologue in the cell of the invention preferably is a gene encoding a amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to SEQ ID NO: 10.
- the activity of the ACCI gene product can be reduced by adding the phospholipid precursors inositol and choline as ACCI is repressed in the presence of the phospholipid precursors, or by reducing the expression of the transcription factors Ino2p and Ino4p or by upregulating the negative ACCI regulator Opilp.
- the activity of the ACCI gene product or that of its orthologue is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in expression, at least under anaerobic conditions.
- Methods for reducing or eliminating acetyl-CoA carboxylase activity in the cell of the invention are as described above in 2.1 for pyruvate decarboxylase as target protein.
- FAS2 is reduced or eliminated in the host cell so as to avoid or reduce (the initial steps of) fatty acid biosynthesis in which acetyl-CoA is consumed.
- FAS1 and FAS2 encode the ⁇ - and a-subunits, respectively, of the fatty acid synthetase, which catalyzes the synthesis of long-chain saturated fatty acids.
- the FAS1- encoded ⁇ -subunit contains acetyltransacylase, dehydratase, enoyl reductase, malonyl transacylase, and palmitoyl transacylase activities.
- the ⁇ S ⁇ -encoded a-subunit contains the acyl-carrier protein domain and ⁇ -ketoacyl reductase, beta-ketoacyl synthase and self-pantetheinylation activities.
- At least one the S. cerevisiae FAS1 FAS2 genes or their orthologues in another species are modified in order to avoid or reduce the initial steps of fatty acid biosynthesis in which acetyl-CoA is consumed.
- S. cerevisiae FAS1 and FAS2 genes encode the amino acid sequences of SEQ ID NO's:
- a gene to be modified for reducing or eliminating the initial steps of fatty acid biosynthesis in which acetyl-CoA is consumed preferably is a gene encoding a amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to at least one of SEQ ID NO's: 11 and 12.
- fatty acid synthetase activity preferably is reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in expression, at least under anaerobic conditions.
- Methods for reducing or eliminating the fatty acid synthetase activity in the cell of the invention are as described above in 2.1 for pyruvate decarboxylase as target protein.
- the activity of the glyoxylate cycle is reduced or eliminated in the host cell.
- the activity of the glyoxylate cycle is preferably at least reduced in the host cell of the invention because this cycle is another pathway competing (at least under aerobic conditions) for cytosolic acetyl-CoA. Its activity can be reduced or abolished by directly addressing the corresponding genes (CIT2, ICL1, MLS1 and MDH3) or by down-regulating their expression via down-regulation of the genes encoding one or more of the transcription factors HAP2, HAP3, HAP4 and HAP5.
- At least one the S. cerevisiae preferably in a host cell of the invention, at least one the S. cerevisiae
- CIT2, ICL1, MLS1, MDH3, HAP2, HAP3, HAP4 and HAP5 genes or their orthologues in another species are modified to reduce or eliminate activity of the glyoxylate cycle in the host cell.
- the S. cerevisiae CIT2, ICL1, MLS1 and MDH3 genes respectively encode enzymes with citrate synthase, isocitrate lyase, malate synthase and (peroxisomal) NAD-dependent malate dehydrogenase activities, which enzymes have the amino acid sequences of SEQ ID NO's: 13, 14, 15 and 16, respectively.
- a gene to be modified for reducing or eliminating activity of the glyoxylate cycle in the host cell preferably is a gene encoding a amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to at least one of SEQ ID NO's: 13, 14, 15, 16, 17, 18, 19 and 20.
- the activity of the glyoxylate cycle is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in expression, at least under anaerobic conditions.
- Methods for reducing or eliminating the activity of the glyoxylate cycle in the cell of the invention are as described above in 2.1 for pyruvate decarboxylase as target protein.
- the specific pyruvate dehydrogenase activity is reduced or eliminated in the host cell.
- Endogenous pyruvate dehydrogenase activity is located in the mitochondria in yeast and catalyzes oxidative decarboxylation of pyruvate to form acetyl-CoA.
- Acetyl-CoA is used in the TCA cycle and in fatty acid biosynthesis.
- the pyruvate dehydrogenase enzyme is one enzyme of a multi-enzyme pyruvate dehydrogenase complex.
- Pyruvate dehydrogenase (EC 1.2.4.1) itself has alpha and beta subunits: encoded by the PDAI and PDBI genes, respectively, forming the El component.
- the complex includes an E2 core which has dihydrolipoamide acetyltransferase activity (EC 2.3.1.12) and E3 which has dihydrolipoamide dehydrogenase activity (ECl .8.1.4).
- E2 may be encoded by the LATI and E3 by LPDI genes.
- An additional complex protein is encoded by the PDXl gene.
- the pyruvate dehydrogenase complex may include the enzymes or subunits encoded by the PDAI, PDBI, LATI, LPDI, and PDXl genes. Any of the genes encoding pyruvate dehydrogenase complex enzymes of yeast may be modified to reduce pyruvate dehydrogenase activity in a yeast cell to prepare a strain of one embodiment of the invention.
- At least one the S. cerevisiae PDAI, PDBI, LATI, LPDI, and PDXl genes or their orthologues in another species are modified to reduce or eliminate pyruvate dehydrogenase activity in the host cell.
- the S. cerevisiae PDAI, PDBI, LATI, LPDI, and PDXl genes have the amino acid sequences of SEQ ID NO's: 21 , 22, 23, 24 and 25, respectively.
- a gene to be modified for reducing or eliminating pyruvate dehydrogenase activity in the host cell preferably is a gene encoding a amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to at least one of SEQ ID NO's: 21, 22, 23, 24 and 25.
- the pyruvate dehydrogenase activity is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in expression, at least under anaerobic conditions.
- Methods for reducing or eliminating the pyruvate dehydrogenase activity in the cell of the invention are as described above in 2.1 for pyruvate decarboxylase as target protein.
- the activity of mitochondrial pyruvate carriers is reduced or eliminated in the host cell in order to reduce or to avoid loss of pyruvate in the citric acid cycle.
- one or more of the S. cerevisiae MPCl, YIA6 and YEA6 genes is genetically modified, so as to reduce or eliminate the activity of mitochondrial pyruvate carriers in the cell.
- MPCl encodes a highly conserved subunit of the mitochondrial pyruvate carrier; a mitochondrial inner membrane complex comprised of Fmp37p/Mpclp and either Mpc2p or Fmp43p/Mpc3p mediates mitochondrial pyruvate uptake.
- YIA6 and YEA6 are members of the mitochondrial carrier subfamily and encode for a mitochondrial NAD + transporter, involved in the transport of NAD + and pyruvate into the mitochondria.
- At least one the S. cerevisiae MPCl, YIA6 and YEA6 genes or their orthologues in another species are modified to reduce or eliminate the activity of mitochondrial pyruvate carriers in the cell.
- the S. cerevisiae MPCl, YIA6 and YEA6 genes have the amino acid sequences of SEQ ID NO's: 26, 27 and 28, respectively.
- a gene to be modified for reducing or eliminating the activity of mitochondrial pyruvate carriers in the cell preferably is a gene encoding a amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to at least one of SEQ ID NO's: 26, 27 and 28.
- the host cell of the invention is genetically modified so as to reduce or eliminate transport of acetyl-CoA from cytosol into mitochondria. This is preferably achieved by reducing or eliminating the activity of the carnitine shuttle by genetically modifying at least one of the S. cerevisiae YAT1, YAT2 and CRC1 genes or their orthologue in another species.
- YAT1 encodes an outer mitochondrial carnitine acetyltransferase, minor ethanol- inducible enzyme involved in transport of activated acyl groups from the cytoplasm into the mitochondrial matrix.
- YAT2 encodes a carnitine acetyltransferase; has similarity to Yatlp, which is a carnitine acetyltransferase associated with the mitochondrial outer membrane.
- CRC1 encodes a mitochondrial inner membrane carnitine transporter, required for carnitine-dependent transport of acetyl-CoA from peroxisomes to mitochondria during fatty acid ⁇ -oxidation.
- At least one the S. cerevisiae YAT1, YAT2 and CRC1 genes or their orthologues in another species are modified to reduce or eliminate transport of acetyl-CoA from cytosol into mitochondria in the cell via the carnitine shuttle.
- the S. cerevisiae YAT1, YAT2 and CRC1 genes have the amino acid sequences of SEQ ID NO's: 29, 30 and 31, respectively.
- a gene to be modified for reducing or eliminating transport of acetyl-CoA from cytosol into mitochondria in the cell preferably is a gene encoding a amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to at least one of SEQ ID NO's: 29, 30 and 31.
- the transport of acetyl-CoA from cytosol into mitochondria in the cell is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in expression, at least under anaerobic conditions.
- the formation of glycerol as by-product is prevented or reduced by genetically modifying a plasma membrane channel involved in the efflux of glycerol from the host cell so as to reduce or eliminate its activity.
- Reduction of glycerol efflux from the cell leads to a decreased production of glycerol by feed-back regulation as glycerol accumulates within the cells, thereby reducing the carbon flux towards glycerol biosynthesis.
- the FSP1 gene encodes a aquaglyceroporin involved in efflux of glycerol.
- the FSP1 gene encoded aquaglyceroporin is a plasma membrane (glycerol) channel and a member of major intrinsic protein (MIP) family.
- the S. cerevisiae FSP1 gene is genetically modified to reduce or eliminate the efflux of glycerol from the cell.
- the S. cerevisiae FSP1 gene has the amino acid sequence of SEQ ID NO: 32, respectively. Therefore a gene to be modified for reducing or eliminating the activity of the plasma membrane channel involved in the efflux of glycerol from the cell, preferably is a gene encoding a amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to SEQ ID NO: 32.
- the efflux of glycerol from the cell is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in expression, under aerobic or anaerobic conditions.
- the cell of the invention has a genetic modification whereby NADH-dependent glycerol synthesis is eliminated or reduced.
- NADH-dependent glycerol synthesis is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction expression, at least under anaerobic conditions.
- NADH-dependent glycerol synthesis can be reduced or eliminated by reducing or eliminating in the cell at least one of the specific glycero 1-3 -phosphate dehydrogenase activity and the specific glycero 1-3 -phosphatase activity.
- the specific glycero 1-3 -phosphate dehydrogenase activity is reduced or eliminated in the host cell to prevent or reduce the formation of glycerol as by-product.
- Endogenous NAD-dependent glycero 1-3 -phosphate dehydrogenase is a key enzyme in glycerol synthesis.
- Glycerol 3-phosphate dehydrogenase or glycero lphosphate dehydrogenase (EC 1.1.1.8) catalyses the reduction of dihydroxyacetone phosphate to sn-glycerol 3-phosphate while oxidizing NADH to NAD + .
- Yeast strains may have one or more genes encoding NAD-dependent glycero 1-3 -phosphate dehydrogenase (GPD).
- GPD NAD-dependent glycero 1-3 -phosphate dehydrogenase
- GPD I and GPD2 are functional homologues for NAD-dependent glycero 1-3 -phosphate dehydrogenase.
- At least one the S. cerevisiae preferably in a host cell of the invention, at least one the S. cerevisiae
- GPD1 and GPD2 genes are genetically modified to reduce or eliminate the specific glycero 1-3 -phosphate dehydrogenase activity in the cell.
- the S. cerevisiae GPD1 and GPD2 genes have the amino acid sequences of SEQ ID NO's: 33 and 34, respectively. Therefore a gene to be modified for reducing or eliminating the glycero 1-3 -phosphate dehydrogenase activity in the cell, preferably is a gene encoding a amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to at least one of SEQ ID NO's: 33 and 34.
- the specific glycero 1-3 -phosphate dehydrogenase activity is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in expression, at least under anaerobic conditions.
- Methods for reducing or eliminating the glycero 1-3 -phosphate dehydrogenase activity in the cell of the invention are as described above in 2.1 for pyruvate decarboxylase as target protein.
- the host cell of the invention comprises a functional high-osmolarity glycerol response pathway.
- the S. cerevisiae GPD2 or its corresponding orthologue in another species is genetically modified for reducing or eliminating the glycero 1-3 -phosphate dehydrogenase activity in the cell, while in the S. cerevisiae GPD I or its corresponding orthologue in another species (as defined above) is functional and, preferably, not modified.
- the S. cerevisiae GPD1 gene is the stress- induced glycero lphosphate dehydrogenase of S.
- a host cell of the invention has at least one functional copy of a endogenous S. cerevisiae GPD1 or its corresponding orthologue in another species.
- the specific glycero 1-3 -phosphatase activity is reduced or eliminated in the host cell to prevent or reduce the formation of glycerol as by-product.
- S. cerevisiae glycero 1-3 -phosphatase activity is encoded by endogenous HOR2 and RHR2 genes.
- At least one the S. cerevisiae HOR2 and RHR2 genes, or at least one of their orthologues in another species, is genetically modified to reduce or eliminate the specific glycero 1-3 -phosphatase activity in the cell.
- the S. cerevisiae HOR2 and RHR2 genes have the amino acid sequences of SEQ ID NO's: 35 and 35, respectively.
- a gene to be modified for reducing or eliminating the glycero 1-3 -phosphatase activity in the cell preferably is a gene encoding a amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to at least one of SEQ ID NO's: 35 and 36.
- the specific glycero 1-3 -phosphatase activity is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in expression, at least under anaerobic conditions.
- Methods for reducing or eliminating the glycero 1-3 -phosphatase activity in the cell of the invention are as described above in 2.1 for pyruvate decarboxylase as target protein.
- the host cell is modified to de-repress catabolite (glucose) repressed genes by modification or inactivation of at least one of the endogenous SNF1 and MIG1 genes, or their orthologues.
- catabolite glycose
- the host cell preferably provides acetyl-CoA to feed into and drive the ⁇ - oxidation cycle in the reverse, i.e. biosynthetic direction.
- the acetyl-CoA is preferably provided in the cytosol of the host cell through metabolic conversion from pyruvate. In microbes, several routes occur for converting pyruvate into acetyl-CoA.
- the host cells of the invention preferably at least comprise one of the following routes for converting pyruvate into acetyl-CoA.
- Yeast has an endogenous pyruvate dehydrogenase.
- this enzyme complex is very slow and provides mitochondrial acetyl-CoA.
- heterologous pyruvate oxidoreductase or dehydrogenase is available for expression in the host cells of the invention, including enzymes which use NAD + , NADP + , ferredoxin or flavin as co-factors (EC 1.2.4.1, EC 1.2.1.51, EC 1.2.7.1).
- the heterologous pyruvate dehydrogenase expressed in the host cell uses the same co-factor as the co-factor that is used by the acyl-CoA dehydrogenase / transenoyl-CoA reductase (see 4.4 herein below).
- Suitable heterologous pyruvate dehydrogenases for expression in the host cells of the invention may be obtained from E. coli (aceE, aceF, and IpdA), Zymomonas mobilis (pdhA[alpha], pdhA[beta], pdhB, and lpd), S. aureus (pdhA, pdhB, pdhC, and lpd), Bacillus subtilis, Corymb acterium glutamicum, or Pseudomonas aeruginosa US20100062505 (US20100248233: NADP+ dependent enzyme is oxygen sensitive and is large multimeric enzyme.
- PDH-complex of Enterococcus faecalis is active under anoxic conditions (US20100062505).
- the yeast native PDH pyruvate dehydrogenase complex which uses NADH as co factor and which includes the enzymes or subunits encoded by the PDA1, PDB1, LAT1, LPD I, and PDX1 genes could also be used, when overexpressed in the cytosol, by deletion or inactivation of the mitochondrial targeting signals of each of the subunits and using promoters described in 1.2 above.
- Preferred pyruvate dehydrogenases are (acetyl-transferring) enzymes which use NADH as co-factor (EC 1.2.4.1). Nucleotide sequences encoding such enzymes can be derived e.g. from Enterococcus faecalis, Arabidopsis thaliana, Bos taurus, Corymb acterium glutamicum, Escherichia coli, Homo sapiens, Zymononas mobilis, Pseudomonas aeruginosa, Saccharomyces cerevisiae and Bacillus subtilis.
- Another route for converting pyruvate into acetyl-CoA that can be used in the host cells of the invention is the direct conversion of cytosolic acetaldehyde (produced from pyruvate by pyruvate decarboxylase activity in the cytosol) to acetyl-CoA by introduction of a heterologous acetylating (NAD + -dependent) acetaldehyde dehydrogenase (E.C. 1.2.1.10).
- cytosolic acetaldehyde produced from pyruvate by pyruvate decarboxylase activity in the cytosol
- NAD + -dependent heterologous acetylating
- An acetylating acetaldehyde dehydrogenases is also referred to as (CoA-acetylating) acetaldehyde :NAD -oxidoreductase or an acetyl-CoA reductase.
- the conversion of acetaldehyde into acetyl-CoA by the acetylating acetaldehyde dehydrogenase is reversible and runs in the direction of acetyl-CoA when acetaldehyde accumulates in the cytosol. Such an accumulation can e.g.
- ADH1 alcohol dehydrogenase
- ALD6 acetaldehyde dehydrogenase
- the heterologous acetaldehyde dehydrogenases for expression in the host cell of the invention preferably is a mono functional enzyme having only acetaldehyde dehydrogenase activity (i.e. an enzyme only having the ability to oxidize acetaldehyde into acetyl-CoA), such as e.g. the enzyme encoded by the E. coli mhpF gene, as opposed bifunctional enzymes with both acetaldehyde dehydrogenase and alcohol dehydrogenase activities, such as e.g. the bifunctional enzyme encoded by the E. coli adhE gene.
- a suitable heterologous gene for expressing a mono functional enzyme having only acetaldehyde dehydrogenase activity is e.g. the E. coli mhpF gene.
- a suitable exogenous gene coding for a mono functional enzyme with acetaldehyde dehydrogenase activity therefore comprises a nucleotide sequence coding for an amino acid sequence with at least 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 37 (the sequence of the E. coli mhpF gene).
- Suitable examples of prokaryotes comprising mono functional enzymes with acetaldehyde dehydrogenase activity are provided in Table 1.
- amino acid sequences of these mono functional enzymes are available in public databases and can be used by the skilled person to design codon-optimized nucleotide sequences coding for the corresponding mono functional enzyme such as e.g. coding sequence of the E. coli mhpF gene codon optimized for expression in S. cerevisiae as depicted in SEQ ID NO's: 38 or 74).
- Table 1 Enzymes with acetaldehyde dehydrogenase activity related to E. coli mhpF
- a further route for converting pyruvate into acetyl-CoA that can be used in the host cells of the invention is the direct conversion of pyruvate into acetyl-CoA by introduction into the host cell of expression of a heterologous pyruvate formate lyase.
- a pyruvate formate lyase is an enzyme with the ability to convert pyruvate and coenzyme-A into formate and acetyl-CoA catalyses the reaction (EC 2.3.1.54): pyruvate + coenzyme A (CoA) ⁇ acetyl-CoA + formate
- Such an enzyme is herein understood as an enzyme having pyruvate formate lyase activity and is referred to as a pyruvate formate lyase (PFL) or formate C- acetyltransferase .
- PFL pyruvate formate lyase
- a suitable heterologous gene coding for an enzyme with pyruvate formate lyase activity is e.g. a prokaryotic pyruvate formate lyase, such as the pyruvate formate lyase from E. coli.
- the E. coli pyruvate formate lyase is a dimer of PflB (encoded by pflB), whose maturation requires the activating enzyme PflAE (encoded by pflA), radical S- adenosylmethionine, and a single electron donor, which in the case of E. coli is flavodoxin (Buis and Broderick, 2005, Arch. Biochem. Biophys.
- a suitable heterologous gene coding for an enzyme with pyruvate formate lyase activity preferably comprises a nucleotide sequence coding for an amino acid sequence with at least 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 39 (the amino acid sequence of the E. coli PflB).
- SEQ ID NO: 39 the amino acid sequence of the E. coli PflB.
- Suitable examples of organisms comprising an enzyme with pyruvate formate lyase activity are provided in Table 2. Further examples of such organisms are listed by Lehtio and Goldman (2004, Prot. Engin. Design & Selection, 17:545-552).
- amino acid sequences of these enzymes are available in public databases and can be used by the skilled person to design codon-optimized nucleotide sequences coding for the corresponding enzyme with pyruvate formate lyase activity (see e.g. SEQ ID NO: 40 depicting the coding sequence of the E. coli pflB gene optimized for expression in S. cerevisiae).
- the host cell of the invention further preferably comprises a heterologous gene coding for the PflA activating enzyme for activation of the pyruvate formate lyase.
- the pyruvate formate lyase activating enzyme is herein understood as an enzyme that catalyses the reaction:
- the heterologous gene coding for the pyruvate formate lyase activating enzyme preferably comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 41.
- Suitable examples of organisms comprising an enzyme with pyruvate formate lyase activity are provided in Table 3.
- amino acid sequences of these enzymes are available in public databases and can be used by the skilled person to design codon-optimized nucleotide sequences coding for the corresponding enzyme with pyruvate formate lyase activity (see e.g. SEQ ID NO: 42, depicting the coding sequence of the E. coli pflA gene optimized for expression in S. cerevisiae).
- SEQ ID NO: 42 depicting the coding sequence of the E. coli pflA gene optimized for expression in S. cerevisiae.
- Table 3 Pyruvate formate lyase activating enzymes related to E.coli pflA
- the heterologous genes coding for the enzyme with pyruvate formate lyase activity and the pyruvate formate lyase activating enzyme are from the same donor organism, i.e. be homologous to each other.
- the exogenous genes coding for the enzyme with pyruvate formate lyase activity and the pyruvate formate lyase activating enzyme may also be from different donor organisms, i.e. be heterologous to each other.
- a preferred host cell expressing pyruvate formate lyase activity further comprises a genetic modification that increases the specific NAD + -dependent formate dehydrogenase activity in the cell to dispose of the potentially harmful formate that is produced by the pyruvate formate lyase.
- a NAD + -dependent formate dehydrogenase is herein understood as an enzyme that catalyses the reaction: formate + NAD + ⁇ C0 2 + NADH + H + (EC 1.2.1.2).
- a preferred gene encoding such a formate dehydrogenase whose activity is to be increased in the cell of the invention expressing heterologous pyruvate formate lyase activity is at least one of the endogenous S. cerevisiae FDH1 and FDH2 genes, or their orthologues in another species.
- the S. cerevisiae FDH1 is described by van den Berg and Steensma (1997, Yeast 13:551-559) and the S. cerevisiae FDH2 is described by Overkamp et al. (2002, Yeast 19:509-520).
- a gene encoding a formate dehydrogenase whose activity is to be increased in the cell of the invention preferably is a gene encoding a formate dehydrogenase having an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to at least one of SEQ ID NO's: 43 and 44.
- a heterologous formate dehydrogenase gene may be introduced into the cell in order to increase specific NAD + -dependent formate dehydrogenase activity in the cell, such as e.g. the FDH1 gene from Candida boidinii.
- the specific formate dehydrogenase activity is preferably increased by at least a factor 1.1, 1.2, 1.5, 2, 5, 10 or 20 as compared to a strain which is genetically identical except for the genetic modification causing the reduction in specific activity, preferably under anaerobic conditions.
- Formate dehydrogenase activity may be determined as described by Overkamp et al. (2002, supra).
- Formate dehydrogenase activity is decreased in the cell of the invention.
- Formate dehydrogenase activity is decreased in the cell by a genetic modification that reduces or eliminates expression of the above-defined formate dehydrogenase genes, using methods described in 2.1 above.
- Another preferred host cell expressing pyruvate formate lyase activity comprises a further genetic modification that reduces or eliminates endogenous pyruvate decarboxylase activity as described in 2.1 above.
- pyruvate decarboxylase acetyl-CoA synthetase and acetaldehyde dehydrogenase genes from other fungal and bacterial species can be expressed for the modulation of this pathway.
- a variety of organisms could serve as sources for (nucleotide sequences coding for) these enzymes, including, but not limited to, Saccharomyces sp., including S. cerevisiae mutants and S. uvarum, Kluyveromyces, including K. thermotolerans, K. lactis, and K. mandanus, Pichia, Hansenula, including H. polymorpha, Candidia, Trichosporon, Yamadazyma, including Y.
- pyruvate decarboxylase examples include those from Saccharomyces bay anus (1PYD), Candida glabrata, K. lactis (KIPDCl), or Aspergillus nidulans (PdcA), and acetyl-CoA synthetase from Candida albicans, Neurospora crassa, A. nidulans, or K.
- prokaryotic enzymes include, but are not limited to, E. coli, Z. mobilis, Bacillus sp., Clostridium sp., Pseudomonas sp., Lactococcus sp., Enterobacter sp. and Salmonella sp. Further enhancement of this pathway can be obtained through engineering of these enzymes for enhanced activity by site-directed mutagenesis and other evolution methods (which include techniques known to those of skill in the art).
- the acetyl-CoA synthetase that is expressed in the cell of the invention is a (heterologous) ADP-forming acetyl-CoA synthetase (EC 6.2.1.13), i.e. an acetyl-CoA synthetase which catalyzes the reaction:
- Such an ADP-forming acetyl-CoA synthetase only consumes one ATP molecule for each acetyl- CoA synthesized, instead of two ATP molecules as is done by the native yeast enzyme which hydro lyses ATP to AMP and pyrophosphate.
- the use of an ADP-forming acetyl-CoA synthetase thus avoids loss of energy by the formation of AMP + pyrophosphate.
- Examples of ADP-forming acetyl-CoA synthetases include those of Salmonella enterica, P. aeruginosa, Pyrococcus furiosus, Archaeoglobus fulgidus and Pyrobaculum islandicum.
- a preferred ADP-forming acetyl-CoA synthetase for expression in the cell of the invention is a variant of the Salmonella enterica acetyl-CoA synthetase (acssE), which acssE contains a point mutation (L641P) that prevents the enzyme from being inhibited by acetylation (Shiba et al. 2007; see SEQ ID NO. 45).
- a preferred ADP-forming acetyl-CoA synthetase that is expressed in the cell is an ADP-forming acetyl-CoA synthetase comprising an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to SEQ ID NO: 45.
- ADP-forming acetyl-CoA synthetase further has a mutation that prevents the enzyme from being inhibited by acetylation, such as a point mutation in a position corresponding to position 641 in SEQ ID NO: 45 in an alignment with SEQ ID NO: 45, preferably the point mutation is a mutation to a proline.
- a co don-optimized sequence is used for expression of the ADP-forming acetyl-CoA synthetase, such as SEQ ID NO: 76, a sequence encoding SEQ ID NO: 45 optimized for expression in S. cerevisiae.
- a heterologous acetaldehyde dehydrogenase is expressed in the cell which uses NAD + as co factor (instead of NADP + as the native yeast enzyme Ald6p does).
- NAD + as co factor
- a NAD + -dependent aldehyde dehydrogenase is expressed (optionally in combination with the inactivation of the endogenous yeast NADP + -dependent ALD6).
- a suitable NAD + -dependent aldehyde dehydrogenase is e.g. an enzyme encoded by the aid gene of Pseudomonas aeruginosa, or an orthologue thereof.
- a preferred NAD + -dependent aldehyde dehydrogenase that is expressed in the cell is an aldehyde dehydrogenase comprising an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to SEQ ID NO: 46.
- a co don-optimized sequence is used for expression of a NAD + -dependent aldehyde dehydrogenase, such as SEQ ID NO: 75, a sequence encoding the P. aeruginosa aid optimized for expression in S. cerevisiae.
- the host cell of the invention expresses enzymes of the fatty acid ⁇ -oxidation cycle.
- enzymes of the fatty acid ⁇ -oxidation cycle are understood to comprise one or more or all enzymes having at least the following activities:
- CoA molecule resp. an acetoacetyl-CoA thiolases and an acetoacetyl-CoA synthase
- acetoacetyl-CoA thiolases and/or that catalyses the synthesis of ⁇ -ketoacyl-CoA from acetyl-CoA and a higher acyl-CoA (3-ketoacyl-CoA thiolases) as defined in 4.1 and 4.5;
- the at least one or all of the enzymes of fatty acid ⁇ -oxidation cycle are preferably expressed in the absence of fatty acids and in the presence of a non-fatty acid carbon source.
- the at least one or all enzymes do not require the presence of fatty acids in the growth medium for expression and, preferably, the expression of the at least one or all enzymes is insensitive to catabolite (glucose) repression, i.e. the enzymes are expressed in the presence of source of glucose.
- the at least one or all enzymes are expressed at least under anoxic (anaerobic) and optionally also under oxic (aerobic) conditions. Examples of suitable promoters for the expressing the at least one or all enzymes are given in 1.2 above herein.
- the enzymes of the fatty acid ⁇ -oxidation cycle are expressed in the cytosol of the eukaryotic host cell.
- the enzymes of the fatty acid ⁇ -oxidation cycle are present in peroxisomes and/or in mitochondria.
- the at least one or all of the enzymes of fatty acid ⁇ - oxidation cycle are preferably expressed in the cytosol of the host cell. Therefore, preferably, the ⁇ -oxidation enzymes are expressed in the cell without any targeting signal, e.g. for entry into peroxisomes or mitochondria such peroxisomal targeting signals (PTS-1 or -2) or mitochondrial targeting signals.
- PTS-1 or -2 peroxisomal targeting signals
- Nucleotide sequences coding for ⁇ -oxidation enzymes originating from eukaryotes are therefore preferably modified so as to delete or inactivated the targeting signals on the enzyme.
- prokaryotic ⁇ -oxidation enzymes can be used that do not have any (cryptic) targeting signals.
- expression of ⁇ -oxidation enzymes in the absence of inducing substrates is effected by de-regulation of transcription factors involved in ⁇ - oxidation (ADR1, OAF I, PIP2) thus causing overexpression of yeast's endogenous ⁇ - oxidation enzymes (POT1, FOX2, POX1), which preferably have been modified to delete or inactivate their peroxisomal targeting signals (PTS-1 or -2).
- ADR1, OAF I, PIP2 transcription factors involved in ⁇ - oxidation
- POT1, FOX2, POX1 yeast's endogenous ⁇ - oxidation enzymes
- the invention relates to enzymes that condense acetyl-CoA either with another acetyl-CoA or with a higher acyl-CoA into a ⁇ -ketoacyl-CoA.
- thiolases are known as acetoacetyl-CoA thiolases (EC 2.3.1.9) or 3-ketoacyl- CoA thiolases (EC 2.3.1.16), respectively.
- Yeast own thiolase (POT1) has no isoenzymes, therefore the enzyme must be able to metabolize substrates of all chain- length (Mursula 2002).
- the yeast own enzyme could be used or as an alternative a heterologous enzyme could be used in case the yeasts enzyme exhibits poor conversion rate towards ⁇ -ketoacyl-CoA (acetoacetyl-CoA in case of C 4 ).
- acetoacetyl-CoA endogenous cytosolic ERG10 could be used as thiolase (as acetoacetyl-CoA thiolase for short chain products).
- the yeast POT I should be expressed without a functional N-terminal peroxisomal targeting sequence (PTS-2, peroxisome-targeting signal sequence) to enable cytosolic expression.
- an N-terminally truncated or mutated POT1 is expressed, as e.g. described in Glover et al. (1994, J. Biol. Chem. 269: 7558-7563) (SEQ ID NO: 47 depicts the POT1 encoded S. cerevisiae thiolase lacking the N-terminal 16 amino acid PTS-2).
- ketoacyl-thiolases occur within the mitochondria and within the peroxisomes. They differ with respect to their substrate and stereospecifity.
- the mitochondria contain two short- and medium chain specific 3-ketoacyl-CoA thiolases. One is specific for acetoacetyl-CoA and 2-methylacetoacetyl-CoA and the other for substrates ranging from C 6 to C 16 (Eaton et al, 1996, Biochem. J. 320:345-357).
- peroxisomes multiple enzyme iso forms exist (some inducible by peroxisome proliferators).
- Suitable nucleotide sequences coding for homologous or heterologous thiolases are available from a number of sources, for example, Escherichia coli (GenBank No.'s: NP-416728, NC-000913); Clostridium acetobutylicum (GenBank Nos: NP-349476.1; NC-003030; NP-149242; NC-001988), Bacillus subtilis (GenBank Nos: NP-390297; NC-000964), and Saccharomyces cerevisiae (GenBank Nos: ERG10: NP-015297; POT1 : EEU05467.1), C. acetobutylicum sp.
- Clostridium perfringens sp. e.g., protein ID ABG86544.1, ABG83108.1
- thermosaccharolyticum e.g., protein ID CAJ67900.1 or ZP-01231975.1
- Thermoanaerobacterium thermosaccharolyticum e.g., protein ID CAB07500.1
- Thermoanaerobacter tengcongensis e.g., AAM23825.1
- Carboxydothermus hydrogenoformans e.g., protein ID ABB13995.1
- Desulfotomaculum reducens MI-1 e.g., protein ID EAR45123.1
- Candida tropicalis e.g., protein ID BAA02716.1 or BAA02715.1
- Saccharomyces cerevisiae e.g., protein ID AAA62378.1 or CAA30788.1
- Bacillus sp. Megasphaera elsdenii
- Butryivibrio fibrisolvens e.g., Megasphaera elsdenii, and Butryivibrio fibrisolvens.
- S. cerevisiae thiolases could also be active in a heterologously expressed pathway (ScERGlO, POT1) (see e.g. US20100062505). Further suitable thiolase coding sequences are listed in US2008182308.
- a suitable gene coding for an enzyme with short chain specific thiolase activity for expression in a cell according to the invention is preferably derived from S. cerevisiae (ERG 10), E. coli (atoB), Ralstonia eutrophus (PhaA) and orthologues thereof comprising a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with at least one of SEQ ID NO: 48, 49 and 50 respectively.
- a suitable gene coding for an enzyme with broad chain-length specificity thiolase activity for expression in a cell according to the invention is preferably derive from S. cerevisiae (POT1) or E. coli (FadA) and comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 47 or 51, respectively.
- thiolases are encoded by the PhaA gene from Ralstonia eutrophus (Zhang et al. 2011, Curr. Op. Biotechnol, 22:775-783; Bond- Watts et al, 2011, Nat Chem Biol, 7:222-227) or the E. coli yqeF gene, which has an affinity for short chain substrates (Dellomonaco et al, 2011, supra).
- PhaA PhaA gene from Ralstonia eutrophus
- Curr. Op. Biotechnol, 22:775-783 Bond- Watts et al, 2011, Nat Chem Biol, 7:222-227
- E. coli yqeF gene which has an affinity for short chain substrates (Dellomonaco et al, 2011, supra).
- the invention relates to enzymes that reduce a ⁇ -ketoacyl- CoA into a trans-P-hydroxyacyl-CoA.
- Yeast's own hydroxyacyl-CoA dehydrogenase (FOX2) is a multifunctional peroxisomal enzyme catalyzing the D-specific hydroxyacyl-CoA dehydrogenase and D-specific enoyl-CoA hydratase activity.
- FOX2 catalyzes the same D-specific reactions as the mammalian MFE-2.
- the yeast FOX2 encoded hydroxyacyl-CoA dehydrogenase has no isoenzymes, therefore the enzyme must be able to metabolize substrates of a broad range of chain- lengths (Mursula, A., 2002, "A3-A2-Enoyl-CoA Isomerase from the yeast Saccharomyces cerevisiae. Molecular and structural characterization". Academic Dissertation, Faculty of Science, University of Oulu, FI,). Therefore, the yeast endogenous FOX2 encoded enzyme could be used or as an alternative a heterologous enzyme could be used in case the yeasts enzyme exhibits poor conversion rate towards trans-P-hydroxyacyl-CoA.
- the expression of the yeast FOX2 encoded enzyme is relocated from the peroxisome to the cytosol by expression of the enzyme without a functional peroxisome-targeting signal (PTS-1), i.e. the C-terminal tripeptide having the sequence SKL.
- PTS-1 peroxisome-targeting signal
- an C-terminally truncated or mutated FOX-2 encoded enzyme e.g. comprising an amino acid sequence as depicted in SEQ ID NO: 52 (the S. cerevisiae FOX2 lacking the C-terminal 3 amino acid PTS-1), or an orthologue thereof, is expressed in a cell of the invention.
- Heterologous hydroxyacyl-CoA dehydrogenases may be reduced NADH- dependent, with a substrate preference for (S)-3-hydroxyacyl-CoA or (R)-3- hydroxyacyyl-CoA and are classified as E.C. 1.1.1.35 and E.C. 1.1.1.30, respectively.
- 3-hydroxyacyyl-CoA dehydrogenases may be reduced NADPH- dependent, with a substrate preference for (S)-3-hydroxyacyl-CoA or (R)-3- hydroxyacyyl-CoA and are classified as E.C. 1.1.1.157 and E.C. 1.1.1.36, respectively.
- Suitable (nucleotide sequences coding for) heterologous 3-hydroxybutyryl-CoA dehydrogenase enzymes are available from a number of sources, for example, Clostridium acetobutylicum (GenBank NOs: NP-349314; NC-003030), B. subtilis (GenBank NOs: AAB09614; U29084), Ralstonia eutropha (GenBank NOs: YP- 294481; NC-007347), and Alcaligenes eutrophus (GenBank NOs: AAA21973; J04987). Suitable genes encoding 3-hydroxybutyryl-CoA dehydrogenases are also listed in US2008182308.
- nucleotide sequences coding for are enzymes homologous to the Clostridium acetobutylicum genes include, but are not limited to: Clostridium kluyveri, which expresses two distinct forms of this enzyme (Miller et al, J. Bacteriol. 138:99-104, 1979), and Butyrivibrio fibrisolvens, which contains a bhbd gene which is organized within the same locus of the rest of its butyrate pathway (Asanuma et al, Current Microbiology 51 :91-94, 2005; Asanuma at al, Current Microbiology 47:203-207, 2003).
- SCAD short chain acyl-CoA dehydrogenase
- Clostridium tetani E88 (NP-782952.1), Clostridium perfringens SM101 (YP-699558.1), Clostridium perfringens str. 13 (NP-563213.1), Clostridium saccharobutylicum (AAA23208.1), Clostridium beijerinckii NCIMB 8052 (ZP- 00910128.1), Clostridium beijerinckii (AF494018-5), and in Thermoanaerobacter tengcongensis MB4 (NP-622220.1), Thermoanaerobacterium thermosaccharolyticum (CAB04792.1), Alkaliphilus metalliredigenes QYMF (ZP-00802337.1) and E.
- a suitable gene for expression in a cell according to the invention and coding for an enzyme with 3-hydroxybutyryl-CoA dehydrogenase activity with higher specificity for short chain substrates preferably comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with at least one of SEQ ID NO: 53 (Hbd; C. acetobutylicum) and 54 (Hbd; C. beijerinckii).
- Suitable gene for expression in a cell according to the invention and coding for an enzyme with 3-hydroxybutyryl-CoA dehydrogenase activity with a broader chain- length specificity preferably comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 55 (fadB; E. coli) or 52 (FOX2; S. cerevisiae).
- the invention relates to enzymes that dehydrate a trans- ⁇ - hydroxyacyl-CoA into a trans-A2-enoyl-CoA.
- yeast's own enoyl-CoA hydratase is a multifunctional enzyme that has both D-specific hydroxyacyl-CoA dehydrogenase and D-specific enoyl-CoA hydratase activities and it has a broad chain-length specificity.
- the E.coli FadB gene encodes a bifunctional enzyme having both dehydrogenase and hydratase activities as well as a broad chain-length specificity. Therefore, for the production of longer chain products, i.e.
- a enoyl-CoA hydratase is expressed in the cell of the invention that is part of a multifunctional enzyme that also has hydroxyacyl-CoA dehydrogenase activity, such as described above in 4.2.
- a preferred nucleotide sequence coding for a multifunctional enzyme having hydroxyacyl-CoA dehydrogenase and enoyl-CoA hydratase activities and having a broader chain-length specificity is a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 55 (FadB; E. coli) or 52 (FOX2; S. cerevisiae), whereby the latter is relocated to the cytosol by deleting or inactivating its peroxisomal targeting signal.
- a separate heterologous enoyl- CoA hydratase or crotonase is expressed in the cell of the invention together with a separate 3-hydroxybutyryl-CoA dehydrogenase with short chain substrate specificity such as the Hbd enzymes from Clostridium having amino acid sequence identity with at least one of SEQ ID NO: 53 and 54, as defined above in 4.2.
- Such heterologous enoyl-CoA hydratases may have a substrate preference for (S)-3-hydroxyacyl-CoA or (R)-3-hydroxyacyl-CoA and are classified as E.C. 4.2.1.17 and E.C. 4.2.1.55, respectively.
- Suitable (nucleotide sequences coding for) enoyl-CoA hydratases are available from a number of sources, for example, E. coli (GenBank NOs: NP-415911; NC-000913), C acetobutylicum (GenBank NOs: NP-349318; NC- 003030), B.
- subtilis GenBank NOs: CAB13705; Z99113
- Aeromonas caviae GenBank NOs: BAA21816; D88825
- the crotonases or enoyl-CoA hydratases are enzymes that catalyze the reversible hydration of cis and trans enoyl-CoA substrates to the corresponding ⁇ -hydroxyacyl CoA derivatives.
- this step of the butanoate metabolism is catalyzed by EC 4.2.1.55, encoded by the crt gene (GenBank protein accession AAA95967, Kanehisa, Novartis Found Symp.
- a suitable gene coding for a separate heterologous enzyme with crotonase or enoyl-CoA hydratase activity preferably comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with at least one of SEQ ID NO: 56 (C. acetobutylicum crt) and 57 (C. beijerinckii crt).
- Such genes include, but are not limited to, Clostridium tetani E88 (NP-782956.1), Clostridium perfringens SM101 (YP- 699562.1), Clostridium perfringens str.
- Suitable genes are homologous genes from Fusobacterium nucleatum subsp. Vincentii (Q7P3U9-Q7P3U9_FUSNV), Clostridium difficile (P45361-CRT CLODI), Clostridium pasteurianum (P81357-CRT CLOPA), and Brucella melitensis (Q8YDG2-Q8YDG2 BRUME) (see e.g. US20100062505).
- the invention relates to enzymes that reduce a trans-A2- enoyl-CoA into an acyl-CoA.
- These enzymes may be either NADH- or NADPH- or flavoprotein dependent and are classified as E.C. 1.3.1.44, E.C. 1.3.1.38 or EC 1.3.8.1, respectively.
- trans-2-enoyl-CoA reductase or "TER” are understood herein to refer to enzymes that are capable of catalyzing the conversion of trans-2-enoyl-CoA to acyl- CoA.
- Acyl-CoA dehydrogenases or transenoyl-CoA reductases are available from a number of sources, for example, C. acetobutylicum (GenBank NOs: NP-347102); NC- 003030), Euglena gracilis (GenBank NOs: -AAW66853), AY741582), Streptomyces collinus (GenBank NOs: AAA92890; U37135), and Streptomyces coelicolor (GenBank NOs: CAA22721; AL939127). Further suitable genes are listed in e.g. US2008182308.
- transenoyl-CoA reductases include, but are not limited to, the enzymes from Clostridium tetani E88 (NP-782955.1 or NP-781376.1), Clostridium perfringens str. 13 (NP-563216.1), Clostridium beijerinckii (AF494018-2), Clostridium beijerinckii NCIMB 8052 (ZP-00910125.1 or ZP-00909697.1), and Thermoanaerobacterium thermosaccharolyticum (CAB07496.1), Thermoanaerobacter tengcongensis MB4 (NP- 622217.1).
- TER trans-2-enoyl-CoA reductase
- BLAST BLAST
- TER proteins include, but are not limited to Euglena spp. including, but not limited to, E. gracilis, Aeromonas spp. including, but not limited, to A. hydrophila, Psychromonas spp. including, but not limited to, P. ingrahamii, Photobacterium spp. including, but not limited, to P. profundum, Vibrio spp. including, but not limited, to V. angustum, V.
- cholerae V alginolyticus, V parahaemolyticus, V vulnificus, V fischeri, V spectacularus, Shewanella spp. including, but not limited to, S. amazonensis, S. woodyi, S. frigidimarina, S. paeleana, S. baltica, S. denitrificans, Oceanospirillum spp., Xanthomonas spp. including, but not limited to, X oryzae, X campestris, Chromohalobacter spp. including, but not limited, to C. salexigens, Idiomarina spp. including, but not limited, to /.
- baltica Pseudoalteromonas spp. including, but not limited to, P. atlantica, Alteromonas spp., Saccharophagus spp. including, but not limited to, S. degradans, S. marine gamma proteobacterium, S. alpha proteobacterium, Pseudomonas spp. including, but not limited to, P. aeruginosa, P. putida, P. fluorescens, Burkholderia spp. including, but not limited to, B. phytofirmans, B. cenocepacia, B. cepacia, B. ambifaria, B. vietnamensis, B. multivorans, B.
- Methylbacillus spp. including, but not limited to, M. flageliatus, Stenotrophomonas spp. including, but not limited to, S. maltophilia, Congregibacter spp. including, but not limited to, C. litoralis, Serratia spp. including, but not limited to, S. proteamaculans, Marinomonas spp., Xytella spp. including, but not limited to, X fastidiosa, Reinekea spp., Colweffia spp. including, but not limited to, C. psychrerythraea, Yersinia spp. including, but not limited to, Y.
- TER enzymes are chosen that use the same co-factor as the (heterologous) pyruvate dehydrogenase (see 3.1 above).
- Suitable NADH-dependent enzymes are e.g. the TER enzymes from Treponema denticola (NP_971211; SEQ ID NO: 58) and Euglena gracilis (AAW66853; SEQ ID NO: 59), of which the TER encode by the gene from T. denticola is most preferred (Zhang et al 201 1 supra, Hu et al, 2013 Biochem J. 449(l):79-89).
- a suitable gene coding for an enzyme with transenoyl-CoA reductase activity preferably comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with at least one of SEQ ID NO: 58 ( T. denticola) and 59 (E. gracilis).
- SEQ ID NO: 58 T. denticola
- E. gracilis E. gracilis
- acetoacetyl-CoA instead of or in addition to using the direct condensation of acetyl-CoA by a thiolase (see 4.1. above), an alternative route is used for generation acetoacetyl-CoA through the ATP-driven malonyl-CoA synthesis as described by Lan and Liao (2012, Proc. Natl. Acad. Sci. 109:6018-6023).
- ATP is used to drive the thermodynamically unfavorable condensation of two acetyl-coA molecules to acetoacetyl-CoA.
- the host cell expresses enzymes that catalyze ATP-driven malonyl-CoA synthesis and decarboxylative carbon chain elongation to drive the carbon flux into the formation of acetoacetyl-CoA, which then further undergoes the reverse ⁇ -oxidation to synthesize butyryl-CoA and/or subsequent higher acyl-CoA's.
- the host cell therefore expresses or overexpresses an acetyl-CoA carboxylase (Acc), which synthesizes malonyl-CoA from acetyl-CoA, HCO 3 and ATP.
- Acc acetyl-CoA carboxylase
- a suitable acetyl-CoA carboxylase for expression in the cell of the invention is e.g. (overexpression of) the Saccharomyces cerevisiae ACC1 gene (DAA10557; SEQ ID NO 10) or the Homo sapiens ACC1 (Q13085; SEQ ID NO 60.
- a preferred gene coding for an enzyme with acetyl-CoA carboxylase activity for expression in a cell of the invention preferably comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with at least one of SEQ ID NO's: 10 and 60. It is therefore understood that in this embodiment, preferably, the endogenous acetyl-CoA carboxylase in the host cell is not reduced or eliminated (see 2.5 above).
- the host further expresses an enzyme with acetoacetyl-CoA synthase activity, which catalyses the decarboxylative condensation of acetyl-CoA and malonyl-CoA to form acetoacetyl-CoA.
- a suitable acetoacetyl-CoA synthase is e.g. the Streptomyces sp. CL190 nphT7 gene encoded acetyl-CoA:malonyl-CoA acyltransferase (AB540131 ; SEQ ID NO 61).
- a preferred gene coding for an enzyme with acetoacetyl-CoA synthase activity for expression in a cell of the invention preferably comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 61.
- a thiolase with broad chain-length specificity preferably, in addition also a thiolase with long chain-length specificity (i.e. C 6 and longer), is expressed in accordance with 4.1 above,.
- the invention relates to termination enzymes, which are expressed in the cells of the invention to branch products off from the reverse ⁇ - oxidation cycle for the production of specific products, such as fatty acids, 1 -alcohols, ⁇ -ketoacids, ⁇ -ketoalcohols, ⁇ -hydroxy acids, 1,3-diols, trans-A 2 -fatty acids, alkenes, alkanes and derivatives thereof, whereby the chain-length specificity of the termination enzyme can determine the chain-length of the final product.
- Preferred termination enzymes are enzymes for the production of 1 -alcohols, preferably 1 -alcohols other than methanol and ethanol, such as e.g. butanol, decanol, dodecanol and higher 1 -alcohols.
- the invention relates to enzymes that catalyze the conversion of acyl-CoA to an alcohol.
- the enzyme catalyses the conversion into alcohols with (linear) chains longer than C 2 , preferably at least C 4 .
- a preferred enzyme that catalyzes the conversion of acyl-CoA to an aldehyde is an enzyme that uses NADH or NADPH as co factor (EC 1.2.1.10 or EC 1.2.1.57). It is understood herein that in order to maintain a proper redox-balance either one of an NADH- or NADPH-dependent aldehyde dehydrogenases may be chosen in the host cell of the invention, depending on the co-factor dependencies of other enzymes expressed in the cell.
- a suitable aldehyde dehydrogenases is e.g. encoded by the E.
- coli mhpF gene (GenBank No CAA70751; SEQ ID NO: 37 encoded by the codon optimized SEQ ID NO's: 38 or 74) and orthologues thereof as defined in 3.2.
- aldehyde dehydrogenases may be derived from Clostridium beijerinckii (GenBank NOs: AAD31841), AF157306 and C acetobutylicum (GenBank NOs: NP- 149325), NC-001988). Further suitable genes are listed in US2008182308.
- a preferred enzymes that catalyze the conversion of an aldehyde to a 1 -alcohol uses either NADH or NADPH as cofactor.
- NADH or NADPH as cofactor.
- either one of an NADH- or NADPH-dependent alcohol dehydrogenases may be chosen in the host cell of the invention, depending on the co-factor dependencies of other enzymes expressed in the cell.
- Alcohol dehydrogenases are available from, for example, E. coli (fucO) (GenBank No YP_002927733; SEQ ID NO.
- C acetobutylicum (GenBank NOs: NP-149325, NC- 001988; which enzyme possesses both aldehyde and alcohol dehydrogenase activity); NP-349891 , NC-003030; and NP-349892, NC-003030 and E. coli (GenBank NOs: NP- 417-484, NC-000913).
- AdhE2 of C. acetobutylicum may be less preferred because it is oxygen sensitive.
- a suitable gene coding for an enzyme with NADH-dependent alcohol dehydrogenases activity preferably comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 62 (E. coli fucO) or 63 (C. acetobutylicum adhE2).
- C acetobutylicum aldehyde/alcohol dehydrogenase include without limitation Clostridium tetani E88 (NP-781989.1), Clostridium perfringens str. 13 (NP-563447.1), Clostridium perfringens ATCC 13124 (YP- 697219.1), Clostridium perfringens SM101 (YP-699787.1), Clostridium beijerinckii NCIMB 8052 (ZP-00910108.1), Clostridium acetobutylicum ATCC 824 (NP- 149199.1), Clostridium difficile 630 (CAJ69859.1), Clostridium difficile QCD-32g58 (ZP-01229976.1), and Clostridium thermocellum ATCC 27405 (ZP-00504828.1).
- BDH I Two suitable n-butanol dehydrogenases from C. acetobutylicum (BDH I, BDH II) have been purified, and their genes (bdhA, bdhB) cloned.
- GenBank accession for BDH I is AAA23206.1.
- GenBank accession for BDH II is AAA23207.1.
- BDH I utilizes NADPH as the cofactor, while BDH II utilizes NADH, which is more preferred.
- Even more preferred at least for the production of n-butanol is adhE2 gene of C acetobutylicum (GenBank accession #AF321779; SEQ ID NO: 63).
- a preferred gene coding for an enzyme for the production of n-butanol comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 63.
- Such homologues include, but are not limited to, Clostridium perfringens SM101 (YP-699787.1), Clostridium perfringens str. 13 (NP-563447.1), Clostridium perfringens ATCC 13124 (YP-697219.1), Clostridium tetani E88 (NP-781989.1), Clostridium beijerinckii NCIMB 8052 (ZP-00910108.1), Clostridium difficile QCD- 32g58 (ZP-01229976.1), Clostridium difficile 630 (CAJ69859.1), Clostridium acetobutylicum ATCC 824 (NP- 149325.1), and Clostridium thermocellum ATCC 27405 (ZP-00504828.1) (see e.g. US20100062505).
- NADH-dependent or NADPH-dependent butanol dehydrogenases (E.C. 1.1.1.1), which convert butylaldehyde to 1 -butanol, or bifunctional NADH-dependent or NADPH-dependent aldehyde/alcohol dehydrogenases (E.C. 1.1.1.1./1.2.1.10), which converts butyryl-CoA to 1 -butanol via butyraldehyde (see e.g. US20100248233).
- fatty acyl-CoA reductases can be use as termination enzyme.
- Fatty acyl-CoA reductases can be divided into two classes that differ with respect to the end-product synthesized, i.e. the aldehyde- and the alcohol- forming enzymes.
- Aldehyde-generating FAR catalyze a two- electron reduction of activated fatty acids, so that fatty aldehydes are formed.
- Such enzymes have been described in pea leaves, green algae and bacteria.
- the fatty aldehydes can be further reduced to fatty alcohols by fatty aldehyde reductases or can be involved in the biosynthesis of hydrocarbons.
- alcohol- forming FAR catalyze the reduction of activated fatty acids to fatty alcohols.
- This four-electron reduction takes place in two steps. In the first step an aldehyde is formed, that is subsequently reduced to a fatty alcohol in the second step.
- Proteins have been purified and genes encoding alcohol- forming FAR were identified in plants, mammals, insects, birds and protozoa. They usually require NADPH as electron donor but in certain organisms like Euglena gracilis NADPH can be substituted by NADH.
- the FAR in Euglena gracilis uses 14:0, 16:0 and 18:0 as substrates and requires NADH as cofactor. Functional analysis of EgFAR in yeast indicated that it could effectively convert 14:0 and 16:0 fatty acids to their corresponding alcohols. Compared with other biochemically characterized FARs, EgFAR possesses a narrower substrate range, only using saturated fatty acids with 14 and 16 carbon chains as substrates with the preferred fatty acid being 14:0 when expressed in yeast. (Teerawanichpan and Qiu, 2010, Lipids, 45(3):263-73).
- a preferred gene coding for a termination enzyme for the production of C 14 and/or C 16 alcohols comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 64.
- FAR genes for expression in the cells of the invention for the production of longer chains alcohols are described by Hellenbrand et al. (201 1 , BMC Biochem. 12:64) and include e.g. the bird fatty acyl-CoA reductases: AdFARl JN638548, AmFARl NP 001 180219.1 , AtCER4 NP 567936.5, AtFARl NP 197642.1 , AtFAR4 NP 190040.3, AtFAR5 NP 190041.2, AtFAR6 AEE79553.1 , AtFAR8 NP l 90042.2, AtMS2 AEE75132.1 , BmFAR NP 001036967.1 , EgFAR ADI60057.1 , FAR1 NP 001026350.1 , FAR2 XP 417235.2, HsFARl NP l 15604.1 , HsFAR2 NP 060569.3, MmFARl NP 080419.2, M
- a further suitable termination enzyme for producing longer chain alcohols is an iron-dependent, NAD + -dependent (long chain) aldehyde/alcohol dehydrogenase such as e.g. encoded by the E.coli yiaY gene.
- a preferred gene coding for a termination enzyme for the production of longer chains alcohols comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 65. 6.
- the invention thus pertains to a modified eukaryotic microbial host cell.
- the host cell preferably is modified to comprise: a) cytosolic expression of the enzymes of the fatty acid ⁇ -oxidation cycle, preferably, under anoxic conditions, in the absence of fatty acids and in the presence of a non-fatty acid carbon source; b) a metabolic route for producing under anoxic conditions and preferably in the cytosol, acetyl-CoA from the non- fatty acid carbon source to feed into and drive the ⁇ -oxidation cycle in the bio synthetic direction; and, c) expression of a termination enzyme to convert reaction intermediates of the ⁇ -oxidation cycle into at least one fermentation product selected from the group consisting of a fatty acid, a 1 -alcohol, a ⁇ -ketoacid, a ⁇ -ketoalcohol, a ⁇ -hydroxyacid, a 1,3-diol, a trans-A 2 -fatty acid, an alkene,
- the acetyl-CoA is produced in the cytosol from pyruvate by at least one of: the following routes A, B, C and D.
- the cell expresses a heterologous NAD + -dependent aldehyde dehydrogenase comprising an amino acid sequence with at least 45% amino acid sequence identity to SEQ ID NO: 46
- the cell expresses a heterologous ADP-forming acetyl-CoA synthetase comprising an amino acid sequence with at least 45% amino acid sequence identity to SEQ ID NO: 45
- the cell optionally, comprises a genetic modification that increases cytosolic pyruvate decarboxylase activity, and whereby the cell comprises a genetic modification that reduces or eliminates expression of endogenous ADHI gene or an orthologue thereof.
- the cell expresses a heterologous acetylating NAD + -dependent acetaldehyde dehydrogenase comprising an amino acid sequence with at least 55% amino acid sequence identity to SEQ ID NO: 37, and whereby the cell comprises a genetic modification that reduces or eliminates expression of endogenous ADHI gene or an orthologue thereof and a genetic modification that reduces or eliminates expression of endogenous ALD6 gene or an orthologue thereof.
- the cell expresses a heterologous pyruvate formate lyase comprising an amino acid sequence with at least 50% amino acid sequence identity to SEQ ID NO: 39, the cell expresses a heterologous pyruvate formate lyase activating enzyme comprising an amino acid sequence with at least 45% amino acid sequence identity to SEQ ID NO: 41, and whereby the cell comprises a genetic modification that reduces or eliminates expression of at least the endogenous PDC1 and PDC5 genes or orthologues thereof, and the cell, optionally, comprises a genetic modification that increases formate dehydrogenase activity.
- the cell expresses a heterologous NAD + -dependent acetyl-transferring pyruvate dehydrogenase and whereby the cell comprises a genetic modification that reduces or eliminates expression of at least the endogenous PDCl and PDC5 genes or orthologues thereof.
- a modified cell according to the invention further preferably comprises one or more genetic modifications selected from the group consisting of: a) a genetic modification that reduces or eliminates fatty acid synthesis; b) a genetic modification that reduces or eliminates activity of the glyoxylate cycle; c) a genetic modification that reduces or eliminates activity of the tricarboxylic acid cycle; d) a genetic modification that reduces or eliminates transport of pyruvate into mitochondria; e) a genetic modification that reduces or eliminates transport of acetyl-CoA into mitochondria; f) a genetic modification that reduces or eliminates transport of glycerol; and g) a genetic modification that reduces or eliminates NADH-dependent glycerol synthesis.
- the genetic modification is a modification that reduces or eliminates the expression of one or more of the S. cerevisiae FAS1, FAS2, ACC1, IN02, IN04 genes or orthologues thereof; b) the genetic modification is a modification that reduces or eliminates the expression of one or more of CIT2, ICL1, MLS1, MDH3, HAP2, HAP 3, HAP4 and HAP5 genes or orthologues thereof; c) the genetic modification is a modification that reduces or eliminates the expression of one or more of the S. cerevisiae PDA1, PDB1, LAT1, LPD1, and PDX1 genes or orthologues thereof; d) the genetic modification is a modification that reduces or eliminates the expression of one or more of the S.
- the genetic modification is a modification that reduces or eliminates the expression of one or more of the S. cerevisiae YAT1, YAT2 and CRC1 genes or orthologues thereof; f) the genetic modification is a modification that reduces or eliminates the expression of the S. cerevisiae FPS1 gene or an orthologues thereof; and, g) the genetic modification is a modification that reduces or eliminates the expression of one or more of the S. cerevisiae GPD1, GPD2, HOR2 and RHR2 genes or orthologues thereof.
- the enzymes of the fatty acid ⁇ - oxidation cycle are expressed preferably in the cytosol, and preferably from promoters that are insensitive to catabolite repression.
- the modified cell is a cell for producing fermentation products with a short chain-length, such as e.g. no more than C 8 , C 6 or C 4 .
- the enzymes of the fatty acid ⁇ - oxidation cycle include: a) a thiolase with a short chain-length specificity, whereby, preferably, the thiolase comprises an amino acid sequence with at least 45% amino acid sequence identity with at least one of SEQ ID NO's: 48, 49 and 50; b) an enzyme with 3-hydroxybutyryl-CoA dehydrogenase activity, whereby, preferably, the 3- hydroxybutyryl-CoA dehydrogenase comprises an amino acid sequence with at least 45% amino acid sequence identity with at least one of SEQ ID NO's: 53 and 54; c) a crotonase, whereby, preferably, the crotonase comprises an amino acid sequence with at least 45% amino acid sequence identity with at least one of SEQ ID NO's: 56 and 57; and, d) a NADH-dependent trans-2-enoyl-CoA reductase, whereby, preferably, the trans-2-eno
- the modified cell is a cell for producing fermentation products with a longer chain-length, such as e.g. at least C 6 , C 8 , or C 10 .
- the enzymes of the fatty acid ⁇ -oxidation cycle include: a) at least one of a peroxisomal thiolase that lacks a functional peroxisomal targeting signal and a heterologous thiolase with a broad chain-length specificity, whereby, preferably, the thiolase comprises an amino acid sequence with at least 45% amino acid sequence identity with at least one of SEQ ID NO's: 47 and 51 ; b) at least one of a peroxisomal enzyme with hydroxyacyl-CoA dehydrogenase and enoyl-CoA hydratase activities that lacks a functional peroxisomal targeting signal and a heterologous enzyme with hydroxyacyl-CoA dehydrogenase and enoyl-CoA hydratase activities with a broad chain
- a modified cell according to the invention can further comprise a) expression of an enzyme with acetyl-CoA carboxylase activity, whereby preferably the acetyl-CoA carboxylase comprises an amino acid sequence with at least 45% amino acid sequence identity with at least one of SEQ ID NO's: 10 and 60; and, b) expression of an enzyme with acetoacetyl-CoA synthase activity, which catalyses the decarboxylative condensation of acetyl-CoA and malonyl-CoA to form acetoacetyl-CoA, whereby preferably the acetoacetyl-CoA synthase comprises an amino acid sequence with at least 45% amino acid sequence identity with SEQ ID NO: 61.
- the cell can comprise this alternative route for producing acetoacetyl-CoA, in addition to but preferably as an alternative for the thiolase with short chain-length specificity in the event that products are produced not having a longer chain-length than C 4 .
- the alternative route for producing acetoacetyl-CoA is expressed in addition to the peroxisomal thiolase or the heterologous thiolase with a broad chain-length specificity, which are then needed for further rounds of the reverse ⁇ -oxidation cycle.
- a preferred modified cell of the invention is a cell for producing butanol, wherein the cell expresses termination enzymes that catalyze the conversion of butyryl- CoA via butaldehyde to butanol, whereby, preferably the enzymes are selected from: a) a NADH-dependent enzyme having both aldehyde and alcohol dehydrogenase, preferably comprising an amino acid sequence with at least 45% amino acid sequence identity with SEQ ID NO: 63; and, b) a NADH-dependent aldehyde dehydrogenase, preferably comprising an amino acid sequence with at least 55% amino acid sequence identity with SEQ ID NO: 37, expressed together with a NADH-dependent alcohol dehydrogenase preferably comprising an amino acid sequence with at least 45% amino acid sequence identity with SEQ ID NO: 62.
- Another preferred modified cell of the invention is a cell for producing an alcohol with a chain-length greater than C 6 and preferably including dodecanol, wherein the cell expresses termination enzymes having fatty acyl-CoA reductase activity, whereby, preferably the enzymes are selected from: a) a NADH-dependent alcohol forming fatty acyl-CoA reductase, preferably comprising an amino acid sequence with at least 45% amino acid sequence identity with SEQ ID NO: 64; and, b) an NADH-dependent alcohol dehydrogenase, preferably comprising an amino acid sequence with at least 45%) amino acid sequence identity with SEQ ID NO: 65.
- the cell further comprises a genetic modification that reduces or eliminates the production of the fermentation product (e.g. the 1 -alcohol) under oxic conditions.
- a cell wherein the production of the fermentation product is repressed under oxic conditions allows to separate a first propagation phase, wherein the modified cells are propagated under oxic conditions to efficiently produce biomass, from a second production phase, wherein the biomass of the modified cells obtained in the first propagation phase is fermented under anoxic conditions to produce the fermentation product (e.g. the 1 -alcohol).
- the advantage of such separation is that during the first oxic propagation phase the carbon and energy can be efficiently directed towards the formation of biomass because product formation is repressed, while during the second anoxic production phase, the carbon and energy can be efficiently directed towards the formation of the fermentation product while the biomass formation is minimal due to the anoxic conditions.
- the oxic and anoxic conditions of respectively the first and second phases of the process are preferably as herein defined above.
- the genetic modification that reduces or eliminates the production of the fermentation product (e.g. the 1 -alcohol) under oxic conditions preferably is a modification whereby the expression of at least one enzymatic activity required for the metabolism of pyruvate (via acetyl-CoA) to the fermentation product is controlled by an anoxic promoter (also known as an anaerobic or hypoxic promoter).
- Anoxic promoters are herein understood as promoter from hypoxic genes, i.e. genes that are repressed under oxic conditions and that are upregulated during adaptation to anaerobic growth.
- Suitable anoxic promoters for use in this embodiment of the cell of the invention include e.g. the S.
- S. cerevisiae ANB1 promoter SEQ ID NO: 73
- the promoters of the S. cerevisiae DAN and TIR genes e.g. one or more of the DAN1, TIR1, TIR3, and TIR4 gene promoters (see e.g. Sertil et al, 2007, Mol Cell Biol. 27(6): 2037-2047).
- anoxic promoters from orthologues of these genes in other species may equally be applied in this embodiment.
- Oxic and anoxic conditions may also be defined as those conditions under which the anoxic promoters used in a given cell of the invention are respectively repressed and derepressed.
- the enzymatic activity of which the expression is controlled by an anoxic promoter is selected from:
- Preferred enzyme activities to be controlled by an anoxic promoter include e.g. enzyme activities that are upstream in the metabolism from pyruvate to the product, such as e.g. pyruvate decarboxylase activity (e.g. one or more of the S. cerevisiae PDC1, PDC5, PDC6 and PDC2 genes may be operably linked to an anoxic promoter), or enzyme activities that are a rate- limiting activities in the metabolism from pyruvate to the product, such as e.g. thiolase activity and/or acetoacetyl-CoA synthase activity.
- enzyme activities that are upstream in the metabolism from pyruvate to the product such as e.g. pyruvate decarboxylase activity (e.g. one or more of the S. cerevisiae PDC1, PDC5, PDC6 and PDC2 genes may be operably linked to an anoxic promoter)
- the modified eukaryotic microbial host cell according to the invention preferably is a fungal cell, more preferably a yeast cell, and most preferably the cell is a cell of a yeast genus selected from the group consisting of Saccharomyces, Kluyveromyces, Candida, Pichia, Schizosaccharomyces, Hansenula, Kloeckera, Schwanniomyces, Yarrowia, Cryptococcus, Debaromyces, Saccharomycecopsis, Saccharomycodes, Wickerhamia, Debayomyces, Hanseniaspora, Ogataea, Kuraishia, Komagataella, Metschnikowia, Williopsis, Nakazawaea, Torulaspora, Bullera, Rhodotorula, and Sporobolomyces.
- Saccharomyces Kluyveromyces
- Candida Pichia
- Schizosaccharomyces Hansenula
- Kloeckera
- the cell is a cell of a yeast species selected from the group consisting of Saccharomyces cerevisiae, S. exiguus, S. bay anus, S. delbriickii, S. italicus, S. ellipsoideus, S. fermentati, S. kluyveri, S. krusei, S. lactis, S. marxianus, S. microellipsoides, S. montanus, S. norbensis, S. oleaceus, S. paradoxus, S. pastorianus, S. pretoriensis, S. rosei, S. rouxii, S. uvarum, S.
- yeast species selected from the group consisting of Saccharomyces cerevisiae, S. exiguus, S. bay anus, S. delbriickii, S. italicus, S. ellipsoideus, S. fermentati, S. kluyveri, S. krusei
- a preferred modified cell of the invention has the ability to grow on a hexose, preferably glucose, at a rate of at least 0.01, 0.02, 0.05, 0.1 , 0.2, 0.25 or 0.3 h "1 under at least one of aerobic and anaerobic conditions.
- the invention relates to the use of a cell according to the invention for the preparation of at least one fermentation product that is or is derived from an intermediate in the ⁇ -oxidation cycle with a carbon chain-length of at least C 4 , whereby, preferably, the fermentation product is selected from the group consisting of a fatty acid, a 1 -alcohol, a ⁇ -ketoacid, a ⁇ -ketoalcohol, a ⁇ -hydroxyacid, a 1,3-diol, a trans-A 2 -fatty acid, a trans- ⁇ 2 - fatty acid, an alkene, an alkane and derivatives thereof, more preferably the fermentation product is a 1 -alcohol other than methanol and ethanol, such as e.g. butanol, decanol, dodecanol and higher 1 -alcohols or a derivative thereof.
- the cell according to the invention is preferably used to produce the fermentation product in a anoxic process as defined
- the invention relates to processes for the production of these compounds by the host cells of the invention.
- the invention relates to a process for producing at least one fermentation product that is or is derived from an intermediate in the ⁇ -oxidation cycle with a carbon chain-length of at least C 4 , or wherein, more preferably, the fermentation product is selected from the group consisting of a fatty acid, a 1 -alcohol, a ⁇ -ketoacid, a ⁇ -ketoalcohol, a ⁇ -hydroxyacid, a 1,3-diol, a trans- ⁇ 2 - fatty acid, a trans- ⁇ 2 - fatty acid, an alkene and derivatives thereof.
- the fermentation product is a 1 -alcohol other than methanol and ethanol, such as e.g. butanol, decanol, dodecanol and higher 1 -alcohols or a derivative thereof.
- the process preferably, comprises the step of: a) fermenting a medium with a cell according to the invention, preferably under anoxic conditions, whereby the medium contains or is fed with a non- fatty acid carbon source and whereby the yeast cell ferments the non-fatty acid carbon source to the fermentation product.
- the yeast cell preferably is a (host) cell as herein defined above.
- the process preferably comprises a further step wherein the fermentation product is recovered.
- the process may be a batch process, a fed-batch process or a continuous process as are well known in the art.
- the non-fatty acid carbon source preferably at least comprises a source of hexoses or multimers of hexoses that are assimilable by the cell, e.g. a yeast cell.
- a source of hexoses or multimers of hexoses that are assimilable by the cell, e.g. a yeast cell.
- assimilable hexoses or multimers thereof include e.g. glucose, fructose, galactose, mannose, maltose, saccharose, lactose and maltodextrines.
- the source of hexose comprises or consists of at least glucose.
- the medium fermented by the cells of the invention comprises or is fed with (fractions of) hydrolyzed biomass comprising at least one at least a hexose such as glucose.
- biomass is understood to mean the biodegradable fraction of products, waste and residues from biological origin from agriculture (including vegetal, such as crop residues, and animal substances), forestry (such as wood resources) and related industries including fisheries and aquaculture, as well as biodegradable fraction of industrial and municipal waste, such as municipal solid waste or wastepaper.
- the biomass is plant biomass, more preferably a fermentable hexose/glucose/sugar-rich biomass, such as e.g. sugarcane, a starch-containing biomass, for example, wheat grain, or corn straw.
- plant biomass is cereal grains, such as corn, wheat, barley or mixtures thereof.
- hydrolyzed biomass to be fermented in the processes of the invention is e.g. hydrolyzed cereal biomass.
- Methods for hydrolysis of biomass such as cereal are known in the art per se and include e.g. vapor and enzymes such as glucoamylases.
- Another example of hydrolyzed biomass to be fermented in the processes of the invention is e.g. hydrolyzed sugarcane biomass.
- Methods for hydrolysis of biomass such as sugarcane are also known in the art per se and include e.g. vapor.
- the sources of glucose may be glucose as such (i.e. as monomeric sugars) or it may be in the form of any carbohydrate oligo- or polymer comprising glucose units, such as e.g. sugar cane, starch and the like.
- appropriate carbohydrases such as glucanases, amylases, and the like
- the modified host cell may be genetically engineered to produce and excrete such carbohydrases.
- the fermentation medium will further comprise the appropriate ingredients required for growth of the modified host cell.
- Compositions of fermentation media for growth of eukaryotic microorganisms such as yeasts are well known in the art.
- the fermentation process may be an oxic (aerobic) or an anoxic (anaerobic) fermentation process.
- the process of the invention is an anoxic (anaerobic) fermentation process.
- An anaerobic fermentation process is herein defined as a fermentation process run in the absence of oxygen or in which substantially no oxygen is consumed, preferably less than 5, 2.5 or 1 mmol/L/h, more preferably 0 mmol/L/h is consumed (i.e. oxygen consumption is not detectable), and wherein organic molecules serve as both electron donor and electron acceptors.
- NADH produced in glycolysis and bio mass formation cannot be oxidized by oxidative phosphorylation.
- microorganisms use pyruvate or one of its derivatives as an electron and hydrogen acceptor thereby regenerating NAD + .
- reduced fermentation products such as ethanol, glycerol as well as other fermentation products, such as e.g. the 1 -alcohols described herein, have to be produced in order to maintain a balanced NAD + from NADH redox situation.
- Anaerobic processes of the invention are preferred over aerobic processes because anaerobic processes do not require investments and energy for aeration and in addition, anaerobic processes produce higher product yields than aerobic processes.
- the fermentation process is preferably run at a temperature that is optimal for the modified cells of the invention.
- the fermentation process is performed at a temperature which is less than 42°C, preferably less than 38°C.
- the fermentation process is preferably performed at a temperature which is lower than 35, 33, 30 or 28°C and at a temperature which is higher than 20, 22, or 25°C.
- the volumetric productivity of the fermentation product preferably is at least 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 5.0 or 10.0 g fermentation product per liter per hour.
- the yield of the fermentation product on glucose in the process preferably is at least 50, 60, 70, 80, 90, 95 or 98%.
- the yield is herein defined as a percentage of the theoretical maximum yield on glucose, which is for the following products in gram product per gram glucose:
- the fermentation process according to the invention is a two-stage process comprising a first oxic propagation phase, wherein biomass of the cell of the invention is produced, and a second anoxic production phase, wherein the biomass obtained in the first oxic propagation phase is used to inoculate, or for fermentation in, the second anoxic production phase.
- a cell according to the invention is used comprising a genetic modification that reduces or eliminates the production of the 1 -alcohol under oxic conditions as described above.
- the first oxic propagation phase may be a conventional (oxic) process for the production of yeast biomass as is generally known in the art of yeast production.
- the (yeast) biomass obtained in the first oxic process may optionally be dried and/or stored prior to use in the second anoxic production process.
- the two phases i.e. the oxic propagation phase and the anoxic production phase, may be performed at different locations.
- yeast biomass produced at a first yeast production location may be transported, optionally after drying and/or storage of the yeast biomass, to a second production location to inoculate a medium for the second anoxic production of the fermentation product such as the 1 -alcohol.
- Figure 1 A general pathway overview of a engineered yeast cell (e.g. S. cerevisiae) according to the invention wherein glucose is metabolized via pyruvate to acetyl-CoA to feed into a reversed ⁇ -oxidation cycle that is expressed in the cytosol of the yeast cell.
- a engineered yeast cell e.g. S. cerevisiae
- glucose is metabolized via pyruvate to acetyl-CoA to feed into a reversed ⁇ -oxidation cycle that is expressed in the cytosol of the yeast cell.
- Figure 3 Physical map of plasmid pSH47 (Guldener et al, 1996, Nucleic Acids Res., 24:2519-2524)
- Figure 4 Schematic depiction of expression cassette for expression of aldp A and ACS SE used for genomic integration into the S. cerevisiae FPS1 locus.
- Figure 5 Schematic depiction of expression cassette for expression of E. coli mhpF, used for genomic integration into the S. cerevisiae ALD6 locus
- Figure 6 Schematic depiction of expression cassette for expression of aldp A and ACS SE used for genomic integration into the S. cerevisiae HO locus.
- Figure 7 Physical map of plasmid pMA-C12-l as constructed in Example 6.
- Figure 8 Physical map of plasmid pMA-C4-l as constructed in Example 7.
- Figure 9 Physical map of plasmid pMA-T7-C4 as constructed in Example 8.
- Figure 10 Fermentation of strain CenPK 2a4 (Aadhl Afpsl Aald6::mhpF URA3) transformed with plasmids pMA-C4-l and pMA-T6-C4 in a 5L Labfors fermenter. Concentrations of cell dry weight (g/L), butanol ⁇ g/L), ethanol (mg/L), acetic acid (mg/L) and glycerol (mg/L) are indicated over time.
- Cell extracts for activity assays are prepared from exponentially growing aerobic or anaerobic batch cultures and analyzed for protein content as described by Abbot et al, (2009, Appl. Environ. Microbiol. 75 : 2320-2325).
- NAD + -dependent acetaldehyde dehydrogenase (EC 1.2.1.10) activity is measured at 30°C by monitoring the oxidation of NADH at 340 nm.
- the reaction mixture (total volume 1 ml) contains 50 mM potassium phosphate buffer (pH 7.5), 0.15 mM NADH and cell extract.
- the reaction is started by addition of 0.5 mM acetyl-Coenzyme A.
- the activity of pyruvate formate-lyase is estimated spectrophotometrically by recording the change in absorption at 340 nm at 35°C.
- the assay mixture of pyruvate formate-lyase contains 20 mM sodium pyruvate, 0.08 mM coenzyme A, 1 mM NAD, 6 mM sodium DL-malate, 2 mM dithiothreitol, 1.1 U of citrate synthase (pig heart, EC 4.1.3.7) per ml, 22 U of malate dehydrogenase (pig heart, EC 1.1.1.37) per ml, and cell- free extract in 100 mM potassium phosphate buffer (pH 7.6) (Takahashi et al, 1982, J.
- Thiolase activity is measured by monitoring the disappearance of acetoacetyl- CoA, corresponding to the thiolysis direction of the enzymatic reaction.
- the disappearance of acetoacetyl-CoA is monitored by the decrease in absorbance at 303 nm, which is the characteristic absorption band of an enolatecomplex formed by acetoacetyl-CoA with Mg 2+ .
- the reaction mixture contains 100 mM Tris-HCl, pH 8.0, 10 mM MgS04, 200 ⁇ acetoacetyl-CoA, 200 ⁇ CoA, and cell extract prepared as described above.
- a standard curve is constructed by measuring the absorbance of acetoacetyl-CoA at different concentrations with 10 mM Mg 2+ (Shen et al, 201 1, Appl Environ Microbiol, 77:2905-15).
- the hydroxyacyl-CoA dehydrogenase activity is measured by monitoring the decrease of absorption at 340 nm, corresponding to consumption of NADH.
- the reaction mixture contains 100 mM 3-(N-morpholino) propanesulfonic acid (MOPS), pH 7.0, 200 _M NADH, 200 ⁇ acetoacetyl-CoA, and crude cell extract. The reaction is initiated by the addition of the cell extract. (Shen et al., 2011, supra).
- the enoyl-CoA hydratase activity is measured by the decrease of absorption at
- the assay mixture contains 100 mM Tris-HCl pH 7.6, 100 ⁇ crotonyl-CoA, and the crude extract.
- the reaction is initiated by the addition of the cell extract.
- the standard curves for crotonyl-CoA and 3-hydroxybutyryl-CoA are constructed by measuring the absorbance of the two compounds at 263 nm at different concentrations. (Shen et al, 2011, supra).
- the trans enoyl-CoA reductase activity for crotonyl-CoA is measured at 340 nm.
- the reaction mixture contains 100 mM potassium phosphate buffer, pH 6.2, 200 ⁇ NADH, 200 ⁇ crotonyl-CoA, and crude extract.
- the reaction is initiated by the addition of the extract.
- the reaction mixture contains 1 mM NAD + , 0.4 mM butyryl-CoA, and crude extract in 100 mM Tris HC1, pH 7.5.
- the absorbance is monitored at 340 nm at 30°C.
- the reaction is initiated by the addition of the extract.
- the aldehyde and alcohol dehydrogenase activities of AdhE2 are measured by monitoring the decrease of absorbance at 340 nm corresponding to the consumption of NADH or NADPH.
- the reaction mixture contains 100 mM Tris-HCl, pH 7.5, 5 mM dithiothreitol (DTT), 300 ⁇ NADH, and 1 mM butyryl-CoA for the butyraldehyde dehydrogenase (BYDH) reaction and 50 mM butyraldehyde for the butanol dehydrogenase (BDH) reaction.
- the reaction is initiated by the addition of the extract. (Shen et al, 2011, supra).
- NADH assay A fluorescent NAD/NADH detection kit purchased from Cell Technology (Mountain View, CA) is used. Cells are harvested by centrifugation at 13,200 rpm at 4°C. The pellets are then resuspended with 0.2 ml of the NAD/NADH extraction buffer and 0.2 ml of the lysis buffer (provided). Lysis is allowed to proceed for 10 to 20 min at 60°C until the cell resuspension turns clear. The lysate is then centrifuged at 8,000 rpm for 5 min at 4°C. The supernatant is retrieved for subsequent NADH assays.
- the cell lysates are mixed with the enzyme and the fluorescent detection reagent provided in the kit.
- the reaction is allowed to proceed for 1 to 1.5 h at room temperature in the dark, and then readings are taken with excitation at 530 to 570 nm and emission at 590 to 600 nm.
- strain CEN.PK2-1C MATa; ura3-52; trpl-289; leu2-3,112; his3A 1; MAL2-8 C ; SUC2).
- Table 4 Overview of plasmids used for the strain construction (the plasmids are featured in the following Examples)
- Ec Escherichia coli
- Td Treponema denticola
- Sc Saccharomyces cerevisiae Clostridium acetobutylicum
- Eg Euglena gracilis
- Cb Clostridium beijerinckii.
- Table 5 Overview of basis strains for the strain construction (the construction of the strains is described in Examples 1 to 5).
- a deletion cassette is amplified from plasmid pUG6 (Guldener et al, 1996, Nucleic Acids Research, 24:2519-2524; Figure 2) via PCR with the following oligonucleotides:
- AGC ATA GGC CAC TAG TGG ATC TG-3' (SEQ ID NO: 67)
- the strain is cultivated on YE agar plates containing 200 ⁇ g/ml of geniticin for the selection of resistant cells (transformants carrying the deletion cassette instead of the adhl coding region).
- a deletion cassette is amplified from plasmid pUG6 (Guldener et al, 1996, supra; Figure 2) via PCR with the following oligonucleotides: FPSlcrelox fw:
- the sequential deletion of gene adhl and fpsl in one strain is accomplished by recovering the kanMX marker in the strain resulting from example 1 (adhl deletion strain) via the cre-recombinase procedure described by Guldener et al., (1996, supra) and transforming the resulting yeast strain with the fpsl deletion cassette (see above).
- the cre-recombinase procedure requires the transformation of the yeast strain with the plasmid pSH47 (see Figure 3), which carries the gene for the cre-recombinase. This enzyme is able to recombine the two loxP sites flanking the kanMX resistance gene.
- This recombination event leads to a loss of this marker gene leaving one loxP site at the target locus (in the present example locus adhl).
- the yeast strain is cultivated for at least 10 generations in WMVIII (Lang and Looman, 1995 Appl Microbiol Biotechnol, 44(1-2): 147-56) containing uracil. Colonies, which have lost the plasmid pSH47 are identified via counter selection on plates with 5- fluoroorotic acid and picked for further construction purposes.
- Example 3 Deletion of the gene FPSl and expression of the P. aeruginosa aldpA and S. enterica acssrjgenes
- the P. aeruginosa aldp A gene (codon optimized for yeast: SEQ ID NO: 75) and the S. enterica acss E gene are synthesized (codon optimized for yeast: SEQ ID NO: 76) at GenScript USA Inc. (www.genscript.com) in one cluster (gene cassette).
- the two genes are clustered according to Figure 4 with the URA3 marker gene for selection in yeast (the URA 3 coding region including 400 bp upstream and 200 bp downstream, for sequence see http ://www.
- yeastgenome.org/cgi- flanked by marker rescue sequences MR; for recovery of the URA3 marker via counter selection on plates containing 5-FOA; SEQ ID NO: 70
- Example 4 Deletion of the gene ALD6 and expression of the E. coli mhpF gene
- the E. coli mhpF gene is synthesized (codon optimized for yeast: SEQ ID NO: 74) at GenScript USA Inc. (www . enscript.com) in one cluster (gene cassette).
- Example 5 Expression of the genes P. aeruginosa aldpA and S. enterica acssgjn the HO locus
- the P. aeruginosa aldp A gene (codon optimized for yeast: SEQ ID NO: 75) and the S. enterica acss E gene are synthesized (codon optimized for yeast: SEQ ID NO: 76) at GenScript USA Inc. (www. enscript.com) in one cluster (gene cassette).
- the URA3 marker gene for selection in yeast the URA3 coding region including 400 bp upstream and 200 bp downstream, for sequence see: http://www.yeastgenome.org/
- Example 6 Expression of genes for the production of long chain compounds (e.g. C12) (with plasmid pMA-C12-l and pMA-C12-2
- the Ci2 gene cassette 1 is synthesized by GenScript USA Inc. (www. enscript.com) and cloned into plasmid pMA via the Kpnl restriction site resulting in plasmid pMA-C12-l; see Figure 7).
- the pMA vector comprises an ampicillin resistance gene and an origin of replication for replication in E. coli (for sequence of pMA see: SEQ ID NO: 71).
- a CEN/ARS sequence SEQ ID NO: 72
- TDH3 promoter and the TDH3 terminator are used (600 bp upstream and 300 bp downstream of the TDH3 coding region, for sequences see: http://www.yeastgenome.org/cgi-
- strains resulting from Examples 3, 4 and 5 are used for transformation with plasmid pMA-C 12-1.
- the corresponding yeast strains are transformed with pMA-C12-l via the lithium acetate method described by Gietz et al. (1992, supra) the strains are cultivated on WMVIII (Lang and Looman, 1995, supra) agar plates lacking leucine for the selection of leucine prototrophic strains (transformants carrying the plasmid pMA-C12-l).
- Example 6 Another variant of Example 6 is the construction and transformation of plasmid pMA-C12-2 in the corresponding yeast strains.
- This plasmid is analogous to plasmid pMA-C12-l except that POT1 (S. cerevisiae), FOX2 (S. cerevisiae) genes (both without PTS) are used instead of FadA (E. coli) and FadB (E. coli).
- the gene Ter T. denticola
- Example 7 Expression of genes for the production of short chain compounds (e.g. C4) (with plasmids pMA-C4-l and pMA-C4-2)
- the C4 gene cassette 1 is synthesized by GenScript USA Inc. (www.genscript.com) and cloned into plasmid pMA via the restriction site Kpnl resulting in plasmid pMA-C4-l; see Figure 8).
- the pMA vector comprises an ampicillin resistance gene and an origin of replication for replication in E. coli (for sequence of pMA please see SEQ ID NO: 71).
- the cassette contains in one cluster a CEN/ARS sequence (SEQ ID NO: 72) for autonomous replication and segregation in yeast, the LEU2 expression cassette for selection of positive transformants (the LEU2 coding region including 400 bp upstream and 200 bp downstream, for sequence see: http://www.yeastgenome.org/cgi- and codon optimized variants (codon optimized for S. cerevisiae) of the genes ERG10 (S. cerevisiae), Hbd (C. acetobutylicum), crt (C. acetobutylicum) and Ter (T. denticola).
- a CEN/ARS sequence SEQ ID NO: 72
- the LEU2 expression cassette for selection of positive transformants (the LEU2 coding region including 400 bp upstream and 200 bp downstream, for sequence see: http://www.yeastgenome.org/cgi- and codon optimized variants (codon optimized for S. cerevisiae) of the genes ERG10 (S. cere
- ERG10 For the expression of the ERG10 gene a modified (constitutive) version of the ADH1 promoter (SEQ ID NO: 77) and the TRPl terminator are used (300 bp downstream of the TRP l coding region, for sequences see: htt : 7www.yeastgenomc.org/cgi- while for expression of the Hbd gene the ENOl promoter and ENOl terminator are used (600 bp upstream and 300 bp downstream of the ENOl coding region, for sequences see: http://www.yeastgenome.org/cgi-
- strains resulting from Examples 3, 4 and 5 are used for transformation with plasmid pMA-C4-l .
- the corresponding yeast strains are transformed with pMA-C4-l via the lithium acetate method described by Gietz et al. (1992, supra) the strains are cultivated on WMVIII (Lang and Looman, 1995, supra) agar plates lacking leucine for the selection of leucine prototrophic strains (transformants carrying the plasmid pMA-C4-l).
- Example 7 Another variant of Example 7 concerns the construction and transformation of plasmid pMA-C4-2 in the corresponding yeast strains.
- This plasmid is analogous to plasmid pMA-C4-l except that atoB (E. coli), Hbd (C. beijerinckii), crt (C. beijerinckii)) and Ter (E. gracilis) genes are used instead of ERG10 (S. cerevisiae), Hbd (C. acetobutylicum), crt (C. acetobutylicum) and Ter ( T. denticola).
- ERG10 S. cerevisiae
- Hbd C. acetobutylicum
- crt C. acetobutylicum
- T. denticola T. denticola
- Plasmids pMA-T4-C12 and pMA-T5-C12 are used in combination with plasmids pMA-C12-l and pMA-C12-l (see Example 6) for the production of long chain compounds (in particular C 12 ) and plasmids pMA-T6-C4 and pMA-T7-C4 were used in combination with plasmids pMA-C4-l and pMA-C4-l (see Example 7) for production of short chain compounds (in particular C 4 ).
- E. gracilis FAR or E. coli yiaY or C. acetobutylicum adhE2 or E. coli mhpF+FucO are synthesized by GenScript USA Inc. (www.genscript.com) and cloned into plasmid pMA via the Kpnl restriction site resulting in plasmids pMA-T4-C12, pMA-T5-C12, pMA-T6-C4 and pMA-T7-C4 (see Figure 9 for pMA-T7-C4).
- the pMA vector comprises an ampicillin resistance gene and an origin of replication for replication in E.
- the cassettes contain in one cluster a CEN/ARS sequence (SEQ ID NO: 72) for autonomous replication and segregation in yeast, the HIS3 expression cassette for selection of positive transformants after transformation (the HIS3 coding region including 500 bp upstream and 200 bp downstream, for sequence see: http://www.yeastgenome.org/cgi- and codon optimized variants (codon optimized for S. cerevisiae) of the genes E. gracilis FAR or E. coli yiaY or C. acetobutylicum adhE2 or E. coli mhpF+FucO.
- the strains resulting from Examples 6 and 7 are used for transformation with plasmids pMA-T4-C12, pMA-T5-C12, pMA-T6-C4 and pMA-T7-C4.
- the strains were transformed via the lithium acetate method described by Gietz et al. (1992, supra) and were cultivated on WMVIII (Lang and Looman, 1995, supra) agar plates lacking histidine for the selection of histidine prototrophic strains (trans formants carrying plasmids pMA-T4-C12 or pMA-T5-C12 or pMA-T6-C4 or pMA-T7-C4).
- Example 10 Cultivation procedure for strain evaluation (growth and productivity) The standard cultivation procedure for the strains of the yeast Saccharomyces cerevisiae was:
- Strains with the genetic background of CEN.PK2-1C are auxotrophic for leucine, histidine, uracil and tryptophan. Therefore the medium was supplemented with leucine (400 mg/L), histidine (100 mg/L), uracil (100 mg/L) and tryptophan (100 mg/L) where necessary (to establish selection pressure on plasmids, plasmid containing strains were cultivated in medium lacking the corresponding supplement).
- Composition of WMVIII medium (for 1L); according to Lang and Looman, 1995: 50 g sucrose, 250 mg NH 4 H 2 P0 4 , 2,8 g NH 4 C1, 250 mg MgCl 2 x 6H 2 0, 100 mg CaCl 2 x 2H 2 0, 2 g KH 2 P0 4 , 550 mg MgS0 4 x 7H 2 0, 75 mg meso-Inositol and 10 g Na-glutamate.
- Trace elements lOOOx concentrated: 1,75 g ZnS0 4 x 7H 2 0; 0,5 g Fe 2 S0 4 x 7 H 2 0; 0,1 g CuS0 4 x 5 H 2 0; 0,1 g MnCl 2 x 4 H 2 0; 0,1 g NaMo0 4 x 2 H 2 0, (for one liter).
- Vitamin solution 25 Ox concentrated: 2,5 g Nicotinic acid; 6,25 g Pyridoxine; 2,5 g Thiamine; 0,625 g Biotine; 12,5 g Ca-Pantothenate, (for one liter).
- Example 11 Metabolite analysis (identification and quantification of n-alcohols and fatty acids)
- n-alcohols were conducted through gas chromatography- mass spectroscopy (GC-MS) following a modification of the method reported by Atsumi (2008).
- the analysis was performed on an AGILENT(TM) 6890 GC/5973 MS (AGILENT TECHNOLOGIES,(TM) Palo Alto, CA) instrument with a HP-5ms capillary column (30 m x 0.25 mm x 0.25 ⁇ ).
- AGILENT TECHNOLOGIES,(TM) Palo Alto, CA HP-5ms capillary column (30 m x 0.25 mm x 0.25 ⁇ ).
- 2 ml of culture broth (supernatant and cells) were mixed with 0.8 g of glass beads for cell disruption.
- HPLC high-performance liquid chromatography
- the temperature was then raised with a gradient of 15° C/min to 230° C and held for 4 min.
- Helium (1 ml min-1, MATHESON TRI-GAS,(TM) Longmont, CO) was used as the carrier gas.
- the injector and detector were maintained at 250° C. A 0.5- ⁇ 1 sample was injected in splitless injection mode.
- cell dry weight is determined by harvesting 3 x 6 ml of culture after the desired cultivation time. The culture is centrifuged at 3500 x g for 5 min. Afterwards, the cells are washed once with H 2 0 and the pellet is weighted by a scale after vacuum-drying for 12 h at 80 °C in a cabinet desiccator and cooling to room temperature in a dehydrator.
- Tables 6A, 6B and 6C present the results of shake flask fermentations (Tables
- Table 6A and 6B present the results of aerobic fermentations and Table 6C those of anaerobic fermentations) as obtained with the various background strains as indicated, and transformed with plasmids as indicated.
- Table 6 presents for each of the transformed strains the yields of biomass (cell dry weight) and product of interest (as indicated), as well as the yields of the by-products ethanol and glycerol, after 24 hours of cultivation.
- the strains were cultivated under the conditions described in Example 10.
- Strain CenPK 2a4 (Aadhl Afpsl Aald6::mhpF URA3) transformed with plasmids pMA-C4-l and pMA-T6-C4 was cultured in a 5L Labfors fermenter. The strain was precultured in 20 ml of WMVIII medium supplemented with 100 mg/L tryptophan in a 100 ml shaking flask were inoculated with 20 ⁇ of the corresponding glycerol stock (strain) and cultivated for 48 h at 30°C and 150 rpm on a rotary shaker.
- Example 14 Effects of deletions ⁇ 3 and ADH5 genes
- the ADH3 gene, the ADH5 gene, and both the ADH3 and ADH5 genes were inactivated by deleted in strain CenPK 2a4 (Aadhl Afpsl Aald6::mhpF URA3).
- the deleted strains were then transformed with transformed with plasmids pMA-C4-l and pMA-T6-C4 and tested in oxic shake flask fermentation as described in Examples 12. Metabolites were detected as described in Example 11. The results are presented in Table 7.
- ADH3 gene leads to an increased yield of product (butanol) and to a decrease in the formation of ethanol by-product as compared to the strain that has only the ADHI gene deletion.
- the ethanol by-products formation is not influenced by these additional deletions.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present invention relates to modified eukaryotic microbial cells that have been engineered for producing 1-alcohols and derivatives thereof under anoxic conditions. To this end the eukaryotic microbial cells have been modified to express enzymes of the fatty acid β-oxidation cycle in the cytosol of the cell, under anoxic conditions, in the absence of fatty acids and in the presence of a non-fatty acid carbon source. The cells are further modified to express a metabolic route for producing under anoxic conditions, acetyl-CoA from the non-fatty acid carbon source to feed into and drive the β-oxidation cycle in the bio synthetic direction and, to express termination enzymes for conversion of reaction β-oxidation cycle intermediates into the desired fermentation product. The invention further relates to anoxic processes wherein the cells are used to produce 1-alcohols or derivatives thereof.
Description
Yeast engineered for the production of 1 -alcohols from sugars under anoxic conditions
Field of the invention
The present invention relates to the fields of fermentation and metabolic engineering of yeasts such as Saccharomyces cerevisiae. In particular, the invention relates to S. cerevisiae strains that have been engineered to express in the absence of fatty acids several of the enzymes that are required in the degradation of such acids along with certain other enzymes. The expression of some of the native yeast enzymes has been prevented or minimized in order to prevent the formation of undesired by- products such as ethanol and glycerol. By varying the expression of the various enzymes in yeast, it has been possible to obtain a range of metabolically-engineered yeasts that each produces a particular 1 -alcohol from sugars such as glucose, fructose and sucrose. The invention further relates to the processes wherein the engineered strains of the invention produce 1 -alcohols from sugars, preferentially in the absence of oxygen.
Background of the invention
Ethanol is currently the dominant bio fuel and its production from sugars basically is via an anoxic process. 1-Butanol (systematic name butan-l-ol) has advantages over ethanol as a fuel, but no economic method seems to be available for its production via a fermentation process from sugars. Which is very surprising in view of the early discovery of 1-butanol formation in 1861 by Pasteur and the subsequent enormous work in the field of 1-butanol production from sugars (Jones and Woods, Microbiological Reviews 1986, 50:484-524). The production of 1-butanol (and the byproduct acetone) was one of the first large-scale industrial fermentation processes in the first half of the previous century with volumes that were comparable to the production of ethanol. However, at the 1960s, the fermentation process no longer could compete with the chemical synthesis processes as based on oil. Interest in biobutanol has once more surfaced in view of the desired use of renewable resources as feedstocks in the production of bio fuels. Furthermore, 1-butanol has an important position in the chemical's market with a turnover of 2.8 million tons in 2008 (Green, Current Opinion in Biotechnology 2011, 22:337-343). It is a very significant precursor for paints, polymers and plastics.
Apart from 1-butanol, other 1 -alcohols have a very good potential in replacing ethanol as the biofuel of choice. The longer the carbon chain of the alcohols are to approximately up to C14 chains, the better they will be compatible with current fuel practices of gasoline, diesel and jet fuel. Such alcohols also can find applications, for instance in the production of detergents and surfactants, or as such as lubricant additives.
Production of 1-butanol
The classical production of 1-butanol relied on species of Clostridium that produce a mixture of compounds such as acetone, acetoin and lactic acid along with the desired product 1-butanol. The route leading into 1-butanol from acetyl-CoA involves a thiolase that couples two acetyl-CoA's to form acetoacetyl-CoA which is reduced into 3-hydroxybutyric acid by a dehydrogenase. In two subsequent steps this compound is transformed into butyryl-CoA by crotonase and butyryl-CoA dehydrogenase. Two reductive steps then lead to the formation of 1-butanol.
Potentially, also a so-called 2-keto acid pathway is available for the production of
1 -alcohols but most efforts have gone into the above CoA-dependent pathway of Clostridium and variants thereof. Lamsen and Atsumi (Frontiers in Microbiology 2012, 3:article 196) have reviewed developments in the biological synthesis of higher-chain alcohols. Below a number of specific studies are cited.
Atsumi et al., (Metabolic Engineering 2008, 10:305-311) considered species of
Clostridium as less suitable as production hosts because of their relatively unknown genetic system and their complex physiology resulting in a mixture of end-products they engineered a synthetic pathway in Escherichia coli and demonstrated the production of 1-butanol (maximum level of 552 mg/L) from this non-native user- friendly host.
Inui et al., (Applied Microbiology Biotechnology 2008, 77: 1305-1316) basically followed the reasoning and approaches as given by Atsumi et al. They produced under anoxic conditions a maximal level of 1200 mg/L of 1-butanol.
Nielssen et al., (Metabolic Engineering 2009, 11 :262-273) in an effort to explore other options for hosts constructed the 1-butanol biosynthetic pathway in hosts that are known to have a higher solvent tolerance which is important in view of the toxicity of 1-butanol to microbes. They used Pseudomonas putida and Bacillus subtilis along with
E. coli taken as a baseline organism for comparison. 1-butanol titers obtained were 120 and 24 mg/L from P. putida and B. subtilis, respectively.
Fischer et al., (Applied Microbiology Biotechnology 2010, 88:265-275) quote the above results on 1-butanol production in E. coli which showed only limited product formation. Intracellular pools of key pathway intermediates were assessed and it was proposed that butyryl-CoA dehydrogenation was rate limiting.
Berezina et al., (Applied Microbiology Biotechnology 2010, 87:635-646) employed a Lactobacillus brevis strain for expressing the Clostridial pathway. The recombinant L. brevis strains were able to synthesize up to 300 mg/L of 1-butanol in a glucose-containing medium.
Steen et al., (Microbial Cell Factories 2008, 7:36) used Saccharomyces cerevisiae as host and engineered in it a butanol biosynthetic pathway, in which isozymes from a number of different organisms (S. cerevisiae, Escherichia coli, Clostridium beijerinckii, and Ralstonia eutropha) were substituted for the Clostridial enzymes. Their effect on 1- butanol production was compared and by choosing the appropriate isozymes, it was possible to eventually obtain a production of 2.5 mg/L of 1-butanol under semi- anaerobic conditions.
Garza et al., (J Ind Microbiol Biotechnol 2012, 39: 1101-1107) also introduced a 1-butanol-producing pathway in E. coli from Clostridium. They produced 1254 mg/L of 1-butanol from glucose under anoxic conditions.
Bond- Watts et al., (Nature Chemical Biology 2011, 7:222-227) the construction of a chimeric pathway assembled from three different organisms for the high-level production of 1-butanol (4,7 g/L). Most importantly, the reduction of crotonyl-CoA was studied by testing various enoyl-CoA reductases. The NADH-dependent enzyme trans-enoyl-coenzyme A reductase (TER) from Treponema denticola was a an enzyme that the authors described as potentially irreversible in vivo into the direction of butyryl-CoA.
Shen et al., (Applied and Environmental Microbiology 2011 , 77:2905-2915) also constructed 1-butanol pathway in E. coli to provide an irreversible reaction by TER. Attention was furthermore paid to NADH and to acetyl-CoA in obtaining driving forces to direct the flux into product formation. Under anoxic conditions, concentrations of 30 g/L of butanol were obtained with yields of up to 88% of the theoretical yield.
Dellomonaco et al, (Nature 2011, 476:355-361; WO 2012/109176) disclose the engineered reversal of the β-oxidation cycle for the synthesis of fuels and chemicals in E. coli. They produced long-chain products via elongation of short-chain metabolites. They applied a reversal of the β-oxidation cycle as based on CoA-thioester intermediates that directly uses acetyl-CoA for acyl-chain elongation. They obtained 1- butanol production in E. coli at 14 g/L and with a yield of 0.33 g of 1-butanol produced per gram of glucose consumed.
Gulevich et al., (Biotechnol Letters 2012, 34:463-469) disclose metabolic engineering of E. coli for 1-butanol synthesis through the inverted aerobic fatty acid β- oxidation pathway. They tested 1-butanol formation both under what was termed semi- aerobic and under supposedly anaerobic conditions. The results of oxic versus supposedly anoxic conditions were obscured in their interpretation because relative to 1-butanol large amounts of by-products such as ethanol and acetate were formed.
Photosynthetic production of 1-butanol in cyanobacteria has been obtained by Lan and Liao (PNAS 2012, 109:6018-6023). They reasoned that the CoA-dependent pathways as described above in the production of 1-butanol are critically dependent on the condensation of two molecules of acetyl-CoA to acetoacetyl-CoA. This reaction thermodynamically is unfavorable in the direction of synthesis of acetoacetyl-CoA. They showed that introducing an ATP-dependent route from acetyl-CoA via malonyl- CoA into acetoacetyl-CoA can drive the reaction into the desired biosynthesis direction.
Production of higher 1 -alcohols
Primary 1 -alcohols (n-alcohols) with a carbon chain length greater than 4 can also be produced by microbes from sugar, either via the reversed biodegradative or via the biosynthetic pathway.
Dekishima et al., (J Am Chem Soc 2011, 133: 1 1399-11401) engineered an E. coli strain for the production of 1-hexanol. They produced minute amounts of the compound in engineered E. coli along with large quantities of 1-butanol. Use was made of the ability of enzymes involved in the metabolism of C4-compounds to also catalyze reactions with C6-compounds.
Machado et al., (Metabolic Engineering 2012, 14:504-511) have been building on the work of Dekishima et al. An anaerobic E. coli growth-selection platform (mutant that cannot grow anaerobically if no oxidative outlet for NADH is available) was used
that allowed selection or enrichment of enzymes for increased synthesis of C6 and C8 linear alcohols. Using this approach, it was possible to improve the carbon flux towards the synthesis of C6 and C8 acyl-CoA intermediates. Further directed evolution by random mutagenesis of a 3-hydroxyl-acyl-CoA dehydrogenase improved 1 -hexanol and 1 -octanol production.
Dellomonaco et al, (Nature 2011, 476:355-361; WO 2012/109176) disclose the engineered reversal of the β-oxidation cycle for the synthesis of fuels and chemicals in E. coli. Not only for butanol, but also for higher alcohols including hexanol, octanol and dodecanol but product concentrations remained limited to below 200 mg/L.
Zheng et al., (Microbial Cell Factories 2012, 11 :65) disclose that they have studied the bioproduction of C12/C14 and C16/18 alcohols in E. coli. They in another approach improved the fatty alcohol production by systematically optimizing the fatty alcohol biosynthesis pathway, mainly by targeting three key steps from fatty acyl-acyl carrier proteins (ACPs) to fatty alcohols, which are sequentially catalyzed by thioesterase, acyl-CoA synthase and fatty acyl-CoA reductase.
Yeast and anoxic conditions
Yeasts such as S. cerevisiae are known to be superior hosts in the industrial manufacture of compounds from sugar, especially if large volumes are produced. A large number of metabolic routes in the production of a variety of compounds has been investigated in bacteria such as Escherichia coli. However, in many instances bacteria will not be applied on industrial scales because of their many inherent drawbacks as compared to yeast. Consequently, bacteria-based processes will not lead to economically sound processes. Yeasts on the other hand intrinsically pose technical challenges in constructing the desired production hosts via molecular approaches.
Matsuda et al., (Microb Cell Fact., 2011, 10:70) disclose that S. cerevisiae is a preferred host over E. coli but that their central metabolism are distinct from each other calling for novel metabolic engineering strategies in S. cerevisiae as compared to E. coli. Importantly, production of desired compounds from sugars at industrial scale preferably is done under anoxic conditions (no oxygen present). Production processes in the presence of oxygen are difficult to control at large scales because of challenges in homogenous mixing of oxygen from air. Furthermore, input of air at large scale is a
technical and economic issue in itself. The well-known process of producing ethanol from sugar by the yeast S. cerevisiae is an example of a successful anoxic procedure at industrial scale. However, prior art processes for the production of 1 -alcohols other than ethanol in yeasts like S. cerevisiae require the input of at least some oxygen. There is therefore still a need in the art for modified eukaryotic microbial (host) cells for producing 1 -alcohols other than ethanol under anoxic conditions and for anoxic processes wherein such cells are used to produce a 1 -alcohol other than ethanol. It is an object of the present invention to provide for such cells and processes. Summary of the invention
In a first aspect the invention pertains to a modified eukaryotic microbial host cell. The host cell preferably is modified to comprise: a) cytosolic expression of the enzymes of the fatty acid β-oxidation cycle under anoxic conditions, in the absence of fatty acids and in the presence of a non-fatty acid carbon source; b) a metabolic route for producing under anoxic conditions and preferably in the cytosol, acetyl-CoA from the non-fatty acid carbon source to feed into and drive the β-oxidation cycle in the biosynthetic direction; and, c) expression of a termination enzyme to convert reaction intermediates of the β-oxidation cycle into a 1 -alcohol or derivatives thereof.
In a second aspect the invention pertains to the use of a cell modified according to the invention, for the production of a 1 -alcohol or a derivative thereof.
In a third aspect, the invention relates to processes for producing a 1 -alcohol or a derivative thereof, whereby the process comprises the steps of: a) fermenting a medium with a modified cell according to the invention under anoxic conditions, whereby the medium contains or is fed with a non- fatty acid carbon source and whereby the yeast cell ferments the non- fatty acid carbon source to the 1 -alcohol or derivative; and optionally, b) recovery of the 1 -alcohol or derivative. A preferred process according to the invention, is a process wherein prior to step a) a cell comprising a genetic modification that reduces or eliminates the production of the 1 -alcohol under oxic condition, is cultured under oxic conditions to produce biomass, whereby the biomass obtained under oxic conditions is used to inoculate the medium in step a).
Description of the invention
Definitions
Sequence identity is herein defined as a relationship between two or more amino acid (polypeptide or protein) sequences or two or more nucleic acid (polynucleotide) sequences, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between amino acid or nucleic acid sequences, as the case may be, as determined by the match between strings of such sequences. "Similarity" between two amino acid sequences is determined by comparing the amino acid sequence and its conserved amino acid substitutes of one polypeptide to the sequence of a second polypeptide. "Identity" and "similarity" can be readily calculated by known methods. The terms "sequence identity" or "sequence similarity" means that two (poly)peptide or two nucleotide sequences, when optimally aligned, preferably over the entire length (of at least the shortest sequence in the comparison) and maximizing the number of matches and minimizes the number of gaps such as by the programs ClustalW (1.83), GAP or BESTFIT using default parameters, share at least a certain percentage of sequence identity as defined elsewhere herein. GAP uses the Needleman and Wunsch global alignment algorithm to align two sequences over their entire length, maximizing the number of matches and minimizes the number of gaps. Generally, the GAP default parameters are used, with a gap creation penalty = 50 (nucleotides) / 8 (proteins) and gap extension penalty = 3 (nucleotides) / 2 (proteins). For nucleotides the default scoring matrix used is nwsgapdna and for proteins the default scoring matrix is Blosum62 (Henikoff & Henikoff, 1992, PNAS 89, 915-919). A preferred multiple alignment program for aligning protein sequences of the invention is ClustalW (1.83) using a blosum matrix and default settings (Gap opening penalty: 10; Gap extension penalty: 0.05). It is clear than when RNA sequences are said to be essentially similar or have a certain degree of sequence identity with DNA sequences, thymine (T) in the DNA sequence is considered equal to uracil (U) in the RNA sequence. Sequence alignments and scores for percentage sequence identity may be determined using computer programs, such as the GCG Wisconsin Package, Version 10.3, available from Accelrys Inc., 9685 Scranton Road, San Diego, CA 92121-3752 USA or the open-source software Emboss for Windows (current version 2.7.1- 07). Alternatively percent similarity or identity may be determined by searching against databases such as FASTA, BLAST, etc.
Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include e.g. the GCG program package (Devereux, J., et al, Nucleic Acids Research 12 (1):387 (1984)), BestFit, BLASTP, BLASTN, and FASTA (Altschul, S. F. et al, J. Mol. Biol. 215:403-410 (1990). The BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S., et al, NCBI NLM NIH Bethesda, MD 20894; Altschul, S., et al, J. Mol. Biol. 215:403-410 (1990). The well-known Smith Waterman algorithm may also be used to determine identity.
Preferred parameters for polypeptide sequence comparison include the following: Algorithm: Needleman and Wunsch, J. Mol. Biol. 48:443-453 (1970); Comparison matrix: BLOSSUM62 from Hentikoff and Hentikoff, Proc. Natl. Acad. Sci. USA. 89: 10915-10919 (1992); Gap Penalty: 12; and Gap Length Penalty: 4. A program useful with these parameters is publicly available as the "Ogap" program from Genetics Computer Group, located in Madison, WI. The aforementioned parameters are the default parameters for amino acid comparisons (along with no penalty for end gaps). Preferred parameters for nucleic acid comparison include the following: Algorithm: Needleman and Wunsch, J. Mol. Biol. 48:443-453 (1970); Comparison matrix: matches=+10, mismatch=0; Gap Penalty: 50; Gap Length Penalty: 3. Available as the Gap program from Genetics Computer Group, located in Madison, Wis. Given above are the default parameters for nucleic acid comparisons.
Optionally, in determining the degree of amino acid similarity, the skilled person may also take into account so-called "conservative" amino acid substitutions, as will be clear to the skilled person. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide- containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulphur-containing side chains is cysteine and methionine. Preferred conservative amino acids substitution
groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine- valine, and asparagine-glutamine. Substitutional variants of the amino acid sequence disclosed herein are those in which at least one residue in the disclosed sequences has been removed and a different residue inserted in its place. Preferably, the amino acid change is conservative. Preferred conservative substitutions for each of the naturally occurring amino acids are as follows: Ala to ser; Arg to lys; Asn to gin or his; Asp to glu; Cys to ser or ala; Gin to asn; Glu to asp; Gly to pro; His to asn or gin; He to leu or val; Leu to ile or val; Lys to arg; gin or glu; Met to leu or ile; Phe to met, leu or tyr; Ser to thr; Thr to ser; Trp to tyr; Tyr to trp or phe; and, Val to ile or leu.
Nucleotide sequences of the invention may also be defined by their capability to hybridize with parts of specific nucleotide sequences disclosed herein, respectively, under moderate, or preferably under stringent hybridization conditions. Stringent hybridization conditions are herein defined as conditions that allow a nucleic acid sequence of at least about 25, preferably about 50 nucleotides, 75 or 100 and most preferably of about 200 or more nucleotides, to hybridize at a temperature of about 65 °C in a solution comprising about 1 M salt, preferably 6 x SSC or any other solution having a comparable ionic strength, and washing at 65 °C in a solution comprising about 0.1 M salt, or less, preferably 0.2 x SSC or any other solution having a comparable ionic strength. Preferably, the hybridization is performed overnight, i.e. at least for 10 hours and preferably washing is performed for at least one hour with at least two changes of the washing solution. These conditions will usually allow the specific hybridization of sequences having about 90% or more sequence identity.
Moderate conditions are herein defined as conditions that allow a nucleic acid sequences of at least 50 nucleotides, preferably of about 200 or more nucleotides, to hybridize at a temperature of about 45 °C in a solution comprising about 1 M salt, preferably 6 x SSC or any other solution having a comparable ionic strength, and washing at room temperature in a solution comprising about 1 M salt, preferably 6 x SSC or any other solution having a comparable ionic strength. Preferably, the hybridization is performed overnight, i.e. at least for 10 hours, and preferably washing is performed for at least one hour with at least two changes of the washing solution. These conditions will usually allow the specific hybridization of sequences having up to 50% sequence identity. The person skilled in the art will be able to modify these
hybridization conditions in order to specifically identify sequences varying in identity between 50% and 90%.
A "nucleic acid construct" or "nucleic acid vector" is herein understood to mean a man-made nucleic acid molecule resulting from the use of recombinant DNA technology. The term "nucleic acid construct" therefore does not include naturally occurring nucleic acid molecules although a nucleic acid construct may comprise (parts of) naturally occurring nucleic acid molecules. The terms "expression vector" or expression construct" refer to nucleotide sequences that are capable of affecting expression of a gene in host cells or host organisms compatible with such sequences. These expression vectors typically include at least suitable transcription regulatory sequences and optionally, 3' transcription termination signals. Additional factors necessary or helpful in effecting expression may also be present, such as expression enhancer elements. The expression vector will be introduced into a suitable host cell and be able to effect expression of the coding sequence in an in vitro cell culture of the host cell. The expression vector will be suitable for replication in the host cell or organism of the invention.
As used herein, the term "promoter" or "transcription regulatory sequence" refers to a nucleic acid fragment that functions to control the transcription of one or more coding sequences, and is located upstream with respect to the direction of transcription of the transcription initiation site of the coding sequence, and is structurally identified by the presence of a binding site for DNA-dependent RNA polymerase, transcription initiation sites and any other DNA sequences, including, but not limited to transcription factor binding sites, repressor and activator protein binding sites, and any other sequences of nucleotides known to one of skill in the art to act directly or indirectly to regulate the amount of transcription from the promoter. A "constitutive" promoter is a promoter that is active in most tissues under most physiological and developmental conditions. An "inducible" promoter is a promoter that is physiologically or developmentally regulated, e.g. by the application of a chemical inducer.
The term "selectable marker" is a term familiar to one of ordinary skill in the art and is used herein to describe any genetic entity which, when expressed, can be used to select for a cell or cells containing the selectable marker. The term "reporter" may be used interchangeably with marker, although it is mainly used to refer to visible
markers, such as green fluorescent protein (GFP). Selectable markers may be dominant or recessive or bidirectional.
As used herein, the term "operably linked" refers to a linkage of polynucleotide elements in a functional relationship. A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For instance, a transcription regulatory sequence is operably linked to a coding sequence if it affects the transcription of the coding sequence. Operably linked means that the DNA sequences being linked are typically contiguous and, where necessary to join two protein encoding regions, contiguous and in reading frame.
The terms "protein" or "polypeptide" are used interchangeably and refer to molecules consisting of a chain of amino acids, without reference to a specific mode of action, size, 3-dimensional structure or origin.
"Fungi" (singular fungus) are herein understood as heterotrophic eukaryotic microorganisms that digest their food externally, absorbing nutrient molecules into their cells. Fungi are a separate kingdom of eukaryotic organisms and include yeasts, molds, and mushrooms. The terms fungi, fungus and fungal as used herein thus expressly includes yeasts as well as filamentous fungi.
The term "gene" means a DNA fragment comprising a region (transcribed region), which is transcribed into an RNA molecule (e.g. an mRNA) in a cell, operably linked to suitable regulatory regions (e.g. a promoter). A gene will usually comprise several operably linked fragments, such as a promoter, a 5' leader sequence, a coding region and a 3'-nontranslated sequence (3 'end) comprising a polyadenylation site. "Expression of a gene" refers to the process wherein a DNA region which is operably linked to appropriate regulatory regions, particularly a promoter, is transcribed into an RNA, which is biologically active, i.e. which is capable of being translated into a biologically active protein or peptide. The term "homologous" when used to indicate the relation between a given (recombinant) nucleic acid or polypeptide molecule and a given host organism or host cell, is understood to mean that in nature the nucleic acid or polypeptide molecule is produced by a host cell or organisms of the same species, preferably of the same variety or strain. If homologous to a host cell, a nucleic acid sequence encoding a polypeptide will typically (but not necessarily) be operably linked to another (heterologous) promoter sequence and, if applicable, another (heterologous) secretory signal sequence and/or terminator sequence than in its natural environment. It
is understood that the regulatory sequences, signal sequences, terminator sequences, etc. may also be homologous to the host cell. In this context, the use of only "homologous" sequence elements allows the construction of "self-cloned" genetically modified organisms (GMO's) (self-cloning is defined herein as in European Directive 98/81/EC Annex II). When used to indicate the relatedness of two nucleic acid sequences the term "homologous" means that one single- stranded nucleic acid sequence may hybridize to a complementary single-stranded nucleic acid sequence. The degree of hybridization may depend on a number of factors including the amount of identity between the sequences and the hybridization conditions such as temperature and salt concentration as discussed later.
The terms "heterologous" and "exogenous" when used with respect to a nucleic acid (DNA or RNA) or protein refers to a nucleic acid or protein that does not occur naturally as part of the organism, cell, genome or DNA or RNA sequence in which it is present, or that is found in a cell or location or locations in the genome or DNA or RNA sequence that differ from that in which it is found in nature. Heterologous and exogenous nucleic acids or proteins are not endogenous to the cell into which it is introduced, but have been obtained from another cell or synthetically or recombinantly produced. Generally, though not necessarily, such nucleic acids encode proteins, i.e. exogenous proteins, that are not normally produced by the cell in which the DNA is transcribed or expressed. Similarly exogenous RNA encodes for proteins not normally expressed in the cell in which the exogenous RNA is present. Heterologous/exogenous nucleic acids and proteins may also be referred to as foreign nucleic acids or proteins. Any nucleic acid or protein that one of skill in the art would recognize as foreign to the cell in which it is expressed is herein encompassed by the term heterologous or exogenous nucleic acid or protein. The terms heterologous and exogenous also apply to non-natural combinations of nucleic acid or amino acid sequences, i.e. combinations where at least two of the combined sequences are foreign with respect to each other.
The "specific activity" of an enzyme is herein understood to mean the amount of activity of a particular enzyme per amount of total host cell protein, usually expressed in units of enzyme activity per mg total host cell protein. In the context of the present invention, the specific activity of a particular enzyme may be increased or decreased as compared to the specific activity of that enzyme in an (otherwise identical) wild type host cell.
"Aerobic conditions" "Oxic conditions" or an aerobic or oxic fermentation process is herein defined as conditions or a fermentation process run in the presence of oxygen and in which oxygen is consumed, preferably at a rate of at least 0.5, 1, 2, 5, 10, 20 or 50 mmol/L/h, and wherein organic molecules serve as electron donor and oxygen serves as electron acceptor.
"Anaerobic or anoxic conditions" or an "anaerobic or anoxic fermentation process" is herein defined as conditions or a fermentation process run in the absence of oxygen or in which substantially no oxygen is consumed, preferably less than 5, 2, 1, or 0.5 mmol/L/h, more preferably 0 mmol/L/h is consumed (i.e. oxygen consumption is not detectable), and wherein organic molecules serve as both electron donor and electron acceptors.
Any reference to nucleotide or amino acid sequences accessible in public sequence databases herein refers to the version of the sequence entry as available on the filing date of this document.
Detailed description of the invention
E. coli has been engineered by constitutively expressing enzymes of the aerobic fatty acid β-oxidation cycle (the "β-oxidation cycle") in combination with expressing other relevant enzymes and by also removing certain enzyme activities that would lead to unwanted side products. Such engineered bacteria have been proposed as production organisms in the manufacturing from sugar of several chemicals (see e.g. Clomburg and Gonzalez, 2010 Biotechnol Bioeng. 108(4): 867-79; Dellomonaco et al. supra; and Gulevich et al. supra).
The present inventors have found, however, that under relevant industrial conditions the production processes envisaged will be far from optimal due to the properties of the E. coli host. They have now found that it is possible to (constitutively) express all relevant genes for producing compounds via the reverse aerobic fatty acid β- oxidation cycle in yeasts such as S. cerevisiae. In combination with overexpressing and/or deleting enzymes, the present inventors have demonstrated that the industrially- relevant S. cerevisiae can be successfully employed in producing desired compounds under industrial conditions.
In a first aspect, the invention relates to a eukaryotic microbial host cell, preferably a yeast host cell, that has the desired properties for industrial processes and
that will be modified following standard molecular techniques. A host cell of the invention preferably comprises the following features, which features may already be present in the host cell or which may be newly introduced and/or modified to be improved:
I) The host cell preferably functionally expresses (enzymes of) the fatty acid β- oxidation cycle, preferably in the cytosol of the host cell. Preferably the β-oxidation cycle enzymes are expressed under conditions that include the presence of non-fatty acid carbon sources, i.e. carbohydrates (such as hexoses and disaccharides), including catabolite repressing carbon sources, and preferably also in the absence of oxygen (anoxic/anaerobic conditions). These features are described in more detail under 4) herein.
II) The host cell preferably provides acetyl-CoA to feed into and drive the β- oxidation cycle in the reverse, i.e. biosynthetic direction. The acetyl-CoA is preferably provided in the cytosol of the host cell via pyruvate that is obtained from a non-fatty acid carbon source, preferably through at least (the last) part of the glycolytic pathway. These features are described in more detail under 3) herein. In certain instances, as described in 4.5) herein, the driving force towards product formation can be enhanced by introducing a malonyl-CoA shunt (Lan and Liao 2012, PNAS, 109:6018-6023).
III) The host preferably directs as much as possible of the carbon flow as acetyl- Co A into the reversed β-oxidation cycle. Reactions producing unwanted by-products
(such as e.g. ethanol, acetate, glycerol and/or acetaldehyde) as well as reactions that would compete for cytosolic acetyl-CoA with reversed β-oxidation cycle, are therefore preferably absent or modified so as to reduce or eliminate their activity in the host cell. These features are described in more detail under 2) herein.
IV) The host cell preferably functionally expresses termination enzymes to convert reaction intermediates of the β-oxidation cycle into the desired end product, such as fatty acids, 1 -alcohols, β-ketoacids, β-ketoalcohols, β-hydroxyacids, 1,3-diols, trans-A2-fatty acids, alkanes, alkenes and/or derivatives thereof, preferably, 1 -alcohols other than methanol and ethanol, such as e.g. butanol, decanol, dodecanol and higher 1- alcohols and/or derivatives thereof. These features are described in more detail under 5) herein. These compounds can find use as (bio)fuels) or they can find application outside the fuel's world as chemicals.
Anoxic production in yeast
The key issue in growth and product formation in yeast in the absence of oxygen is at the level of reoxidizing NADH (Bakker et al., FEMS Microbiology Reviews 2001, 25: 15-37). Under strictly anoxic growth conditions, substrate level phosphorylation in glycolysis is the sole source of ATP in S. cerevisiae and enables a net yield of 2 ATP for each molecule of glucose converted to two molecules of pyruvate. Dissimilation of glucose to pyruvate via glycolysis is stoichiometrically linked to the reduction of NAD in the glyceraldehyde-3-phosphate-dehydrogenase reaction. Furthermore, in the production of yeast biomass also some NAD is reduced into NADH. A closed overall redox balance at the level of NAD(H) is achieved by decarboxylation of pyruvate to acetaldehyde, which subsequently acts as the electron acceptor for NADH reoxidation. In wild-type S. cerevisiae, this pathway of ethanol formation is the main mode of fermentative metabolism, but some glycerol is also produced in order to account for the NADH reoxidation as formed in biomass production. Bakker et al have summarized many important issues in Saccharomyces cerevisiae in the reduction of NAD to NADH and the reoxidation of NADH. They discussed mechanisms for reoxidation of NADH in yeast, with special emphasis on the metabolic compartmentation that occurs as a consequence of the impermeability of the mitochondrial inner membrane for NADH and of NAD. At least five mechanisms of NADH reoxidation exist in S. cerevisiae. These are:
1) ethanolic fermentation;
2) glycerol production according to the overall reaction
1 glucose + 2 ATP + 2 NADH = 2 glycerol + 2 ADP + 2 NAD;
3) respiration of cytosolic NADH via external mitochondrial NADH dehydrogenases;
4) respiration of cytosolic NADH via the glycero 1-3 -phosphate shuttle; and
5) oxidation of intramitochondrial NADH via a mitochondrial 'internal' NADH dehydrogenase.
Under anoxic conditions, especially the modes (1) and (2) will be in operation. Apart from glycerol, other reduced compounds might be formed as well to alleviate NADH-stress in yeast. The range of compounds that can be produced in the absence of oxygen is dictated amongst others by:
a) the oxidation/reduction levels of sugars employed as substrate. In most cases the gross formula (CH20)n can be given in describing the oxidation/reduction level of monomeric sugars.
b) the oxidation/reduction level of any other compound in the medium that is metabolized by yeast. In particular the presence of furans and/or of acetic acid is very relevant in fermenting hydro ly sates.
c) the metabolic route taken by the organism in arriving at a certain compound since differences in routes may occur for instance at the level of carbon dioxide production.
d) the oxidation/reduction level of the compound produced. At this level, obviously a great variety is possible in view of the many different compounds that can be obtained.
e) The oxidation/reduction level of any by-product produced, in particular glycerol. f) The energy yield of an overall metabolic route from sugar and other substrates into the product.
As a consequence of the redox balance requirements, only a limited number of compounds can be produced in good yields under anoxic conditions. The production of 1 -alcohols as described herein is possible not only because of redox neutrality but also because sufficient ATP is generated in the pathways employed.
In order to optimize the desired 1 -alcohol formation, it however is preferred to prevent the anoxic reoxidation modes of NADH as a consequence of the formation of ethanol and of excessive amounts of glycerol.
Prevention of ethanol formation
Several approaches have been followed in eliminating the formation of ethanol by S. cerevisiae. An obvious target is the deletion of the structural genes for ethanol dehydrogenases as for instance done by Skory, J. Ind. Microbiol. Biotechnol 2003, 30:22-27 for a S. cerevisiae that was manipulated to produce lactic acid. But this approach is not fully satisfactory, probably because the toxic acetaldehyde accumulates in the modified cells. Another target is the deletion of pyruvate decarboxylases. S. cerevisiae contains 3 structural genes (PDC1, PDC5 and PDC6) that encode for the respective enzymes (Eberhardt et al., Eur. J. Biochem. 1999, 262: 191-201). The enzymes Pdclp and Pdc5p are 88% identical and they are closely related pyruvate decarboxylases from other organisms. Although Pdc6p is an active pyruvate decarboxylase, it apparently is not involved in glucose fermentation. In actively fermenting yeast cells, PDC1 is strongly expressed, whereas expression of PDC5 is hardly detectable. Accordingly, deletion of just PDC5 does not noticeably reduce the
pyruvate decarboxylase activity. Work at the level of pyruvate decarboxylase deletions indeed has prevented the formation of ethanol, but at the same time mutant strains apparently were not able to produce sufficient cytosolic acetyl-CoA (Flikweert et al., Yeast 12:247-257 for normal growth patterns. It is also possible to construct double mutations of both the PDCl and ADHI genes as demonstrated by Tokuhiro et al., Appl Microbiol Biotechnol 2009, 82:883-890. The present inventors have found that the expression of heterologous routes for acetyl-CoA production in yeasts such as S. cerevisiae, as described in 3) herein below, circumvents this otherwise problematic situation of lack of acetyl-CoA in production hosts.
Prevention of excessive glycerol formation in yeast
In yeast, glycerol is of crucial interest as by-product under anoxic conditions. It is a major product in ethanol fermentation and allows S. cerevisiae to balance any excess of NADH in the absence of oxygen. Under osmotic stress conditions, glycerol is accumulated within the cell and acts as an osmolyte. For the production and excretion of glycerol, at least three features are important:
1. The first step in the branch of the glycolytic pathway involves the catalysis of dihydroxyacetone phosphate to glycero 1-3 -phosphate by cytosolic NADH- dependent glycero 1-3 -phosphate dehydrogenases by two isoenzymes (Gpdlp and Gpd2p). Jain et al., (Applied Microbiology and Biotechnology 2012, 93: 131-141) describe that glycerol is a major product of ethanol fermentation by S. cerevisiae. A gpdlAgpd2A double mutant was unable to grow under strict anoxic conditions because NAD regeneration through glycerol production was no longer possible and intracellular NADH did accumulated, resulting in a redox imbalance. The introduction of heterologous proteins which catalyze NADH-coupled reactions should allow the double mutant to restore its redox balance and support anaerobic growth. This contention was proven by inserting alternative pathways for NADH- coupled oxidation for the production of sorbitol and propane- 1,2-diol, respectively. It was demonstrated that insertion of such genes for oxidoreductases indeed restored yeast growth of the gpdlAgpd2A double mutant under anoxic conditions, albeit only partially. Hubman et al., (Applied and Environmental Microbiology 2011, 77:5857-5867) have obtained strains mutated in the expression of both Gpdlp and Gpd2p. They employed lower-strength promoter mutants. Some of the
strains constructed were able to grow in the absence of oxygen but yet produced less glycerol.
2. The second step involves dephosphorylation of glycero 1-3 -phosphate to yield glycerol. S. cerevisiae contains 2 glycerol 3 -phosphatases (Gpplp and Gpp2p) that can convert 3-phosphoglycerol formed by Gpdlp or Gpd2p into glycerol. Pahlman et al., (The Journal of Biological Chemistry 2001, 276:3555-3565) describe that S. cerevisiae contains 2 glycerol 3 -phosphatases (Gpplp and Gpp2p) that can convert 3-phosphoglycerol formed by Gpdlp or Gpd2p into glycerol. Expression of both GPP I and GPP2 is stimulated by osmotic stress. Adaptation to anoxic conditions is dependent on the GPP I gene. A mutant strain devoid of gppl accumulated glycerol
3 -phosphate which is driven by its NADH-driven formation from dihydroxyacetone phosphate. Granath et al., (Yeast 2005, 22: 1257-1268) describe that a protein termed YIGI is involved in the expression of both Gpplp and Gpp2p.
3. Thirdly, glycerol can be exported to the external environment by passive diffusion via the Fpslp plasma membrane glycerol channel which allows S. cerevisiae in part to regulate its internal glycerol levels (Luyten et al., The EMBO Journal 1995, 14: 1360-1371). Under conditions of high osmolarity stress, S. cerevisiae will retain high concentrations of glycerol as a compatible solute (Beese-Sims et al., Yeast 2001, 28:815-819). Increased external osmolarity induces Fpslp closure, whereas decreased osmolarity causes channel opening, both within seconds of the change in external osmolarity (Tamas et al., Mol Microbiol. 1999, 31 : 1087-104). This channel is required for survival of a hypo-osmotic shock when yeast cells have to export glycerol rapidly to prevent bursting and is required for controlling turgor pressure.
The three above mechanisms allow the construction of hosts that are fine-tuned with respect to glycerol production. The natural glycerol-based osmoregulatory system in S. cerevisiae is particularly well understood and it is controlled by the high osmolarity glycerol (HOG) signaling system (Hohmann et al., Methods Enzymol. 2007, 428:29-45). In the modified cells of the invention, this HOG mechanism is overruled in such a way that the producing cells are forming controlled amounts of glycerol and at the same time are still able to thrive in their production environment.
1.1 The parent host cell
The present invention concerns the genetic modification of a host cell so as to enable the host cell to produce desired compounds via the reversal of the fatty acid β- oxidation pathway. To this end a number of genetic modifications will be introduced in a parent host cell in accordance with the invention. These modifications include the introduction of expression of a number of heterologous genes, as well as, the modification of the expression of a number of endogenous genes already present in the parent host cell, by reducing or inactivating the expression of some endogenous genes and/or by increasing, i.e. overexpressing, other endogenous genes. These genetic modification are further set out below herein. A parent host cell is thus understood to be a host cell prior to that any of the genetic modifications in accordance with the invention have been introduced in the host cell.
A parent host cell of the invention preferably is a eukaryotic host cell, more preferably, the host cell is a eukaryotic microorganism such as e.g. a fungal host cell. A most preferred parent host cell to be modified in accordance with the invention is a yeast host cell.
Yeasts are herein defined as eukaryotic microorganisms and include all species of the subdivision Eumycotina (Yeasts: characteristics and identification, J.A. Barnett, R.W. Payne, D. Yarrow, 2000, 3rd ed., Cambridge University Press, Cambridge UK; and, The yeasts, a taxonomic study, CP. Kurtzman and J.W. Fell (eds) 1998, 4th ed., Elsevier Science Publ. B.V., Amsterdam, The Netherlands) that predominantly grow in unicellular form. Yeasts may either grow by budding of a unicellular thallus or may grow by fission of the organism. Preferred yeasts cells for use in the present invention belong to the genera Saccharomyces, Kluyveromyces, Candida, Pichia, Schizosaccharomyces, Hansenula, Kloeckera, Schwanniomyces, Yarrowia, Cryptococcus, Debaromyces, Saccharomycecopsis, Saccharomycodes, Wickerhamia, Debayomyces, Hanseniaspora, Ogataea, Kuraishia, Komagataella, Metschnikowia, Williopsis, Nakazawaea, Torulaspora, Bullera, Rhodotorula, and Sporobolomyces. Preferably the parental yeast host cell is naturally capable of anaerobic fermentation, more preferably alcoholic fermentation and most preferably anaerobic alcoholic fermentation. However, as will become apparent below herein, in one embodiment of the invention, the host cell is modified to avoid or reduce the synthesis of ethanol.
Particularly when compared to bacteria, yeasts, such as Saccharomyces species, have many attractive features for industrial processes, including e.g. their high
tolerance to acids, ethanol and other harmful compounds, their high osmo-tolerance and their capability of anaerobic growth, and of course their high fermentative capacity.
Preferred yeast species as parent host cells for the invention include e.g.
Saccharomyces cerevisiae, S. exiguus, S. bayanus, S. delbriickii, S. italicus, S. ellipsoideus, S. fermentati, S. kluyveri, S. krusei, S. lactis, S. marxianus, S. microellipsoides, S. montanus, S. norbensis, S. oleaceus, S. paradoxus, S. pastorianus,
S. pretoriensis, S. rosei, S. rouxii, S. uvarum, S. ludwigii, Kluyveromyces lactis, K. marxianus, K. marxianus var. marxianus, K. thermotolerans, Candida utilis, C. tropicalis, C. albicans, C. lipolytica, C. versatilis, Pichia stipidis, P. pastoris and P. sorbitophila, Hansenula polymorpha and Schizosaccharomyces pombe.
The parent host cell of the invention preferably contains active glycolysis.
The host cell further preferably has a high tolerance to ethanol, a high tolerance to low pH (i.e. capable of growth at a pH lower than 5, 4, or 3) and towards organic acids like lactic acid, acetic acid or formic acid and sugar degradation products such as furfural and hydroxy-methylfurfural, and a high tolerance to elevated temperatures.
Any of these characteristics or activities of the host cell may be naturally present in the host cell or may be introduced or modified by genetic modification, preferably by self cloning or by the methods of the invention described below.
A suitable cell is a cultured cell, a cell that may be cultured in fermentation process e.g. in submerged or solid state fermentation.
1.2 Methods for modifying and constructing the host cells of the invention
For the genetic modification of the parent host cells of the invention, i.e. for the construction of the modified host cells of the invention, standard genetic and molecular biology techniques are used that are generally known in the art and have e.g. been described by Sambrook and Russell (2001, "Molecular cloning: a laboratory manual" (3rd edition), Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press) and Ausubel et al. (1987, eds., "Current protocols in molecular biology", Green Publishing and Wiley Interscience, New York). Furthermore, the construction of genetically modified (yeast) host strains may be carried out by genetic crosses, sporulation of the resulting diploids, tetrad dissection of the haploid spores containing the desired auxotrophic markers, and colony purification of such haploid host cells in the appropriate selection medium. All of these methods are standard fungal and yeast
genetic methods known to those in the art. See, for example, Sherman et al, Methods Yeast Genetics, Cold Spring Harbor Laboratory, NY (1978) and Guthrie et al. (Eds.) Guide To Yeast Genetics and Molecular Biology Vol. 194, Academic Press, San Diego (1991).
In general, suitable promoters for the expression of the heterologous nucleotide sequence coding for desired enzyme activities and/or for overexpression of endogenous genes in the context of the invention, include promoters that are preferably insensitive to catabolite (glucose) repression, that are active under oxic (aerobic) and under anoxic (anaerobic) conditions and/or that preferably do not require specific carbon sources for induction. Promoters having these characteristics are widely available and known to the skilled person. Suitable examples of such promoters include e.g. promoters from glycolytic genes such as the phosphofructokinase (PPK), triose phosphate isomerase (TPI), glyceraldehyde-3 -phosphate dehydrogenase (GPD, TDH3 or GAPDH), pyruvate kinase (PYK), phosphoglycerate kinase (PGK), glucose-6-phosphate isomerase promoter (PGIl) promoters from yeasts. More details about such promoters from yeast may be found in (WO 93/03159). Other useful promoters are ribosomal protein encoding gene promoters (TEFI), the lactase gene promoter (LAC4), alcohol dehydrogenase promoters (ADHl, preferably a modified (constitutive) version of the ADHl promoter (SEQ ID NO: 77), ADH4, and the like), the enolase promoter (ENO) and the hexose(glucose) transporter promoter (HXT7). Alternatively, a suitable promoter for these purposes is a promoter that allows (over)expression under anaerobic conditions. A preferred example of such an anoxic promoter is e.g. the S. cerevisiae ANB1 promoter (SEQ ID NO: 73). Other promoters, both constitutive and inducible, and enhancers or upstream activating sequences will be known to those of skill in the art. Preferably the promoter that is operably linked to nucleotide sequence as defined above is homologous to the host cell. Suitable terminator sequences are e.g. obtainable from the cytochrome cl (CYC1) gene or an alcohol dehydrogenase gene (e.g. ADHl).
To increase the likelihood that the enzymes are expressed at sufficient levels and in active form in the transformed host cells of the invention, the nucleotide sequence encoding of enzymes of the invention, are preferably adapted to optimize their codon usage to that of the host cell in question. The adaptiveness of a nucleotide sequence encoding an enzyme to the codon usage of a host cell may be expressed as codon adaptation index (CAI). The codon adaptation index is herein defined as a measurement
of the relative adaptiveness of the codon usage of a gene towards the codon usage of highly expressed genes in a particular host cell or organism. The relative adaptiveness (w) of each codon is the ratio of the usage of each codon, to that of the most abundant codon for the same amino acid. The CAI index is defined as the geometric mean of these relative adaptiveness values. Non-synonymous codons and termination codons (dependent on genetic code) are excluded. CAI values range from 0 to 1, with higher values indicating a higher proportion of the most abundant codons (see Sharp and Li , 1987, Nucleic Acids Research 15: 1281-1295; also see: Jansen et al, 2003, Nucleic Acids Res. 3J_(8):2242-51). An adapted nucleotide sequence preferably has a CAI of at least 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8 or 0.9. Most preferred are the sequences which have been codon optimized for expression in the fungal host cell in question such as e.g. S. cerevisiae cells.
2. Inactivation or reduction of unwanted side reactions
In some embodiments of the invention, the host cells of the invention are genetically modified so as to reduce or inactivate unwanted side reactions.
2.1. Reducing pyruvate decarboxylase activity
In one embodiment of the invention, the endogenous pyruvate decarboxylase activity in the host cell is reduced or eliminated as a means to prevent the formation of at least one acetaldehyde, acetate and ethanol.
Endogenous pyruvate decarboxylase activity in yeast converts pyruvate to acetaldehyde, which is then converted to ethanol, or to acetyl-CoA via acetate (see Figure 1). Yeasts may have one or more genes encoding pyruvate decarboxylase. For example, there is one gene encoding pyruvate decarboxylase in Kluyveromyces lactis, while there are three isozymes of pyruvate decarboxylase encoded by the PDC1, PCD 5, and PDC6 (EC 4.1.1.1) genes in Saccharomyces cerevisiae, as well as a pyruvate decarboxylase regulatory gene PDC2. Expression of pyruvate decarboxylase from PDC6 is minimal. In the cells of the invention, the specific pyruvate decarboxylase activity is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in activity, at least under anaerobic conditions.
In the modified host cells of the invention the pyruvate decarboxylase activity can be reduced by modifying at least one gene encoding a pyruvate decarboxylase, or by modifying a gene regulating the expression of pyruvate decarboxylase gene(s). For example, in S. cerevisiae the PDC1 and PDC5 genes, or all three genes, can be modified to reduce or eliminate their expression e.g. by disruption. Alternatively, pyruvate decarboxylase activity may be reduced by modification, e.g. disruption, of the PDC2 regulatory gene in S. cerevisiae.
Thus, preferred genes to be modified for reducing the specific pyruvate decarboxylase activity in the cell of the invention are one or more or all of the S. cerevisiae PDC1, PDC5, PDC6 and PDC2 genes, encoding the amino acid sequences of SEQ ID NO's: 1, 2, 3 and 4, respectively, or orthologues thereof in other species. Therefore genes to be modified for reducing the specific pyruvate decarboxylase activity in the cell of the invention, preferably are one or more or all of the genes encoding an amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to one or more of SEQ ID NO's: 1, 2, 3 and 4, respectively.
Examples of yeast strains with reduced pyruvate decarboxylase activity due to disruption of pyruvate decarboxylase encoding genes have been reported for Saccharomyces in Flikweert et al. (Yeast (1996) 12:247-257), and disruption of the regulatory gene in Hohmann, (Mol Gen Genet. (1993) 241 :657-666). Saccharomyces strains having no pyruvate decarboxylase activity are available from the ATCC with accession no.'s #200027 and #200028.
Genes encoding pyruvate decarboxylases and/or PDC regulatory genes may be modified so as to reduce pyruvate decarboxylase specific activity in host cells of the invention using a variety of methods for genetic modification. Many methods for modifying endogenous target genes in host cells so as to reduce or eliminate the activity of the encoded target proteins are known to one skilled in the art and may be used for modifying the host cells of the invention. Modifications that may be used to reduce or eliminate expression of a target protein are disruptions that include, but are not limited to, deletion of the entire gene or a portion of the gene encoding the target protein (e.g. a pyruvate decarboxylase), inserting a DNA fragment into the target gene (in either the promoter or coding region) so that the protein is not expressed or expressed at lower levels, introducing a mutation into the target coding region which adds a stop codon or frame shift such that a functional protein is not expressed, and
introducing one or more mutations into a target coding region to alter amino acids so that a non-functional target protein, or a target protein with reduced enzymatic activity is expressed. In addition, expression of the target gene may be blocked by expression of an antisense R A or an interfering RNA, and constructs may be introduced that result in co-suppression. Moreover, a target coding sequence may be synthesized whose expression will be low because rare codons are substituted for plentiful ones, when this suboptimal coding sequence is substituted for the corresponding endogenous target coding sequence. Preferably such a suboptimal coding sequence will have a codon adaptation index (see above) of less than 0.5, 0.4, 0.3 0.2, or 0.1. Such a suboptimal coding sequence will produce the same polypeptide but at a lower rate due to inefficient translation. In addition, the synthesis or stability of the transcript may be reduced by mutation. Similarly the efficiency by which a protein is translated from mRNA may be modulated by mutation, e.g. by using suboptimal translation initiation codons. All of these methods may be readily practiced by one skilled in the art making use of the known or identified sequences encoding target proteins such as the pyruvate decarboxylase proteins.
DNA sequences flanking a target coding sequence such as the pyruvate decarboxylase coding sequences are also useful in some modification procedures and are available for yeasts such as for Saccharomyces cerevisiae in the complete genome sequence coordinated by Genome Project ID9518 of Genome Projects coordinated by NCBI (National Center for Biotechnology Information) with identification GOPID #13838.
In particular, DNA sequences surrounding a target coding sequence are useful for modification methods using homologous recombination. For example, in this method sequences flanking the target gene are placed on either site of a selectable marker gene to mediate homologous recombination whereby the marker gene replaces the target gene. Also partial target gene sequences and target gene flanking sequences bounding a selectable marker gene may be used to mediate homologous recombination whereby the marker gene replaces a portion of the target gene, e.g. a pyruvate decarboxylase gene. In addition, the selectable marker may be flanked by site-specific recombination sites, so that following expression of the corresponding site-specific recombinase, the resistance gene is excised from the genomic locus where the target gene was present without reactivating the latter. The site-specific recombination leaves behind a
recombination site which disrupts expression of the target protein. The homologous recombination vector may be constructed to also leave a deletion in the target gene following excision of the selectable marker, as is well known to one skilled in the art.
Deletions may be made using mitotic recombination as described in Wach et al. ((1994) Yeast 10: 1793-1808). This method involves preparing a DNA fragment that contains a selectable marker between genomic regions that may be as short as 20 bp, and which bound, i.e. flank the target DNA sequence. This DNA fragment can be prepared by PCR amplification of the selectable marker gene using as primers oligonucleotides that hybridize to the ends of the marker gene and that include the genomic regions that can recombine with the yeast genome. The linear DNA fragment can be efficiently transformed into yeast and recombined into the genome resulting in gene replacement including with deletion of the target DNA sequence (as described in Methods in Enzymology, v 194, pp 281-301 (1991)).
Moreover, promoter replacement methods may be used to exchange the endogenous transcriptional control elements allowing another means to modulate expression such as described in Mnaimneh et al. ((2004) Cell 118(1):31-44) and in the Examples herein.
In addition, the activity of target proteins in any yeast cell may be disrupted using random mutagenesis, which is followed by screening to identify strains with reduced activity of the target proteins such as e.g. a pyruvate decarboxylase. Using this type of method, the DNA sequence coding for the target proteins (e.g. the pyruvate decarboxylase encoding region), or any other region of the genome affecting expression of pyruvate decarboxylase activity, need not even be known.
Methods for creating genetic mutations are common and well known in the art and may be applied to the exercise of creating mutants. Commonly used random genetic modification methods (reviewed in Methods in Yeast Genetics, 2005, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.) include spontaneous mutagenesis, mutagenesis caused by mutator genes, chemical mutagenesis, irradiation with UV or X-rays, or transposon mutagenesis.
Chemical mutagenesis of yeast commonly involves treatment of yeast cells with one of the following DNA mutagens: ethyl methanesulfonate (EMS), nitrous acid, diethyl sulfate, or N-methyl-N'-nitro-N-nitroso-guanidine (MNNG). These methods of mutagenesis have been reviewed in Spencer et al (Mutagenesis in Yeast, 1996, Yeast
Protocols: Methods in Cell and Molecular Biology. Humana Press, Totowa, N.J.). Chemical mutagenesis with EMS may be performed as described in Methods in Yeast Genetics, 2005, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Irradiation with ultraviolet (UV) light or X-rays can also be used to produce random mutagenesis in yeast cells. The primary effect of mutagenesis by UV irradiation is the formation of pyrimidine dimers which disrupt the fidelity of DNA replication. Protocols for UV-mutagenesis of yeast can be found in Spencer et al (Mutagenesis in Yeast, 1996, Yeast Protocols: Methods in Cell and Molecular Biology. Humana Press, Totowa, N.J.). Introduction of a mutator phenotype can also be used to generate random chromosomal mutations in yeast. Common mutator phenotypes can be obtained through disruption of one or more of the following genes: PMSI, MAGI, RAD18 or RAD51. Restoration of the non-mutator phenotype can be easily obtained by insertion of the wild type allele. Collections of modified cells produced from any of these or other known random mutagenesis processes may be screened for reduced activity of the target protein (US20090305363).
In a preferred embodiment of the host cell wherein the pyruvate decarboxylase activity is reduced or eliminated, the host comprises a further genetic modification of at least one copy of a transcriptional regulator involved in glucose sensing. S. cerevisiae strains in which the structural genes encoding pyruvate decarboxylase (PDC1, PDC5 and PDC6) are deleted are unable to grow in the presence of high glucose concentrations or under glucose-limited conditions without additional C2 carbon sources such as ethanol or acetate - due to their inability to form cytosolic acetyl-CoA for e.g. fatty acid synthesis. The addition of C2 carbon sources is however preferably avoided for processes at industrial scale. This ability of PDC-minus strain to grow on glucose in the absence of additional C2 sources can be restored by increasing the steady state level of a transcriptional regulator involved in glucose sensing, as described by Oud et al. (2012, Microbial Cell Factories, 11 : 131). The transcriptional regulator is preferably encoded by the MTH1 gene or an orthologue thereof. The genetic modification preferably is a genetic modification that increases the steady state level of the THi-encoded protein, by at least one of overexpressing the protein and inactivation of a phosphorylation site required for degradation of the transcriptional regulator. The transcriptional regulator to be modified preferably has an amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to SEQ ID
NO: 5. The genetic modification that inactivates the phosphorylation site, preferably is an internal in- frame deletion of a segment comprising amino acid positions 57 - 131 of SEQ ID NO: 5, or a corresponding segment in an orthologue of SEQ ID NO: 5. 2.2 Reducing cytosolic acetaldehyde dehydrogenase activity
In one embodiment of the invention, the endogenous cytosolic acetaldehyde dehydrogenase activity in the host cell is reduced or eliminated so as to avoid or reduce the synthesis of acetate from acetaldehyde.
In the yeast genome, there are five genes known to encode aldehyde dehydrogenases, as well as an additional gene with sequence similarity. Ald2p and Ald3p are cytosolic enzymes which use only NAD+ as cofactor (EC 1.2.1.3). Both genes are induced in response to ethanol or stress and repressed by glucose. Ald4p and Ald5p are mitochondrial, use NAD and NADP as co factors, and are K+ dependent. Ald4p, the major isoform, is glucose repressed and ald4 mutants do not grow on ethanol, while Ald5p, the minor isoform, is constitutively expressed. ALD6 encodes the Mg2+ activated cytosolic enzyme, which uses NADP+ as cofactor and is constitutively expressed (EC 1.2.1.4). However, the cytosolic ALD6 gene product is the major enzyme responsible for catalyzing the oxidation of acetaldehyde to acetate in yeast.
Thus, in a preferred cell according to the invention the gene to be modified for reducing or eliminating the specific cytosolic acetaldehyde dehydrogenase activity in the cell of the invention is at least the S. cerevisiae ALD6 gene, encoding the amino acid sequence of SEQ ID NO: 6, or an orthologue thereof in another species. Therefore a gene to be modified for reducing or eliminating the specific cytosolic acetaldehyde dehydrogenase activity in the cell of the invention, preferably is a gene encoding a amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to SEQ ID NO: 6. However, in other preferred cells the expression of one or more or all of the ALDl, ALD2, ALD3, ALD4, ALD5 and ALD6 genes or their corresponding orthologues is reduced or eliminated.
In the cells of the invention, the specific cytosolic acetaldehyde dehydrogenase activity is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in activity, at least under anaerobic conditions.
Methods for reducing or eliminating the specific cytosolic acetaldehyde dehydrogenase activity in the cell of the invention are as described above in 2.1 for pyruvate decarboxylase as target protein. 2.3. Reducing alcohol dehydrogenase activity
In one embodiment of the invention, the endogenous alcohol dehydrogenase activity in the host cell is reduced or eliminated so as to avoid or reduce the synthesis of ethanol from acetaldehyde.
In S. cerevisiae, there are five genes that encode alcohol dehydrogenases involved in ethanol metabolism, ADH1 to ADH5. Four of these enzymes, Adhlp, Adh3p, Adh4p, and Adh5p, reduce acetaldehyde to ethanol during glucose fermentation, while Adh2p catalyzes the reverse reaction of oxidizing ethanol to acetaldehyde. However, the cytosolic ADH1 gene product is the major enzyme responsible for catalyzing the reduction of acetaldehyde to ethanol with the concomitant regeneration o f NAD+ (EC 1.1.1.1).
Thus, a preferred gene to be modified for reducing or eliminating the specific ADH1 -encoded alcohol dehydrogenase activity in the cell of the invention is the S. cerevisiae ADH1 gene, encoding the amino acid sequence of SEQ ID NO: 7, or an orthologue thereof in another species. Therefore a gene to be modified for reducing or eliminating the specific ADH1 -encoded alcohol dehydrogenase activity in the cell of the invention, preferably is a gene encoding an amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to SEQ ID NO: 7.
Alternatively, preferred genes to be modified for reducing or eliminating the specific alcohol dehydrogenase activity in the cell of the invention are one or more of the S. cerevisiae ADH3, ADH4 and ADH5 genes or orthologues thereof in another species. The S. cerevisiae ADH3, ADH4 and ADH5 genes or their orthologues may be modified as such, or in combination with the above modification of the ADH1 gene or its orthologue. Preferably, at least the S. cerevisiae ADH3 gene or its orthologue is modified for reducing or eliminating its specific activity in the cell of the invention, more preferably, in combination with the modification of at least one of the S. cerevisiae ADH1, ADH4 and ADH5 genes or their orthologues. Therefore further genes to be modified for reducing or eliminating the specific alcohol dehydrogenase activity in the cell of the invention, preferably are genes encoding an amino acid sequence with
at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to the amino acid sequences of the S. cerevisiae ADH3, ADH4 and ADH5 genes (with respectively Genbank accession no.'s CAA89229.1, CAA64131.1 and CAA85103.1 and SEQ ID NO's 78 - 80).
In the cells of the invention, the specific (ADH1 -encoded or overall) alcohol dehydrogenase activity is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in activity, at least under anaerobic conditions.
In the cells of the invention, the specific (^DHJ-encoded) alcohol dehydrogenase activity is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in activity, at least under anaerobic conditions.
In the cells of the invention, the specific (^4ZXH¥-encoded) alcohol dehydrogenase activity is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in activity, at least under anaerobic conditions.
In the cells of the invention, the specific (^4DH5-encoded) alcohol dehydrogenase activity is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in activity, at least under anaerobic conditions.
Methods for reducing or eliminating the endogenous alcohol dehydrogenase activity in the cell of the invention are as described above in 2.1 for pyruvate decarboxylase as target protein.
2.4 Reducing endogenous acetyl- Co A synthetase activity
In one embodiment of the invention, the endogenous acetyl-CoA synthetase activity in the host cell is reduced or eliminated so as to avoid or reduce the synthesis of acetyl-CoA from acetate. In this embodiment, whether or not one or all of the endogenous acetyl-CoA synthetase genes are inactivated depends on the introduction of heterologous genes for the production of cytosolic acetyl-CoA; see 3.1, 3.2 and 3.3 below).
An acetyl-CoA synthetase or acetate-CoA ligase (EC 6.2.1.1) is herein understood as an enzyme that catalyzes the formation of a new chemical bond between acetate and coenzyme A (CoA). In the modified host cells of the invention the acetyl- CoA synthetase activity can be reduced by modifying at least one gene encoding a acetyl-CoA synthetase. For example, in S. cerevisiae one or both (all) of the ACS1 and ACS2 genes can be modified to reduce or eliminate their expression e.g. by disruption.
Thus, preferred genes to be modified for reducing or eliminating the specific acetyl-CoA synthetase activity in the cell of the invention are at least one of the S. cerevisiae ACS1 and ACS2 genes, encoding the amino acid sequence of SEQ ID NO's: 8 and 9, respectively, or orthologues thereof in another species.
Therefore genes to be modified for reducing the specific acetyl-CoA synthetase activity in the cell of the invention, preferably are one or both of the genes encoding an amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to one or more of SEQ ID NO's: 8 and 9, respectively.
In the cells of the invention, the specific acetyl-CoA synthetase activity is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in activity, at least under anaerobic conditions.
Methods for reducing or eliminating the specific acetyl-CoA synthetase activity in the cell of the invention are as described above in 2.1 for pyruvate decarboxylase as target protein.
2.5 Inactivation or repression of A CC1
In one embodiment of the invention, the activity of the product of the ACC1 gene or an orthologue thereof is reduced in the host cell by genetically modifying the gene so as to avoid or reduce the formation of fatty acids, via the yeast native fatty acid forming pathway because this pathway would compete with the reversed β-oxidation pathway introduced in the host cell of the invention.
The S. cerevisiae ACC1 gene encodes the acetyl-CoA carboxylase (EC 6.4.1.2) which catalyzes the carboxylation of cytosolic acetyl-CoA to form malonyl-CoA and regulates histone acetylation by regulating the availability of acetyl-CoA; required for de novo biosynthesis of long-chain fatty acids.
Thus, preferably in a host cell of the invention, the S. cerevisiae ACCI gene or an orthologue thereof in another species, is modified to reduce or eliminate activity of its gene product. The S. cerevisiae ACCI gene encodes the amino acid sequence of SEQ ID NO: 10. Therefore a gene to be modified for reducing or eliminating the activity of the ACCI gene product or that of its orthologue in the cell of the invention, preferably is a gene encoding a amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to SEQ ID NO: 10.
Alternatively, the activity of the ACCI gene product can be reduced by adding the phospholipid precursors inositol and choline as ACCI is repressed in the presence of the phospholipid precursors, or by reducing the expression of the transcription factors Ino2p and Ino4p or by upregulating the negative ACCI regulator Opilp.
In the cells of the invention, the activity of the ACCI gene product or that of its orthologue is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in expression, at least under anaerobic conditions. Methods for reducing or eliminating acetyl-CoA carboxylase activity in the cell of the invention are as described above in 2.1 for pyruvate decarboxylase as target protein.
2.6 Reducing fatty acid biosynthesis
In one embodiment of the invention, the expression of at least one of FAS1 and
FAS2 is reduced or eliminated in the host cell so as to avoid or reduce (the initial steps of) fatty acid biosynthesis in which acetyl-CoA is consumed.
FAS1 and FAS2 encode the β- and a-subunits, respectively, of the fatty acid synthetase, which catalyzes the synthesis of long-chain saturated fatty acids. The FAS1- encoded β-subunit contains acetyltransacylase, dehydratase, enoyl reductase, malonyl transacylase, and palmitoyl transacylase activities. The ^S^-encoded a-subunit contains the acyl-carrier protein domain and β-ketoacyl reductase, beta-ketoacyl synthase and self-pantetheinylation activities.
Thus, preferably in a host cell of the invention, at least one the S. cerevisiae FAS1 FAS2 genes or their orthologues in another species, are modified in order to avoid or reduce the initial steps of fatty acid biosynthesis in which acetyl-CoA is consumed. The
S. cerevisiae FAS1 and FAS2 genes encode the amino acid sequences of SEQ ID NO's:
11 and 12, respectively. Therefore, a gene to be modified for reducing or eliminating
the initial steps of fatty acid biosynthesis in which acetyl-CoA is consumed, preferably is a gene encoding a amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to at least one of SEQ ID NO's: 11 and 12.
In the cells of the invention, fatty acid synthetase activity preferably is reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in expression, at least under anaerobic conditions.
Methods for reducing or eliminating the fatty acid synthetase activity in the cell of the invention are as described above in 2.1 for pyruvate decarboxylase as target protein.
2.7 Reducing the activity of the glyoxylate cycle
In one embodiment, the activity of the glyoxylate cycle is reduced or eliminated in the host cell. The activity of the glyoxylate cycle is preferably at least reduced in the host cell of the invention because this cycle is another pathway competing (at least under aerobic conditions) for cytosolic acetyl-CoA. Its activity can be reduced or abolished by directly addressing the corresponding genes (CIT2, ICL1, MLS1 and MDH3) or by down-regulating their expression via down-regulation of the genes encoding one or more of the transcription factors HAP2, HAP3, HAP4 and HAP5.
Thus, preferably in a host cell of the invention, at least one the S. cerevisiae
CIT2, ICL1, MLS1, MDH3, HAP2, HAP3, HAP4 and HAP5 genes or their orthologues in another species, are modified to reduce or eliminate activity of the glyoxylate cycle in the host cell. The S. cerevisiae CIT2, ICL1, MLS1 and MDH3 genes respectively encode enzymes with citrate synthase, isocitrate lyase, malate synthase and (peroxisomal) NAD-dependent malate dehydrogenase activities, which enzymes have the amino acid sequences of SEQ ID NO's: 13, 14, 15 and 16, respectively. Therefore a gene to be modified for reducing or eliminating activity of the glyoxylate cycle in the host cell, preferably is a gene encoding a amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to at least one of SEQ ID NO's: 13, 14, 15, 16, 17, 18, 19 and 20.
In the cells of the invention, the activity of the glyoxylate cycle is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a
strain which is genetically identical except for the genetic modification causing the reduction in expression, at least under anaerobic conditions.
Methods for reducing or eliminating the activity of the glyoxylate cycle in the cell of the invention are as described above in 2.1 for pyruvate decarboxylase as target protein.
2.8 Reducing pyruvate dehydrogenase activity
In one embodiment, the specific pyruvate dehydrogenase activity is reduced or eliminated in the host cell. Endogenous pyruvate dehydrogenase activity is located in the mitochondria in yeast and catalyzes oxidative decarboxylation of pyruvate to form acetyl-CoA. Acetyl-CoA is used in the TCA cycle and in fatty acid biosynthesis.
The pyruvate dehydrogenase enzyme is one enzyme of a multi-enzyme pyruvate dehydrogenase complex. Pyruvate dehydrogenase (EC 1.2.4.1) itself has alpha and beta subunits: encoded by the PDAI and PDBI genes, respectively, forming the El component. The complex includes an E2 core which has dihydrolipoamide acetyltransferase activity (EC 2.3.1.12) and E3 which has dihydrolipoamide dehydrogenase activity (ECl .8.1.4). E2 may be encoded by the LATI and E3 by LPDI genes. An additional complex protein is encoded by the PDXl gene. Thus, the pyruvate dehydrogenase complex may include the enzymes or subunits encoded by the PDAI, PDBI, LATI, LPDI, and PDXl genes. Any of the genes encoding pyruvate dehydrogenase complex enzymes of yeast may be modified to reduce pyruvate dehydrogenase activity in a yeast cell to prepare a strain of one embodiment of the invention.
Thus, preferably in a host cell of the invention, at least one the S. cerevisiae PDAI, PDBI, LATI, LPDI, and PDXl genes or their orthologues in another species, are modified to reduce or eliminate pyruvate dehydrogenase activity in the host cell. The S. cerevisiae PDAI, PDBI, LATI, LPDI, and PDXl genes have the amino acid sequences of SEQ ID NO's: 21 , 22, 23, 24 and 25, respectively. Therefore a gene to be modified for reducing or eliminating pyruvate dehydrogenase activity in the host cell, preferably is a gene encoding a amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to at least one of SEQ ID NO's: 21, 22, 23, 24 and 25.
In the cells of the invention, the pyruvate dehydrogenase activity is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a
strain which is genetically identical except for the genetic modification causing the reduction in expression, at least under anaerobic conditions.
Methods for reducing or eliminating the pyruvate dehydrogenase activity in the cell of the invention are as described above in 2.1 for pyruvate decarboxylase as target protein.
2.9 Reduced transport of pyruvate into mitochondria
In one embodiment, the activity of mitochondrial pyruvate carriers is reduced or eliminated in the host cell in order to reduce or to avoid loss of pyruvate in the citric acid cycle. Preferably therefore, one or more of the S. cerevisiae MPCl, YIA6 and YEA6 genes (or their orthologues in another species) is genetically modified, so as to reduce or eliminate the activity of mitochondrial pyruvate carriers in the cell.
MPCl encodes a highly conserved subunit of the mitochondrial pyruvate carrier; a mitochondrial inner membrane complex comprised of Fmp37p/Mpclp and either Mpc2p or Fmp43p/Mpc3p mediates mitochondrial pyruvate uptake.
YIA6 and YEA6 are members of the mitochondrial carrier subfamily and encode for a mitochondrial NAD+ transporter, involved in the transport of NAD+ and pyruvate into the mitochondria.
Thus, preferably in a host cell of the invention, at least one the S. cerevisiae MPCl, YIA6 and YEA6 genes or their orthologues in another species, are modified to reduce or eliminate the activity of mitochondrial pyruvate carriers in the cell. The S. cerevisiae MPCl, YIA6 and YEA6 genes have the amino acid sequences of SEQ ID NO's: 26, 27 and 28, respectively. Therefore a gene to be modified for reducing or eliminating the activity of mitochondrial pyruvate carriers in the cell, preferably is a gene encoding a amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to at least one of SEQ ID NO's: 26, 27 and 28.
In the cells of the invention, the activity of mitochondrial pyruvate carriers is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in expression, at least under anaerobic conditions.
Methods for reducing or eliminating the activity of mitochondrial pyruvate carriers in the cell of the invention are as described above in 2.1 for pyruvate decarboxylase as target protein.
2.10 Reduction of transport of acetyl-CoA from cytosol into mitochondria
In one embodiment, the host cell of the invention is genetically modified so as to reduce or eliminate transport of acetyl-CoA from cytosol into mitochondria. This is preferably achieved by reducing or eliminating the activity of the carnitine shuttle by genetically modifying at least one of the S. cerevisiae YAT1, YAT2 and CRC1 genes or their orthologue in another species.
YAT1 encodes an outer mitochondrial carnitine acetyltransferase, minor ethanol- inducible enzyme involved in transport of activated acyl groups from the cytoplasm into the mitochondrial matrix.
YAT2 encodes a carnitine acetyltransferase; has similarity to Yatlp, which is a carnitine acetyltransferase associated with the mitochondrial outer membrane.
CRC1 encodes a mitochondrial inner membrane carnitine transporter, required for carnitine-dependent transport of acetyl-CoA from peroxisomes to mitochondria during fatty acid β-oxidation.
Thus, preferably in a host cell of the invention, at least one the S. cerevisiae YAT1, YAT2 and CRC1 genes or their orthologues in another species, are modified to reduce or eliminate transport of acetyl-CoA from cytosol into mitochondria in the cell via the carnitine shuttle. The S. cerevisiae YAT1, YAT2 and CRC1 genes have the amino acid sequences of SEQ ID NO's: 29, 30 and 31, respectively. Therefore a gene to be modified for reducing or eliminating transport of acetyl-CoA from cytosol into mitochondria in the cell, preferably is a gene encoding a amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to at least one of SEQ ID NO's: 29, 30 and 31.
In the cells of the invention, the transport of acetyl-CoA from cytosol into mitochondria in the cell is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in expression, at least under anaerobic conditions.
Methods for reducing or eliminating transport of acetyl-CoA from cytosol into mitochondria in the cell of the invention are as described above in 2.1 for pyruvate decarboxylase as target protein.
2.11 Reduced glycerol transmembrane transporter activity
In another embodiment, the formation of glycerol as by-product is prevented or reduced by genetically modifying a plasma membrane channel involved in the efflux of glycerol from the host cell so as to reduce or eliminate its activity. Reduction of glycerol efflux from the cell leads to a decreased production of glycerol by feed-back regulation as glycerol accumulates within the cells, thereby reducing the carbon flux towards glycerol biosynthesis. In S. cerevisiae the FSP1 gene encodes a aquaglyceroporin involved in efflux of glycerol. The FSP1 gene encoded aquaglyceroporin is a plasma membrane (glycerol) channel and a member of major intrinsic protein (MIP) family.
Thus, preferably in a host cell of the invention, the S. cerevisiae FSP1 gene, or its orthologue in another species, is genetically modified to reduce or eliminate the efflux of glycerol from the cell. The S. cerevisiae FSP1 gene has the amino acid sequence of SEQ ID NO: 32, respectively. Therefore a gene to be modified for reducing or eliminating the activity of the plasma membrane channel involved in the efflux of glycerol from the cell, preferably is a gene encoding a amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to SEQ ID NO: 32.
In the cells of the invention, the efflux of glycerol from the cell is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in expression, under aerobic or anaerobic conditions.
Methods for reducing or eliminating the efflux of glycerol from the cell of the invention are as described above in 2.1 for pyruvate decarboxylase as target protein. 2.12 Reduced glycero 1-3 -phosphate dehydrogenase activity
In one embodiment, the cell of the invention has a genetic modification whereby NADH-dependent glycerol synthesis is eliminated or reduced. NADH-dependent glycerol synthesis is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction expression, at least under anaerobic conditions. NADH-dependent glycerol synthesis can be reduced or eliminated by reducing or eliminating in the cell at least one of the specific glycero 1-3 -phosphate dehydrogenase activity and the specific glycero 1-3 -phosphatase activity.
Thus, in one embodiment, the specific glycero 1-3 -phosphate dehydrogenase activity is reduced or eliminated in the host cell to prevent or reduce the formation of glycerol as by-product. Endogenous NAD-dependent glycero 1-3 -phosphate dehydrogenase is a key enzyme in glycerol synthesis. Glycerol 3-phosphate dehydrogenase or glycero lphosphate dehydrogenase (EC 1.1.1.8) catalyses the reduction of dihydroxyacetone phosphate to sn-glycerol 3-phosphate while oxidizing NADH to NAD+. Yeast strains may have one or more genes encoding NAD-dependent glycero 1-3 -phosphate dehydrogenase (GPD). In S. cerevisiae, GPD I and GPD2 are functional homologues for NAD-dependent glycero 1-3 -phosphate dehydrogenase.
Thus, preferably in a host cell of the invention, at least one the S. cerevisiae
GPD1 and GPD2 genes, or at least one of their orthologues in another species, is genetically modified to reduce or eliminate the specific glycero 1-3 -phosphate dehydrogenase activity in the cell. The S. cerevisiae GPD1 and GPD2 genes have the amino acid sequences of SEQ ID NO's: 33 and 34, respectively. Therefore a gene to be modified for reducing or eliminating the glycero 1-3 -phosphate dehydrogenase activity in the cell, preferably is a gene encoding a amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to at least one of SEQ ID NO's: 33 and 34.
In the cells of the invention, the specific glycero 1-3 -phosphate dehydrogenase activity is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in expression, at least under anaerobic conditions.
Methods for reducing or eliminating the glycero 1-3 -phosphate dehydrogenase activity in the cell of the invention are as described above in 2.1 for pyruvate decarboxylase as target protein.
In a preferred embodiment of the invention, the host cell of the invention comprises a functional high-osmolarity glycerol response pathway. Preferably therefore, only the S. cerevisiae GPD2 or its corresponding orthologue in another species (as defined above) is genetically modified for reducing or eliminating the glycero 1-3 -phosphate dehydrogenase activity in the cell, while in the S. cerevisiae GPD I or its corresponding orthologue in another species (as defined above) is functional and, preferably, not modified. The S. cerevisiae GPD1 gene is the stress- induced glycero lphosphate dehydrogenase of S. cerevisiae, which is important for growth under osmotic stress as may occur under industrial fermentations conditions. Its
expression is inter alia regulated by the high-osmolarity glycerol response pathway. It can therefore be advantageous that a host cell of the invention has at least one functional copy of a endogenous S. cerevisiae GPD1 or its corresponding orthologue in another species.
2.13 Reduced glycero 1-3 -phosphatase activity
In one embodiment, the specific glycero 1-3 -phosphatase activity is reduced or eliminated in the host cell to prevent or reduce the formation of glycerol as by-product. In S. cerevisiae glycero 1-3 -phosphatase activity is encoded by endogenous HOR2 and RHR2 genes.
Thus, preferably in a host cell of the invention, at least one the S. cerevisiae HOR2 and RHR2 genes, or at least one of their orthologues in another species, is genetically modified to reduce or eliminate the specific glycero 1-3 -phosphatase activity in the cell. The S. cerevisiae HOR2 and RHR2 genes have the amino acid sequences of SEQ ID NO's: 35 and 35, respectively. Therefore a gene to be modified for reducing or eliminating the glycero 1-3 -phosphatase activity in the cell, preferably is a gene encoding a amino acid sequence with at least 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to at least one of SEQ ID NO's: 35 and 36.
In the cells of the invention, the specific glycero 1-3 -phosphatase activity is preferably reduced by at least a factor 0.8, 0.5, 0.3, 0.1, 0.05 or 0.01 as compared to cells of a strain which is genetically identical except for the genetic modification causing the reduction in expression, at least under anaerobic conditions.
Methods for reducing or eliminating the glycero 1-3 -phosphatase activity in the cell of the invention are as described above in 2.1 for pyruvate decarboxylase as target protein.
2.14 Catabolite derepression
In one embodiment the host cell is modified to de-repress catabolite (glucose) repressed genes by modification or inactivation of at least one of the endogenous SNF1 and MIG1 genes, or their orthologues.
3. Conversion of pyruvate into acetyl-CoA
The host cell preferably provides acetyl-CoA to feed into and drive the β- oxidation cycle in the reverse, i.e. biosynthetic direction. The acetyl-CoA is preferably provided in the cytosol of the host cell through metabolic conversion from pyruvate. In microbes, several routes occur for converting pyruvate into acetyl-CoA. The host cells of the invention preferably at least comprise one of the following routes for converting pyruvate into acetyl-CoA.
3.1 Direct conversion of pyruvate to acetyl-CoA by a pyruvate oxidoreductase/dehydrogenase
Yeast has an endogenous pyruvate dehydrogenase. However, this enzyme complex is very slow and provides mitochondrial acetyl-CoA. In the host cells of the invention it is therefore preferred to introduce a heterologous pyruvate oxidoreductase or dehydrogenase in order to provide for acetyl-CoA in the cytosol of the host cell.
A variety of heterologous pyruvate oxidoreductase or dehydrogenase is available for expression in the host cells of the invention, including enzymes which use NAD+, NADP+, ferredoxin or flavin as co-factors (EC 1.2.4.1, EC 1.2.1.51, EC 1.2.7.1).
Preferably, the heterologous pyruvate dehydrogenase expressed in the host cell uses the same co-factor as the co-factor that is used by the acyl-CoA dehydrogenase / transenoyl-CoA reductase (see 4.4 herein below).
Suitable heterologous pyruvate dehydrogenases for expression in the host cells of the invention may be obtained from E. coli (aceE, aceF, and IpdA), Zymomonas mobilis (pdhA[alpha], pdhA[beta], pdhB, and lpd), S. aureus (pdhA, pdhB, pdhC, and lpd), Bacillus subtilis, Corymb acterium glutamicum, or Pseudomonas aeruginosa US20100062505 (US20100248233: NADP+ dependent enzyme is oxygen sensitive and is large multimeric enzyme. PDH-complex of Enterococcus faecalis is active under anoxic conditions (US20100062505). The yeast native PDH pyruvate dehydrogenase complex which uses NADH as co factor and which includes the enzymes or subunits encoded by the PDA1, PDB1, LAT1, LPD I, and PDX1 genes could also be used, when overexpressed in the cytosol, by deletion or inactivation of the mitochondrial targeting signals of each of the subunits and using promoters described in 1.2 above.
Preferred pyruvate dehydrogenases are (acetyl-transferring) enzymes which use NADH as co-factor (EC 1.2.4.1). Nucleotide sequences encoding such enzymes can be derived e.g. from Enterococcus faecalis, Arabidopsis thaliana, Bos taurus,
Corymb acterium glutamicum, Escherichia coli, Homo sapiens, Zymononas mobilis, Pseudomonas aeruginosa, Saccharomyces cerevisiae and Bacillus subtilis.
3.2 Conversion of acetaldehyde to acetyl-CoA by an acetylating acetaldehyde dehydrogenase
Another route for converting pyruvate into acetyl-CoA that can be used in the host cells of the invention is the direct conversion of cytosolic acetaldehyde (produced from pyruvate by pyruvate decarboxylase activity in the cytosol) to acetyl-CoA by introduction of a heterologous acetylating (NAD+-dependent) acetaldehyde dehydrogenase (E.C. 1.2.1.10). An acetylating acetaldehyde dehydrogenases is also referred to as (CoA-acetylating) acetaldehyde :NAD -oxidoreductase or an acetyl-CoA reductase. The conversion of acetaldehyde into acetyl-CoA by the acetylating acetaldehyde dehydrogenase is reversible and runs in the direction of acetyl-CoA when acetaldehyde accumulates in the cytosol. Such an accumulation can e.g. be achieved by reducing or eliminating the activities of alcohol dehydrogenase (ADH1, see 2.3 above) and acetaldehyde dehydrogenase (ALD6, see 2.2 above) in the cytosol of the host cell (see e.g. US20100248233).
The heterologous acetaldehyde dehydrogenases for expression in the host cell of the invention preferably is a mono functional enzyme having only acetaldehyde dehydrogenase activity (i.e. an enzyme only having the ability to oxidize acetaldehyde into acetyl-CoA), such as e.g. the enzyme encoded by the E. coli mhpF gene, as opposed bifunctional enzymes with both acetaldehyde dehydrogenase and alcohol dehydrogenase activities, such as e.g. the bifunctional enzyme encoded by the E. coli adhE gene.
A suitable heterologous gene for expressing a mono functional enzyme having only acetaldehyde dehydrogenase activity is e.g. the E. coli mhpF gene. A suitable exogenous gene coding for a mono functional enzyme with acetaldehyde dehydrogenase activity therefore comprises a nucleotide sequence coding for an amino acid sequence with at least 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 37 (the sequence of the E. coli mhpF gene). Suitable examples of prokaryotes comprising mono functional enzymes with acetaldehyde dehydrogenase activity are provided in Table 1. The amino acid sequences of these mono functional enzymes are available in public databases and can be used by the skilled person to
design codon-optimized nucleotide sequences coding for the corresponding mono functional enzyme such as e.g. coding sequence of the E. coli mhpF gene codon optimized for expression in S. cerevisiae as depicted in SEQ ID NO's: 38 or 74). Table 1 : Enzymes with acetaldehyde dehydrogenase activity related to E. coli mhpF
3.3 Direct conversion of pyruvate to acetyl-CoA by a pyruvate formate lyase
A further route for converting pyruvate into acetyl-CoA that can be used in the host cells of the invention is the direct conversion of pyruvate into acetyl-CoA by introduction into the host cell of expression of a heterologous pyruvate formate lyase. A pyruvate formate lyase is an enzyme with the ability to convert pyruvate and coenzyme-A into formate and acetyl-CoA catalyses the reaction (EC 2.3.1.54):
pyruvate + coenzyme A (CoA)→ acetyl-CoA + formate
Such an enzyme is herein understood as an enzyme having pyruvate formate lyase activity and is referred to as a pyruvate formate lyase (PFL) or formate C- acetyltransferase .
A suitable heterologous gene coding for an enzyme with pyruvate formate lyase activity is e.g. a prokaryotic pyruvate formate lyase, such as the pyruvate formate lyase from E. coli. The E. coli pyruvate formate lyase is a dimer of PflB (encoded by pflB), whose maturation requires the activating enzyme PflAE (encoded by pflA), radical S- adenosylmethionine, and a single electron donor, which in the case of E. coli is flavodoxin (Buis and Broderick, 2005, Arch. Biochem. Biophys. 433:288-296; Sawers and Watson, 1998, Mol. Microbiol. 29:945-954). However, Waks and Silver (supra) have shown that for activation of the pyruvate formate lyase in yeast, only co- expression of an activating enzyme is required but expression of flavodoxin is not necessary.
A suitable heterologous gene coding for an enzyme with pyruvate formate lyase activity preferably comprises a nucleotide sequence coding for an amino acid sequence with at least 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 39 (the amino acid sequence of the E. coli PflB). Suitable examples of organisms comprising an enzyme with pyruvate formate lyase activity are provided in Table 2. Further examples of such organisms are listed by Lehtio and Goldman (2004, Prot. Engin. Design & Selection, 17:545-552). The amino acid sequences of these enzymes are available in public databases and can be used by the skilled person to design codon-optimized nucleotide sequences coding for the corresponding enzyme with pyruvate formate lyase activity (see e.g. SEQ ID NO: 40 depicting the coding sequence of the E. coli pflB gene optimized for expression in S. cerevisiae).
Table 2: Enzymes with pyruvate formate lyase activity related to E.coli pflB
Organism Amino acid
identity (%)
Escherichia coli str. K12 substr. MG1655 100%
Shigella boydii 100%
Escherichia albertii TW07627 99%
Salmonella enterica 97%
Citrobacter rodentium ICC 168 97%
Klebsiella pneumoniae NTUH-K2044 96%
Yersinia aldovae ATCC 35236 91%
Proteus mirabilis HI4320 87%
Haemophilus influenzae Rd KW20 86%
Actinobacillus succinogenes 130Z 83%
Piromyces sp. E2 57%
The host cell of the invention further preferably comprises a heterologous gene coding for the PflA activating enzyme for activation of the pyruvate formate lyase. The pyruvate formate lyase activating enzyme is herein understood as an enzyme that catalyses the reaction:
S-adenosyl-L-methionine + dihydroflavodoxin + [pyruvate formate lyase] -glycine
X
5'-deoxyadenosine + L-methionine + flavodoxin semiquinone +
[formate C-acetyltransferase]-glycin-2-yl radical The heterologous gene coding for the pyruvate formate lyase activating enzyme preferably comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 41. Suitable examples of organisms comprising an enzyme with pyruvate formate lyase activity are provided in Table 3. The amino acid sequences of these enzymes are available in public databases and can be used by the skilled person to design codon-optimized nucleotide sequences coding for the corresponding enzyme with pyruvate formate lyase activity (see e.g. SEQ ID NO: 42, depicting the coding sequence of the E. coli pflA gene optimized for expression in S. cerevisiae). Table 3: Pyruvate formate lyase activating enzymes related to E.coli pflA
Organism Amino
acid identity
(%)
Escherichia coli str. K12 substr. MG1655 100%
Shigella boydii 100%
Escherichia albertii TW07627 99%
Salmonella enterica 98%
Citrobacter rodentium ICC 168 98%
Klebsiella pneumoniae NTUH-K2044 97%
Yersinia rohdei ATCC 43380 89%
Proteus penneri ATCC 35198 85%
Haemophilus parasuis 29755 70%
In a preferred host cell of the invention, the heterologous genes coding for the enzyme with pyruvate formate lyase activity and the pyruvate formate lyase activating enzyme are from the same donor organism, i.e. be homologous to each other. However, the exogenous genes coding for the enzyme with pyruvate formate lyase activity and the pyruvate formate lyase activating enzyme may also be from different donor organisms, i.e. be heterologous to each other.
A preferred host cell expressing pyruvate formate lyase activity further comprises a genetic modification that increases the specific NAD+-dependent formate dehydrogenase activity in the cell to dispose of the potentially harmful formate that is produced by the pyruvate formate lyase. A NAD+-dependent formate dehydrogenase is herein understood as an enzyme that catalyses the reaction: formate + NAD+→ C02 + NADH + H+ (EC 1.2.1.2).
A preferred gene encoding such a formate dehydrogenase whose activity is to be increased in the cell of the invention expressing heterologous pyruvate formate lyase activity is at least one of the endogenous S. cerevisiae FDH1 and FDH2 genes, or their orthologues in another species. The S. cerevisiae FDH1 is described by van den Berg and Steensma (1997, Yeast 13:551-559) and the S. cerevisiae FDH2 is described by Overkamp et al. (2002, Yeast 19:509-520). Therefore a gene encoding a formate dehydrogenase whose activity is to be increased in the cell of the invention preferably is a gene encoding a formate dehydrogenase having an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to at least one of SEQ ID NO's: 43 and 44. Alternatively a heterologous formate dehydrogenase gene may be introduced into the cell in order to increase specific NAD+-dependent formate dehydrogenase activity in the cell, such as e.g. the FDH1 gene from Candida boidinii.
In the cells of the invention, the specific formate dehydrogenase activity is preferably increased by at least a factor 1.1, 1.2, 1.5, 2, 5, 10 or 20 as compared to a strain which is genetically identical except for the genetic modification causing the reduction in specific activity, preferably under anaerobic conditions. Formate dehydrogenase activity may be determined as described by Overkamp et al. (2002, supra).
Alternatively, it may be advantageous to accumulate formate, in which case the formate dehydrogenase activity is decreased in the cell of the invention. Formate dehydrogenase activity is decreased in the cell by a genetic modification that reduces or eliminates expression of the above-defined formate dehydrogenase genes, using methods described in 2.1 above.
Another preferred host cell expressing pyruvate formate lyase activity comprises a further genetic modification that reduces or eliminates endogenous pyruvate decarboxylase activity as described in 2.1 above.
3.4 Conversion of pyruvate to acetyl-CoA via the "PDH-bypass" route
Conversion of pyruvate to acetyl-CoA via the "PDH-bypass" route by, optionally, overexpression of pyruvate decarboxylase (PDC1, PDC5 and/or PDC6) and acetaldehyde dehydrogenase (ALD6) and acetyl-CoA synthetase (ACSI or ACS2 or both) and optional reduction ethanol production by reduction or elimination of expression of an alcohol dehydrogenase encoded by at least one of ADH1, -3, -4 and -5 or their orthologues in other species.
In addition, pyruvate decarboxylase, acetyl-CoA synthetase and acetaldehyde dehydrogenase genes from other fungal and bacterial species can be expressed for the modulation of this pathway. A variety of organisms could serve as sources for (nucleotide sequences coding for) these enzymes, including, but not limited to, Saccharomyces sp., including S. cerevisiae mutants and S. uvarum, Kluyveromyces, including K. thermotolerans, K. lactis, and K. mandanus, Pichia, Hansenula, including H. polymorpha, Candidia, Trichosporon, Yamadazyma, including Y. stipitis, Torulaspora pretoriensis, Schizosaccharomyces pombe, Cryptococcus sp., Aspergillus sp., Neurospora sp. or Ustilago sp. Examples of useful pyruvate decarboxylase are those from Saccharomyces bay anus (1PYD), Candida glabrata, K. lactis (KIPDCl), or Aspergillus nidulans (PdcA), and acetyl-CoA synthetase from Candida albicans,
Neurospora crassa, A. nidulans, or K. lactis (ACS1), and acetaldehyde dehydrogenase from Aspergillus niger (ALDDH), C. albicans, Cryptococcus neoformans (alddh). Sources of prokaryotic enzymes that are useful include, but are not limited to, E. coli, Z. mobilis, Bacillus sp., Clostridium sp., Pseudomonas sp., Lactococcus sp., Enterobacter sp. and Salmonella sp. Further enhancement of this pathway can be obtained through engineering of these enzymes for enhanced activity by site-directed mutagenesis and other evolution methods (which include techniques known to those of skill in the art).
In a preferred embodiment of the invention, the acetyl-CoA synthetase that is expressed in the cell of the invention, is a (heterologous) ADP-forming acetyl-CoA synthetase (EC 6.2.1.13), i.e. an acetyl-CoA synthetase which catalyzes the reaction:
ATP + acetate + CoA <→ ADP + phosphate + acetyl-CoA
Such an ADP-forming acetyl-CoA synthetase only consumes one ATP molecule for each acetyl- CoA synthesized, instead of two ATP molecules as is done by the native yeast enzyme which hydro lyses ATP to AMP and pyrophosphate. The use of an ADP-forming acetyl-CoA synthetase thus avoids loss of energy by the formation of AMP + pyrophosphate. Examples of ADP-forming acetyl-CoA synthetases (EC 6.2.1.13) include those of Salmonella enterica, P. aeruginosa, Pyrococcus furiosus, Archaeoglobus fulgidus and Pyrobaculum islandicum. A preferred ADP-forming acetyl-CoA synthetase for expression in the cell of the invention is a variant of the Salmonella enterica acetyl-CoA synthetase (acssE), which acssE contains a point mutation (L641P) that prevents the enzyme from being inhibited by acetylation (Shiba et al. 2007; see SEQ ID NO. 45). Thus, a preferred ADP-forming acetyl-CoA synthetase that is expressed in the cell is an ADP-forming acetyl-CoA synthetase comprising an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to SEQ ID NO: 45. Preferably, ADP-forming acetyl-CoA synthetase further has a mutation that prevents the enzyme from being inhibited by acetylation, such as a point mutation in a position corresponding to position 641 in SEQ ID NO: 45 in an alignment with SEQ ID NO: 45, preferably the point mutation is a mutation to a proline. Preferably, a co don-optimized sequence is used for expression of the ADP-forming acetyl-CoA synthetase, such as SEQ ID NO: 76, a sequence encoding SEQ ID NO: 45 optimized for expression in S. cerevisiae.
In another preferred embodiment of the invention, a heterologous acetaldehyde dehydrogenase is expressed in the cell which uses NAD+ as co factor (instead of NADP+ as the native yeast enzyme Ald6p does). Thus, preferably a NAD+-dependent aldehyde dehydrogenase is expressed (optionally in combination with the inactivation of the endogenous yeast NADP+-dependent ALD6). A suitable NAD+-dependent aldehyde dehydrogenase is e.g. an enzyme encoded by the aid gene of Pseudomonas aeruginosa, or an orthologue thereof. Thus, a preferred NAD+-dependent aldehyde dehydrogenase that is expressed in the cell is an aldehyde dehydrogenase comprising an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98 or 99% sequence identity to SEQ ID NO: 46. Preferably, a co don-optimized sequence is used for expression of a NAD+-dependent aldehyde dehydrogenase, such as SEQ ID NO: 75, a sequence encoding the P. aeruginosa aid optimized for expression in S. cerevisiae.
4. Enzymes of the fatty acid β-oxidation cycle
In one embodiment, the host cell of the invention expresses enzymes of the fatty acid β-oxidation cycle. In the context of the present invention, the term "enzymes of the fatty acid β-oxidation cycle" are understood to comprise one or more or all enzymes having at least the following activities:
a) an enzyme that catalyses the synthesis of acetoacetyl-CoA (either directly from two acetyl-CoA molecules or indirectly via a malonyl-CoA molecule and an acetyl-
CoA molecule, resp. an acetoacetyl-CoA thiolases and an acetoacetyl-CoA synthase) and/or that catalyses the synthesis of β-ketoacyl-CoA from acetyl-CoA and a higher acyl-CoA (3-ketoacyl-CoA thiolases) as defined in 4.1 and 4.5;
b) an enzyme having hydroxyacyl-CoA dehydrogenase activity, as defined in 4.2; c) an enzyme having enoyl-CoA hydratase or crotonase activity, as defined in
4.3; and
d) an enzyme that catalyses the reduction of a trans-A2-enoyl-CoA into an acyl-
CoA.
In the host, the at least one or all of the enzymes of fatty acid β-oxidation cycle are preferably expressed in the absence of fatty acids and in the presence of a non-fatty acid carbon source. Thus, the at least one or all enzymes do not require the presence of fatty acids in the growth medium for expression and, preferably, the expression of the at least one or all enzymes is insensitive to catabolite (glucose) repression, i.e. the
enzymes are expressed in the presence of source of glucose. Further, preferred, the at least one or all enzymes are expressed at least under anoxic (anaerobic) and optionally also under oxic (aerobic) conditions. Examples of suitable promoters for the expressing the at least one or all enzymes are given in 1.2 above herein.
Further preferred is that the enzymes of the fatty acid β-oxidation cycle are expressed in the cytosol of the eukaryotic host cell. In most eukaryotes the enzymes of the fatty acid β-oxidation cycle are present in peroxisomes and/or in mitochondria. In cells of the invention, however, the at least one or all of the enzymes of fatty acid β- oxidation cycle are preferably expressed in the cytosol of the host cell. Therefore, preferably, the β-oxidation enzymes are expressed in the cell without any targeting signal, e.g. for entry into peroxisomes or mitochondria such peroxisomal targeting signals (PTS-1 or -2) or mitochondrial targeting signals. Nucleotide sequences coding for β-oxidation enzymes originating from eukaryotes are therefore preferably modified so as to delete or inactivated the targeting signals on the enzyme. Alternatively prokaryotic β-oxidation enzymes can be used that do not have any (cryptic) targeting signals.
In one embodiment, expression of β-oxidation enzymes in the absence of inducing substrates is effected by de-regulation of transcription factors involved in β- oxidation (ADR1, OAF I, PIP2) thus causing overexpression of yeast's endogenous β- oxidation enzymes (POT1, FOX2, POX1), which preferably have been modified to delete or inactivate their peroxisomal targeting signals (PTS-1 or -2).
4.1 Thiolases
In one embodiment, the invention relates to enzymes that condense acetyl-CoA either with another acetyl-CoA or with a higher acyl-CoA into a β-ketoacyl-CoA. These thiolases are known as acetoacetyl-CoA thiolases (EC 2.3.1.9) or 3-ketoacyl- CoA thiolases (EC 2.3.1.16), respectively. Yeast own thiolase (POT1) has no isoenzymes, therefore the enzyme must be able to metabolize substrates of all chain- length (Mursula 2002). Therefore, the yeast own enzyme could be used or as an alternative a heterologous enzyme could be used in case the yeasts enzyme exhibits poor conversion rate towards β-ketoacyl-CoA (acetoacetyl-CoA in case of C4). For the synthesis of acetoacetyl-CoA endogenous cytosolic ERG10 could be used as thiolase (as acetoacetyl-CoA thiolase for short chain products). However, the yeast POT I
should be expressed without a functional N-terminal peroxisomal targeting sequence (PTS-2, peroxisome-targeting signal sequence) to enable cytosolic expression. Thus, preferably an N-terminally truncated or mutated POT1 is expressed, as e.g. described in Glover et al. (1994, J. Biol. Chem. 269: 7558-7563) (SEQ ID NO: 47 depicts the POT1 encoded S. cerevisiae thiolase lacking the N-terminal 16 amino acid PTS-2).
In mammalian cells ketoacyl-thiolases occur within the mitochondria and within the peroxisomes. They differ with respect to their substrate and stereospecifity. The mitochondria contain two short- and medium chain specific 3-ketoacyl-CoA thiolases. One is specific for acetoacetyl-CoA and 2-methylacetoacetyl-CoA and the other for substrates ranging from C6 to C16 (Eaton et al, 1996, Biochem. J. 320:345-357). In peroxisomes multiple enzyme iso forms exist (some inducible by peroxisome proliferators).
Suitable nucleotide sequences coding for homologous or heterologous thiolases are available from a number of sources, for example, Escherichia coli (GenBank No.'s: NP-416728, NC-000913); Clostridium acetobutylicum (GenBank Nos: NP-349476.1; NC-003030; NP-149242; NC-001988), Bacillus subtilis (GenBank Nos: NP-390297; NC-000964), and Saccharomyces cerevisiae (GenBank Nos: ERG10: NP-015297; POT1 : EEU05467.1), C. acetobutylicum sp. (e.g., protein ID AAC26026.1), C. pasteurianum (e.g., protein ID ABA18857.1), C. beijerinckii sp. (e.g., protein ID EAP59904.1 or EAP59331.1), Clostridium perfringens sp. (e.g., protein ID ABG86544.1, ABG83108.1), Clostridium difficile sp. (e.g., protein ID CAJ67900.1 or ZP-01231975.1), Thermoanaerobacterium thermosaccharolyticum (e.g., protein ID CAB07500.1), Thermoanaerobacter tengcongensis (e.g., AAM23825.1), Carboxydothermus hydrogenoformans (e.g., protein ID ABB13995.1), Desulfotomaculum reducens MI-1 (e.g., protein ID EAR45123.1), Candida tropicalis (e.g., protein ID BAA02716.1 or BAA02715.1), Saccharomyces cerevisiae (e.g., protein ID AAA62378.1 or CAA30788.1), Bacillus sp., Megasphaera elsdenii, and Butryivibrio fibrisolvens. In addition, the endogenous S. cerevisiae thiolases could also be active in a heterologously expressed pathway (ScERGlO, POT1) (see e.g. US20100062505). Further suitable thiolase coding sequences are listed in US2008182308.
A suitable gene coding for an enzyme with short chain specific thiolase activity for expression in a cell according to the invention is preferably derived from S.
cerevisiae (ERG 10), E. coli (atoB), Ralstonia eutrophus (PhaA) and orthologues thereof comprising a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with at least one of SEQ ID NO: 48, 49 and 50 respectively.
A suitable gene coding for an enzyme with broad chain-length specificity thiolase activity for expression in a cell according to the invention is preferably derive from S. cerevisiae (POT1) or E. coli (FadA) and comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 47 or 51, respectively.
Further preferred thiolases are encoded by the PhaA gene from Ralstonia eutrophus (Zhang et al. 2011, Curr. Op. Biotechnol, 22:775-783; Bond- Watts et al, 2011, Nat Chem Biol, 7:222-227) or the E. coli yqeF gene, which has an affinity for short chain substrates (Dellomonaco et al, 2011, supra). 4.2 Hydroxyacyl-CoA dehydrogenases
In one embodiment, the invention relates to enzymes that reduce a β-ketoacyl- CoA into a trans-P-hydroxyacyl-CoA. Yeast's own hydroxyacyl-CoA dehydrogenase (FOX2) is a multifunctional peroxisomal enzyme catalyzing the D-specific hydroxyacyl-CoA dehydrogenase and D-specific enoyl-CoA hydratase activity. FOX2 catalyzes the same D-specific reactions as the mammalian MFE-2.
The yeast FOX2 encoded hydroxyacyl-CoA dehydrogenase has no isoenzymes, therefore the enzyme must be able to metabolize substrates of a broad range of chain- lengths (Mursula, A., 2002, "A3-A2-Enoyl-CoA Isomerase from the yeast Saccharomyces cerevisiae. Molecular and structural characterization". Academic Dissertation, Faculty of Science, University of Oulu, FI,). Therefore, the yeast endogenous FOX2 encoded enzyme could be used or as an alternative a heterologous enzyme could be used in case the yeasts enzyme exhibits poor conversion rate towards trans-P-hydroxyacyl-CoA.
However, preferably the expression of the yeast FOX2 encoded enzyme is relocated from the peroxisome to the cytosol by expression of the enzyme without a functional peroxisome-targeting signal (PTS-1), i.e. the C-terminal tripeptide having the sequence SKL.. Thus, preferably an C-terminally truncated or mutated FOX-2 encoded enzyme, e.g. comprising an amino acid sequence as depicted in SEQ ID NO:
52 (the S. cerevisiae FOX2 lacking the C-terminal 3 amino acid PTS-1), or an orthologue thereof, is expressed in a cell of the invention.
Heterologous hydroxyacyl-CoA dehydrogenases (Hdb) may be reduced NADH- dependent, with a substrate preference for (S)-3-hydroxyacyl-CoA or (R)-3- hydroxyacyyl-CoA and are classified as E.C. 1.1.1.35 and E.C. 1.1.1.30, respectively. Alternatively, 3-hydroxyacyyl-CoA dehydrogenases may be reduced NADPH- dependent, with a substrate preference for (S)-3-hydroxyacyl-CoA or (R)-3- hydroxyacyyl-CoA and are classified as E.C. 1.1.1.157 and E.C. 1.1.1.36, respectively.
Suitable (nucleotide sequences coding for) heterologous 3-hydroxybutyryl-CoA dehydrogenase enzymes are available from a number of sources, for example, Clostridium acetobutylicum (GenBank NOs: NP-349314; NC-003030), B. subtilis (GenBank NOs: AAB09614; U29084), Ralstonia eutropha (GenBank NOs: YP- 294481; NC-007347), and Alcaligenes eutrophus (GenBank NOs: AAA21973; J04987). Suitable genes encoding 3-hydroxybutyryl-CoA dehydrogenases are also listed in US2008182308. Further suitable (nucleotide sequences coding for) are enzymes homologous to the Clostridium acetobutylicum genes include, but are not limited to: Clostridium kluyveri, which expresses two distinct forms of this enzyme (Miller et al, J. Bacteriol. 138:99-104, 1979), and Butyrivibrio fibrisolvens, which contains a bhbd gene which is organized within the same locus of the rest of its butyrate pathway (Asanuma et al, Current Microbiology 51 :91-94, 2005; Asanuma at al, Current Microbiology 47:203-207, 2003). A gene encoding a short chain acyl-CoA dehydrogenase (SCAD) was cloned from Megasphaera elsdenii and expressed in E. coli. In vitro activity could be determined (Becker et al., Biochemistry 32: 10736- 10742, 1993). Other homologues were identified in other Clostridium strains such as C. kluyveri (Hillmer et al, FEBS Lett. 21 :351-354, 1972; Madan et al, Eur. J. Biochem. 32:51-56, 1973), Clostridium tetani E88 (NP-782952.1), Clostridium perfringens SM101 (YP-699558.1), Clostridium perfringens str. 13 (NP-563213.1), Clostridium saccharobutylicum (AAA23208.1), Clostridium beijerinckii NCIMB 8052 (ZP- 00910128.1), Clostridium beijerinckii (AF494018-5), and in Thermoanaerobacter tengcongensis MB4 (NP-622220.1), Thermoanaerobacterium thermosaccharolyticum (CAB04792.1), Alkaliphilus metalliredigenes QYMF (ZP-00802337.1) and E. coli (see e.g. US20100062505).
Thus, a suitable gene for expression in a cell according to the invention and coding for an enzyme with 3-hydroxybutyryl-CoA dehydrogenase activity with higher specificity for short chain substrates preferably comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with at least one of SEQ ID NO: 53 (Hbd; C. acetobutylicum) and 54 (Hbd; C. beijerinckii).
Suitable gene for expression in a cell according to the invention and coding for an enzyme with 3-hydroxybutyryl-CoA dehydrogenase activity with a broader chain- length specificity preferably comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 55 (fadB; E. coli) or 52 (FOX2; S. cerevisiae).
4.3. Enoyl-CoA hydratases / crotonase
In one embodiment, the invention relates to enzymes that dehydrate a trans-β- hydroxyacyl-CoA into a trans-A2-enoyl-CoA.
As explained above in 4.2, yeast's own enoyl-CoA hydratase (FOX2) is a multifunctional enzyme that has both D-specific hydroxyacyl-CoA dehydrogenase and D-specific enoyl-CoA hydratase activities and it has a broad chain-length specificity. Similarly, also the E.coli FadB gene encodes a bifunctional enzyme having both dehydrogenase and hydratase activities as well as a broad chain-length specificity. Therefore, for the production of longer chain products, i.e. longer than 4, 6, 8 or 10 carbon atoms, preferably, a enoyl-CoA hydratase is expressed in the cell of the invention that is part of a multifunctional enzyme that also has hydroxyacyl-CoA dehydrogenase activity, such as described above in 4.2. Thus a preferred nucleotide sequence coding for a multifunctional enzyme having hydroxyacyl-CoA dehydrogenase and enoyl-CoA hydratase activities and having a broader chain-length specificity is a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 55 (FadB; E. coli) or 52 (FOX2; S. cerevisiae), whereby the latter is relocated to the cytosol by deleting or inactivating its peroxisomal targeting signal. For the production of shorter chain-length products, preferably a separate heterologous enoyl- CoA hydratase or crotonase is expressed in the cell of the invention together with a separate 3-hydroxybutyryl-CoA dehydrogenase with short chain substrate specificity
such as the Hbd enzymes from Clostridium having amino acid sequence identity with at least one of SEQ ID NO: 53 and 54, as defined above in 4.2.
Such heterologous enoyl-CoA hydratases may have a substrate preference for (S)-3-hydroxyacyl-CoA or (R)-3-hydroxyacyl-CoA and are classified as E.C. 4.2.1.17 and E.C. 4.2.1.55, respectively. Suitable (nucleotide sequences coding for) enoyl-CoA hydratases are available from a number of sources, for example, E. coli (GenBank NOs: NP-415911; NC-000913), C acetobutylicum (GenBank NOs: NP-349318; NC- 003030), B. subtilis (GenBank NOs: CAB13705; Z99113), and Aeromonas caviae (GenBank NOs: BAA21816; D88825). Further genes are listed in US2008182308. The crotonases or enoyl-CoA hydratases are enzymes that catalyze the reversible hydration of cis and trans enoyl-CoA substrates to the corresponding β-hydroxyacyl CoA derivatives. In C. acetobutylicum, this step of the butanoate metabolism is catalyzed by EC 4.2.1.55, encoded by the crt gene (GenBank protein accession AAA95967, Kanehisa, Novartis Found Symp. 247:91-101, 2002; discussion 01-3, 19-28, 244-52). Unlike the mammalian crotonases that have a broad substrate specificity, the bacterial enzyme hydrates only crotonyl-CoA and hexenoyl-CoA. The structures of many of the crotonase family of enzymes have been solved (Engel et al, J. Mol. Biol. 275:847-859, 1998). A ClustalW alignment of 20 closest orthologues of crotonase from bacteria shows that the sequence identity varies from 40-85%.
Therefore, a suitable gene coding for a separate heterologous enzyme with crotonase or enoyl-CoA hydratase activity preferably comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with at least one of SEQ ID NO: 56 (C. acetobutylicum crt) and 57 (C. beijerinckii crt). Such genes include, but are not limited to, Clostridium tetani E88 (NP-782956.1), Clostridium perfringens SM101 (YP- 699562.1), Clostridium perfringens str. 13 (NP-563217.1), Clostridium beijerinckii NCIMB 8052 (ZP-00909698.1 or ZP-00910124.1), Syntrophomonas wolfei subsp. wolfei str. Goettingen (YP-754604.1), Desulfotomaculum reducens MI-1 (ZP- 01147473.1 or ZP-01149651.1), Thermoanaerobacterium thermosaccharolyticum (CAB07495.1), and Carboxydothermus hydrogenoformans Z-2901 (YP-360429.1).
Studies in Clostridia demonstrate that the crt gene that codes for crotonase is encoded as part of the larger BCS operon. However, studies on B. fibriosolvens, a butyrate producing bacterium from the rumen, show a slightly different arrangement.
While Type I B. fibriosolvens have the thl, crt, hbd, bed, etfA and etfB genes clustered and arranged as part of an operon, Type II strains have a similar cluster but lack the crt gene (Asanuma et al, Curr. Microbiol. 51 :91-94, 2005; Asanuma et al, Curr. Microbiol. 47:203-207, 2003). Other suitable genes are homologous genes from Fusobacterium nucleatum subsp. Vincentii (Q7P3U9-Q7P3U9_FUSNV), Clostridium difficile (P45361-CRT CLODI), Clostridium pasteurianum (P81357-CRT CLOPA), and Brucella melitensis (Q8YDG2-Q8YDG2 BRUME) (see e.g. US20100062505).
4.4. Enzymes that reduce a trans-A2-enoyl-CoA into an acyl-CoA
In one embodiment, the invention relates to enzymes that reduce a trans-A2- enoyl-CoA into an acyl-CoA. These enzymes (either acyl-CoA dehydrogenases or transenoyl-CoA reductases) may be either NADH- or NADPH- or flavoprotein dependent and are classified as E.C. 1.3.1.44, E.C. 1.3.1.38 or EC 1.3.8.1, respectively. Thus, the terms "trans-2-enoyl-CoA reductase" or "TER" are understood herein to refer to enzymes that are capable of catalyzing the conversion of trans-2-enoyl-CoA to acyl- CoA.
Acyl-CoA dehydrogenases or transenoyl-CoA reductases are available from a number of sources, for example, C. acetobutylicum (GenBank NOs: NP-347102); NC- 003030), Euglena gracilis (GenBank NOs: -AAW66853), AY741582), Streptomyces collinus (GenBank NOs: AAA92890; U37135), and Streptomyces coelicolor (GenBank NOs: CAA22721; AL939127). Further suitable genes are listed in e.g. US2008182308.
Such transenoyl-CoA reductases include, but are not limited to, the enzymes from Clostridium tetani E88 (NP-782955.1 or NP-781376.1), Clostridium perfringens str. 13 (NP-563216.1), Clostridium beijerinckii (AF494018-2), Clostridium beijerinckii NCIMB 8052 (ZP-00910125.1 or ZP-00909697.1), and Thermoanaerobacterium thermosaccharolyticum (CAB07496.1), Thermoanaerobacter tengcongensis MB4 (NP- 622217.1). Suitable trans-2-enoyl-CoA reductase (TER) enzymes can also be identified by generally well known bio informatics methods, such as BLAST. Examples of TER proteins include, but are not limited to Euglena spp. including, but not limited to, E. gracilis, Aeromonas spp. including, but not limited, to A. hydrophila, Psychromonas spp. including, but not limited to, P. ingrahamii, Photobacterium spp. including, but not limited, to P. profundum, Vibrio spp. including, but not limited, to V. angustum, V. cholerae, V alginolyticus, V parahaemolyticus, V vulnificus, V fischeri, V splendidus,
Shewanella spp. including, but not limited to, S. amazonensis, S. woodyi, S. frigidimarina, S. paeleana, S. baltica, S. denitrificans, Oceanospirillum spp., Xanthomonas spp. including, but not limited to, X oryzae, X campestris, Chromohalobacter spp. including, but not limited, to C. salexigens, Idiomarina spp. including, but not limited, to /. baltica, Pseudoalteromonas spp. including, but not limited to, P. atlantica, Alteromonas spp., Saccharophagus spp. including, but not limited to, S. degradans, S. marine gamma proteobacterium, S. alpha proteobacterium, Pseudomonas spp. including, but not limited to, P. aeruginosa, P. putida, P. fluorescens, Burkholderia spp. including, but not limited to, B. phytofirmans, B. cenocepacia, B. cepacia, B. ambifaria, B. vietnamensis, B. multivorans, B. dolosa, Methylbacillus spp. including, but not limited to, M. flageliatus, Stenotrophomonas spp. including, but not limited to, S. maltophilia, Congregibacter spp. including, but not limited to, C. litoralis, Serratia spp. including, but not limited to, S. proteamaculans, Marinomonas spp., Xytella spp. including, but not limited to, X fastidiosa, Reinekea spp., Colweffia spp. including, but not limited to, C. psychrerythraea, Yersinia spp. including, but not limited to, Y. pestis, Y. pseudotuberculosis, Methylobacillus spp. including, but not limited to, M flagellatus, Cytophaga spp. including, but not limited to, C. hutchinsonii, Flavobacterium spp. including, but not limited to, F. johnsoniae, Microscilla spp. including, but not limited to, M marina, Polaribacter spp. including, but not limited to, P. irgensii, Clostridium spp. including, but not limited to, C. acetobutylicum, C. beijerinckii, C. cellulolyticum, Coxiella spp. including, but not limited to, C. burnetii. These and other suitable TER enzymes are e.g. described in US2007022497, Hoffmeister et al, J. Biol. Chem., 280:4329-4338, 2005 and US20100062505.
It is understood herein that with respect to redox-balance, preferably TER enzymes are chosen that use the same co-factor as the (heterologous) pyruvate dehydrogenase (see 3.1 above). Suitable NADH-dependent enzymes (EC 1.3.1.44) are e.g. the TER enzymes from Treponema denticola (NP_971211; SEQ ID NO: 58) and Euglena gracilis (AAW66853; SEQ ID NO: 59), of which the TER encode by the gene from T. denticola is most preferred (Zhang et al 201 1 supra, Hu et al, 2013 Biochem J. 449(l):79-89). A ferrodoxin-dependent acyl-CoA dehydrogenase (coupled with NADH oxidation) from Clostridium kluyveri was characterized by Li (Li et al 2008). Thus, a suitable gene coding for an enzyme with transenoyl-CoA reductase activity preferably
comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with at least one of SEQ ID NO: 58 ( T. denticola) and 59 (E. gracilis). 4.5 Acetoacetyl-CoA synthases
In one embodiment, instead of or in addition to using the direct condensation of acetyl-CoA by a thiolase (see 4.1. above), an alternative route is used for generation acetoacetyl-CoA through the ATP-driven malonyl-CoA synthesis as described by Lan and Liao (2012, Proc. Natl. Acad. Sci. 109:6018-6023). In this embodiment, along with the acetyl-CoA pool, ATP is used to drive the thermodynamically unfavorable condensation of two acetyl-coA molecules to acetoacetyl-CoA. Thus, in this embodiment, the host cell expresses enzymes that catalyze ATP-driven malonyl-CoA synthesis and decarboxylative carbon chain elongation to drive the carbon flux into the formation of acetoacetyl-CoA, which then further undergoes the reverse β-oxidation to synthesize butyryl-CoA and/or subsequent higher acyl-CoA's.
The host cell therefore expresses or overexpresses an acetyl-CoA carboxylase (Acc), which synthesizes malonyl-CoA from acetyl-CoA, HCO3 and ATP. A suitable acetyl-CoA carboxylase for expression in the cell of the invention is e.g. (overexpression of) the Saccharomyces cerevisiae ACC1 gene (DAA10557; SEQ ID NO 10) or the Homo sapiens ACC1 (Q13085; SEQ ID NO 60. Thus, a preferred gene coding for an enzyme with acetyl-CoA carboxylase activity for expression in a cell of the invention, preferably comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with at least one of SEQ ID NO's: 10 and 60. It is therefore understood that in this embodiment, preferably, the endogenous acetyl-CoA carboxylase in the host cell is not reduced or eliminated (see 2.5 above).
In this embodiment the host further expresses an enzyme with acetoacetyl-CoA synthase activity, which catalyses the decarboxylative condensation of acetyl-CoA and malonyl-CoA to form acetoacetyl-CoA. A suitable acetoacetyl-CoA synthase is e.g. the Streptomyces sp. CL190 nphT7 gene encoded acetyl-CoA:malonyl-CoA acyltransferase (AB540131 ; SEQ ID NO 61). Thus a preferred gene coding for an enzyme with acetoacetyl-CoA synthase activity for expression in a cell of the invention, preferably comprises a nucleotide sequence coding for an amino acid
sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 61.
The skilled person will understand that for the production of C4-products this alternative route through the ATP-driven malonyl-CoA synthesis can replace the short chain thiolases of 4.1 above. In fact, in order to prevent a futile cycle it is preferred in this embodiment that the cell does not express a (heterologous) short-chain specific thiolase in the cytosol and/or that the activity of the endogenous cytosolic S. cerevisiae ERG10 short-chain thiolase (or its orthologue in another species) is reduced or eliminated. However, for the production of products with a carbon chain-length longer than 4, preferably, in addition also a thiolase with broad chain-length specificity, more preferably a thiolase with long chain-length specificity (i.e. C6 and longer), is expressed in accordance with 4.1 above,.
5. Termination enzymes
In further embodiments, the invention relates to termination enzymes, which are expressed in the cells of the invention to branch products off from the reverse β- oxidation cycle for the production of specific products, such as fatty acids, 1 -alcohols, β-ketoacids, β-ketoalcohols, β-hydroxy acids, 1,3-diols, trans-A2-fatty acids, alkenes, alkanes and derivatives thereof, whereby the chain-length specificity of the termination enzyme can determine the chain-length of the final product. Preferred termination enzymes are enzymes for the production of 1 -alcohols, preferably 1 -alcohols other than methanol and ethanol, such as e.g. butanol, decanol, dodecanol and higher 1 -alcohols.
5.1 An acyl-CoA into an alcohol
In one embodiment, the invention relates to enzymes that catalyze the conversion of acyl-CoA to an alcohol. Preferably the enzyme catalyses the conversion into alcohols with (linear) chains longer than C2, preferably at least C4.
A preferred enzyme that catalyzes the conversion of acyl-CoA to an aldehyde is an enzyme that uses NADH or NADPH as co factor (EC 1.2.1.10 or EC 1.2.1.57). It is understood herein that in order to maintain a proper redox-balance either one of an NADH- or NADPH-dependent aldehyde dehydrogenases may be chosen in the host cell of the invention, depending on the co-factor dependencies of other enzymes expressed in the cell. A suitable aldehyde dehydrogenases is e.g. encoded by the E. coli
mhpF gene (GenBank No CAA70751; SEQ ID NO: 37 encoded by the codon optimized SEQ ID NO's: 38 or 74) and orthologues thereof as defined in 3.2. Further suitable aldehyde dehydrogenases may be derived from Clostridium beijerinckii (GenBank NOs: AAD31841), AF157306 and C acetobutylicum (GenBank NOs: NP- 149325), NC-001988). Further suitable genes are listed in US2008182308.
A preferred enzymes that catalyze the conversion of an aldehyde to a 1 -alcohol, uses either NADH or NADPH as cofactor. Again, it is understood herein that in order to maintain a proper redox-balance either one of an NADH- or NADPH-dependent alcohol dehydrogenases may be chosen in the host cell of the invention, depending on the co-factor dependencies of other enzymes expressed in the cell. Alcohol dehydrogenases are available from, for example, E. coli (fucO) (GenBank No YP_002927733; SEQ ID NO. 62), C acetobutylicum (GenBank NOs: NP-149325, NC- 001988; which enzyme possesses both aldehyde and alcohol dehydrogenase activity); NP-349891 , NC-003030; and NP-349892, NC-003030 and E. coli (GenBank NOs: NP- 417-484, NC-000913). Depending on the culture conditions, the AdhE2 of C. acetobutylicum may be less preferred because it is oxygen sensitive. Alternatively, at least one the endogenous yeast alcohol dehydrogenases ADH1 and/or ADH2 used, e.g. by overexpression of the gene. Further suitable genes encoding alcohol dehydrogenases are listed in US2008182308.
Thus, a suitable gene coding for an enzyme with NADH-dependent alcohol dehydrogenases activity preferably comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 62 (E. coli fucO) or 63 (C. acetobutylicum adhE2).
Further homologues to the C acetobutylicum aldehyde/alcohol dehydrogenase include without limitation Clostridium tetani E88 (NP-781989.1), Clostridium perfringens str. 13 (NP-563447.1), Clostridium perfringens ATCC 13124 (YP- 697219.1), Clostridium perfringens SM101 (YP-699787.1), Clostridium beijerinckii NCIMB 8052 (ZP-00910108.1), Clostridium acetobutylicum ATCC 824 (NP- 149199.1), Clostridium difficile 630 (CAJ69859.1), Clostridium difficile QCD-32g58 (ZP-01229976.1), and Clostridium thermocellum ATCC 27405 (ZP-00504828.1).
Two suitable n-butanol dehydrogenases from C. acetobutylicum (BDH I, BDH II) have been purified, and their genes (bdhA, bdhB) cloned. The GenBank accession for
BDH I is AAA23206.1. The GenBank accession for BDH II is AAA23207.1. BDH I utilizes NADPH as the cofactor, while BDH II utilizes NADH, which is more preferred. Even more preferred at least for the production of n-butanol is adhE2 gene of C acetobutylicum (GenBank accession #AF321779; SEQ ID NO: 63). Thus, a preferred gene coding for an enzyme for the production of n-butanol comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 63.
Such homologues include, but are not limited to, Clostridium perfringens SM101 (YP-699787.1), Clostridium perfringens str. 13 (NP-563447.1), Clostridium perfringens ATCC 13124 (YP-697219.1), Clostridium tetani E88 (NP-781989.1), Clostridium beijerinckii NCIMB 8052 (ZP-00910108.1), Clostridium difficile QCD- 32g58 (ZP-01229976.1), Clostridium difficile 630 (CAJ69859.1), Clostridium acetobutylicum ATCC 824 (NP- 149325.1), and Clostridium thermocellum ATCC 27405 (ZP-00504828.1) (see e.g. US20100062505).
Other useful termination enzymes for the production of e.g. butanol include
NADH-dependent or NADPH-dependent butanol dehydrogenases (E.C. 1.1.1.1), which convert butylaldehyde to 1 -butanol, or bifunctional NADH-dependent or NADPH- dependent aldehyde/alcohol dehydrogenases (E.C. 1.1.1.1./1.2.1.10), which converts butyryl-CoA to 1 -butanol via butyraldehyde (see e.g. US20100248233). Further genes coding for aldehyde- forming acyl-CoA reductases and aldehyde/alcohol dehydrogenases and that are useful as termination enzymes for the production of a wide variety of aldehydes and/or alcohols are listed in Table 7 of WO2012/109176.
For the biosynthesis of longer chain alcohols fatty acyl-CoA reductases (FAR) can be use as termination enzyme. Fatty acyl-CoA reductases (FAR) can be divided into two classes that differ with respect to the end-product synthesized, i.e. the aldehyde- and the alcohol- forming enzymes. Aldehyde-generating FAR catalyze a two- electron reduction of activated fatty acids, so that fatty aldehydes are formed. Such enzymes have been described in pea leaves, green algae and bacteria. The fatty aldehydes can be further reduced to fatty alcohols by fatty aldehyde reductases or can be involved in the biosynthesis of hydrocarbons. On the other hand, alcohol- forming FAR catalyze the reduction of activated fatty acids to fatty alcohols. This four-electron reduction takes place in two steps. In the first step an aldehyde is formed, that is subsequently reduced to a fatty alcohol in the second step. Proteins have been purified
and genes encoding alcohol- forming FAR were identified in plants, mammals, insects, birds and protozoa. They usually require NADPH as electron donor but in certain organisms like Euglena gracilis NADPH can be substituted by NADH.
The FAR in Euglena gracilis (EgFAR accession no. ADI60057; SEQ ID NO: 64) uses 14:0, 16:0 and 18:0 as substrates and requires NADH as cofactor. Functional analysis of EgFAR in yeast indicated that it could effectively convert 14:0 and 16:0 fatty acids to their corresponding alcohols. Compared with other biochemically characterized FARs, EgFAR possesses a narrower substrate range, only using saturated fatty acids with 14 and 16 carbon chains as substrates with the preferred fatty acid being 14:0 when expressed in yeast. (Teerawanichpan and Qiu, 2010, Lipids, 45(3):263-73). Thus, a preferred gene coding for a termination enzyme for the production of C14 and/or C16 alcohols comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 64.
Further suitable FAR genes for expression in the cells of the invention for the production of longer chains alcohols are described by Hellenbrand et al. (201 1 , BMC Biochem. 12:64) and include e.g. the bird fatty acyl-CoA reductases: AdFARl JN638548, AmFARl NP 001 180219.1 , AtCER4 NP 567936.5, AtFARl NP 197642.1 , AtFAR4 NP 190040.3, AtFAR5 NP 190041.2, AtFAR6 AEE79553.1 , AtFAR8 NP l 90042.2, AtMS2 AEE75132.1 , BmFAR NP 001036967.1 , EgFAR ADI60057.1 , FAR1 NP 001026350.1 , FAR2 XP 417235.2, HsFARl NP l 15604.1 , HsFAR2 NP 060569.3, MmFARl NP 080419.2, MmFAR2 NP 848912.1 , OnFARa ACY07547.1 , OnFARb ACY07546.1 , OsFARVIII ACJ06520.1 , ScFAR AAD38039.1 , TaFARl JN638549, TaFAR2 JN638550, TaTAAla CAD30693.1 , YeFARI ADD62438.1 , YeFARII ADD62439.1 , YeFARIII ADD62440.1 , YpFARII, ADD62442.1 and YrFARII ADD62441.1.
A further suitable termination enzyme for producing longer chain alcohols, i.e. C6, Cs, or Cio or longer, is an iron-dependent, NAD+-dependent (long chain) aldehyde/alcohol dehydrogenase such as e.g. encoded by the E.coli yiaY gene. Thus, a preferred gene coding for a termination enzyme for the production of longer chains alcohols comprises a nucleotide sequence coding for an amino acid sequence with at least 45, 50, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99% amino acid sequence identity with SEQ ID NO: 65.
6. Modified host cells of the invention
In a first aspect the invention thus pertains to a modified eukaryotic microbial host cell. The host cell preferably is modified to comprise: a) cytosolic expression of the enzymes of the fatty acid β-oxidation cycle, preferably, under anoxic conditions, in the absence of fatty acids and in the presence of a non-fatty acid carbon source; b) a metabolic route for producing under anoxic conditions and preferably in the cytosol, acetyl-CoA from the non- fatty acid carbon source to feed into and drive the β-oxidation cycle in the bio synthetic direction; and, c) expression of a termination enzyme to convert reaction intermediates of the β-oxidation cycle into at least one fermentation product selected from the group consisting of a fatty acid, a 1 -alcohol, a β-ketoacid, a β-ketoalcohol, a β-hydroxyacid, a 1,3-diol, a trans-A2-fatty acid, an alkene, an alkane and derivatives thereof, more preferably the fermentation product is a 1 -alcohol other than methanol and ethanol, such as e.g. butanol, decanol, dodecanol and higher 1- alcohols or a derivative thereof.
In a preferred modified cell according to the invention, the acetyl-CoA is produced in the cytosol from pyruvate by at least one of: the following routes A, B, C and D.
A) Conversion of pyruvate to acetyl-CoA by decarboxylation of pyruvate to acetaldehyde by expression of pyruvate decarboxylase activity, conversion of acetaldehyde to acetate by expression of acetaldehyde dehydrogenase activity, preferably, a heterologous NAD+-dependent aldehyde dehydrogenase, and conversion of acetate to acetyl-CoA by expression of acetyl-CoA synthetase activity, preferably the acetyl-CoA synthetase is an heterologous ADP-forming acetyl-CoA synthetase (EC 6.2.1.13), whereby the host comprises a genetic modification that reduces or eliminates endogenous cytosolic alcohol dehydrogenase activity. Preferably, in A) the cell expresses a heterologous NAD+-dependent aldehyde dehydrogenase comprising an amino acid sequence with at least 45% amino acid sequence identity to SEQ ID NO: 46, the cell expresses a heterologous ADP-forming acetyl-CoA synthetase comprising an amino acid sequence with at least 45% amino acid sequence identity to SEQ ID NO: 45, the cell, optionally, comprises a genetic modification that increases cytosolic pyruvate decarboxylase activity, and whereby the cell comprises a genetic modification
that reduces or eliminates expression of endogenous ADHI gene or an orthologue thereof.
B) Conversion of pyruvate to acetyl-CoA by decarboxylation of pyruvate to acetaldehyde by expression of pyruvate decarboxylase activity and by direct conversion of acetaldehyde to acetyl-CoA by expression of acetylating acetaldehyde dehydrogenase (E.C. 1.2.1.10) activity, whereby the host comprises a genetic modification that reduces or eliminates endogenous cytosolic acetaldehyde dehydrogenase activity and a genetic modification that reduces or eliminates endogenous cytosolic alcohol dehydrogenase activity. Preferably, in b) the cell expresses a heterologous acetylating NAD+-dependent acetaldehyde dehydrogenase comprising an amino acid sequence with at least 55% amino acid sequence identity to SEQ ID NO: 37, and whereby the cell comprises a genetic modification that reduces or eliminates expression of endogenous ADHI gene or an orthologue thereof and a genetic modification that reduces or eliminates expression of endogenous ALD6 gene or an orthologue thereof.
C) Direct conversion of pyruvate to acetyl-CoA and formate by expression of pyruvate formate lyase (EC 2.3.1.54) activity, whereby the host comprises a genetic modification that reduces or eliminates endogenous pyruvate decarboxylase activity and whereby the cell comprises formate dehydrogenase activity. Preferably, in C) the cell expresses a heterologous pyruvate formate lyase comprising an amino acid sequence with at least 50% amino acid sequence identity to SEQ ID NO: 39, the cell expresses a heterologous pyruvate formate lyase activating enzyme comprising an amino acid sequence with at least 45% amino acid sequence identity to SEQ ID NO: 41, and whereby the cell comprises a genetic modification that reduces or eliminates expression of at least the endogenous PDC1 and PDC5 genes or orthologues thereof, and the cell, optionally, comprises a genetic modification that increases formate dehydrogenase activity.
D) Direct conversion of pyruvate to acetyl-CoA by expression of pyruvate dehydrogenase (EC 1.2.4.1) activity, whereby the host comprises a genetic modification that reduces or eliminates endogenous pyruvate decarboxylase activity. Preferably, in d) the cell expresses a heterologous NAD+-dependent acetyl-transferring pyruvate dehydrogenase and whereby the cell comprises a genetic modification that
reduces or eliminates expression of at least the endogenous PDCl and PDC5 genes or orthologues thereof.
A modified cell according to the invention further preferably comprises one or more genetic modifications selected from the group consisting of: a) a genetic modification that reduces or eliminates fatty acid synthesis; b) a genetic modification that reduces or eliminates activity of the glyoxylate cycle; c) a genetic modification that reduces or eliminates activity of the tricarboxylic acid cycle; d) a genetic modification that reduces or eliminates transport of pyruvate into mitochondria; e) a genetic modification that reduces or eliminates transport of acetyl-CoA into mitochondria; f) a genetic modification that reduces or eliminates transport of glycerol; and g) a genetic modification that reduces or eliminates NADH-dependent glycerol synthesis. Preferably, a) the genetic modification is a modification that reduces or eliminates the expression of one or more of the S. cerevisiae FAS1, FAS2, ACC1, IN02, IN04 genes or orthologues thereof; b) the genetic modification is a modification that reduces or eliminates the expression of one or more of CIT2, ICL1, MLS1, MDH3, HAP2, HAP 3, HAP4 and HAP5 genes or orthologues thereof; c) the genetic modification is a modification that reduces or eliminates the expression of one or more of the S. cerevisiae PDA1, PDB1, LAT1, LPD1, and PDX1 genes or orthologues thereof; d) the genetic modification is a modification that reduces or eliminates the expression of one or more of the S. cerevisiae MPC1, YIA6 and YEA6 genes or orthologues thereof; e) the genetic modification is a modification that reduces or eliminates the expression of one or more of the S. cerevisiae YAT1, YAT2 and CRC1 genes or orthologues thereof; f) the genetic modification is a modification that reduces or eliminates the expression of the S. cerevisiae FPS1 gene or an orthologues thereof; and, g) the genetic modification is a modification that reduces or eliminates the expression of one or more of the S. cerevisiae GPD1, GPD2, HOR2 and RHR2 genes or orthologues thereof.
In the modified cells according to the invention, the enzymes of the fatty acid β- oxidation cycle are expressed preferably in the cytosol, and preferably from promoters that are insensitive to catabolite repression. In one preferred embodiment, the modified cell is a cell for producing fermentation products with a short chain-length, such as e.g. no more than C8, C6 or C4. In this embodiment the enzymes of the fatty acid β- oxidation cycle include: a) a thiolase with a short chain-length specificity, whereby, preferably, the thiolase comprises an amino acid sequence with at least 45% amino acid
sequence identity with at least one of SEQ ID NO's: 48, 49 and 50; b) an enzyme with 3-hydroxybutyryl-CoA dehydrogenase activity, whereby, preferably, the 3- hydroxybutyryl-CoA dehydrogenase comprises an amino acid sequence with at least 45% amino acid sequence identity with at least one of SEQ ID NO's: 53 and 54; c) a crotonase, whereby, preferably, the crotonase comprises an amino acid sequence with at least 45% amino acid sequence identity with at least one of SEQ ID NO's: 56 and 57; and, d) a NADH-dependent trans-2-enoyl-CoA reductase, whereby, preferably, the trans-2-enoyl-CoA reductase comprises an amino acid sequence with at least 45% amino acid sequence identity with at least 45% amino acid sequence identity with at least one of SEQ ID NO's: 58 an 59. In another preferred embodiment, the modified cell is a cell for producing fermentation products with a longer chain-length, such as e.g. at least C6, C8, or C10. In this embodiment the enzymes of the fatty acid β-oxidation cycle include: a) at least one of a peroxisomal thiolase that lacks a functional peroxisomal targeting signal and a heterologous thiolase with a broad chain-length specificity, whereby, preferably, the thiolase comprises an amino acid sequence with at least 45% amino acid sequence identity with at least one of SEQ ID NO's: 47 and 51 ; b) at least one of a peroxisomal enzyme with hydroxyacyl-CoA dehydrogenase and enoyl-CoA hydratase activities that lacks a functional peroxisomal targeting signal and a heterologous enzyme with hydroxyacyl-CoA dehydrogenase and enoyl-CoA hydratase activities with a broad chain-length specificity, whereby, preferably, the enzyme with hydroxyacyl-CoA dehydrogenase and enoyl-CoA hydratase activities comprises an amino acid sequence with at least 45% amino acid sequence identity with at least one of SEQ ID NO's: 52 and 55; and, c) a NADH-dependent trans-2-enoyl- CoA reductase, whereby, preferably, the trans-2-enoyl-CoA reductase comprises an amino acid sequence with at least 45% amino acid sequence identity with SEQ ID NO: 58.
A modified cell according to the invention can further comprise a) expression of an enzyme with acetyl-CoA carboxylase activity, whereby preferably the acetyl-CoA carboxylase comprises an amino acid sequence with at least 45% amino acid sequence identity with at least one of SEQ ID NO's: 10 and 60; and, b) expression of an enzyme with acetoacetyl-CoA synthase activity, which catalyses the decarboxylative condensation of acetyl-CoA and malonyl-CoA to form acetoacetyl-CoA, whereby preferably the acetoacetyl-CoA synthase comprises an amino acid sequence with at
least 45% amino acid sequence identity with SEQ ID NO: 61. The cell can comprise this alternative route for producing acetoacetyl-CoA, in addition to but preferably as an alternative for the thiolase with short chain-length specificity in the event that products are produced not having a longer chain-length than C4. In case products are to be produced with a longer chain-length than C4, the alternative route for producing acetoacetyl-CoA is expressed in addition to the peroxisomal thiolase or the heterologous thiolase with a broad chain-length specificity, which are then needed for further rounds of the reverse β-oxidation cycle.
A preferred modified cell of the invention is a cell for producing butanol, wherein the cell expresses termination enzymes that catalyze the conversion of butyryl- CoA via butaldehyde to butanol, whereby, preferably the enzymes are selected from: a) a NADH-dependent enzyme having both aldehyde and alcohol dehydrogenase, preferably comprising an amino acid sequence with at least 45% amino acid sequence identity with SEQ ID NO: 63; and, b) a NADH-dependent aldehyde dehydrogenase, preferably comprising an amino acid sequence with at least 55% amino acid sequence identity with SEQ ID NO: 37, expressed together with a NADH-dependent alcohol dehydrogenase preferably comprising an amino acid sequence with at least 45% amino acid sequence identity with SEQ ID NO: 62.
Another preferred modified cell of the invention is a cell for producing an alcohol with a chain-length greater than C6 and preferably including dodecanol, wherein the cell expresses termination enzymes having fatty acyl-CoA reductase activity, whereby, preferably the enzymes are selected from: a) a NADH-dependent alcohol forming fatty acyl-CoA reductase, preferably comprising an amino acid sequence with at least 45% amino acid sequence identity with SEQ ID NO: 64; and, b) an NADH-dependent alcohol dehydrogenase, preferably comprising an amino acid sequence with at least 45%) amino acid sequence identity with SEQ ID NO: 65.
In a particularly preferred embodiment of the modified cell of the invention, the cell further comprises a genetic modification that reduces or eliminates the production of the fermentation product (e.g. the 1 -alcohol) under oxic conditions. A cell wherein the production of the fermentation product is repressed under oxic conditions allows to separate a first propagation phase, wherein the modified cells are propagated under oxic conditions to efficiently produce biomass, from a second production phase, wherein the biomass of the modified cells obtained in the first propagation phase is fermented under
anoxic conditions to produce the fermentation product (e.g. the 1 -alcohol). The advantage of such separation is that during the first oxic propagation phase the carbon and energy can be efficiently directed towards the formation of biomass because product formation is repressed, while during the second anoxic production phase, the carbon and energy can be efficiently directed towards the formation of the fermentation product while the biomass formation is minimal due to the anoxic conditions. The oxic and anoxic conditions of respectively the first and second phases of the process are preferably as herein defined above.
Preferably in this embodiment, the genetic modification that reduces or eliminates the production of the fermentation product (e.g. the 1 -alcohol) under oxic conditions preferably is a modification whereby the expression of at least one enzymatic activity required for the metabolism of pyruvate (via acetyl-CoA) to the fermentation product is controlled by an anoxic promoter (also known as an anaerobic or hypoxic promoter). Anoxic promoters are herein understood as promoter from hypoxic genes, i.e. genes that are repressed under oxic conditions and that are upregulated during adaptation to anaerobic growth. Suitable anoxic promoters for use in this embodiment of the cell of the invention include e.g. the S. cerevisiae ANB1 promoter (SEQ ID NO: 73) or the promoters of the S. cerevisiae DAN and TIR genes, e.g. one or more of the DAN1, TIR1, TIR3, and TIR4 gene promoters (see e.g. Sertil et al, 2007, Mol Cell Biol. 27(6): 2037-2047). It is understood that likewise anoxic promoters from orthologues of these genes in other species may equally be applied in this embodiment. Oxic and anoxic conditions may also be defined as those conditions under which the anoxic promoters used in a given cell of the invention are respectively repressed and derepressed.
Further preferred in this embodiment, the enzymatic activity of which the expression is controlled by an anoxic promoter is selected from:
a) the activity of an enzyme required for the production of acetyl-CoA in the cytosol from pyruvate by at least one the routes A, B, C and D described above;
b) the activity of an enzyme required for the production of acetoacetyl-CoA from acetyl-CoA or from acetyl-CoA and malonyl-CoA as described above;
c) the activity of an enzyme of the fatty acid β-oxidation cycle as described above; and,
d) the activity of a termination enzyme as described above.
Preferred enzyme activities to be controlled by an anoxic promoter include e.g. enzyme activities that are upstream in the metabolism from pyruvate to the product, such as e.g. pyruvate decarboxylase activity (e.g. one or more of the S. cerevisiae PDC1, PDC5, PDC6 and PDC2 genes may be operably linked to an anoxic promoter), or enzyme activities that are a rate- limiting activities in the metabolism from pyruvate to the product, such as e.g. thiolase activity and/or acetoacetyl-CoA synthase activity.
The modified eukaryotic microbial host cell according to the invention preferably is a fungal cell, more preferably a yeast cell, and most preferably the cell is a cell of a yeast genus selected from the group consisting of Saccharomyces, Kluyveromyces, Candida, Pichia, Schizosaccharomyces, Hansenula, Kloeckera, Schwanniomyces, Yarrowia, Cryptococcus, Debaromyces, Saccharomycecopsis, Saccharomycodes, Wickerhamia, Debayomyces, Hanseniaspora, Ogataea, Kuraishia, Komagataella, Metschnikowia, Williopsis, Nakazawaea, Torulaspora, Bullera, Rhodotorula, and Sporobolomyces. It is further preferred that the cell is a cell of a yeast species selected from the group consisting of Saccharomyces cerevisiae, S. exiguus, S. bay anus, S. delbriickii, S. italicus, S. ellipsoideus, S. fermentati, S. kluyveri, S. krusei, S. lactis, S. marxianus, S. microellipsoides, S. montanus, S. norbensis, S. oleaceus, S. paradoxus, S. pastorianus, S. pretoriensis, S. rosei, S. rouxii, S. uvarum, S. ludwigii, Kluyveromyces lactis, K. marxianus, K. marxianus var. marxianus, K. thermotolerans, Candida utilis, C tropicalis, C albicans, C lipolytica, C versatilis, Pichia stipidis, P. pastoris and P. sorbitophila, Hansenula polymorpha and Schizosaccharomyces pombe.
A preferred modified cell of the invention has the ability to grow on a hexose, preferably glucose, at a rate of at least 0.01, 0.02, 0.05, 0.1 , 0.2, 0.25 or 0.3 h"1 under at least one of aerobic and anaerobic conditions.
7. Processes wherein the host cells of the invention are used for the production various compounds
In a second aspect, the invention relates to the use of a cell according to the invention for the preparation of at least one fermentation product that is or is derived from an intermediate in the β-oxidation cycle with a carbon chain-length of at least C4, whereby, preferably, the fermentation product is selected from the group consisting of a fatty acid, a 1 -alcohol, a β-ketoacid, a β-ketoalcohol, a β-hydroxyacid, a 1,3-diol, a trans-A2-fatty acid, a trans-Δ2- fatty acid, an alkene, an alkane and derivatives thereof,
more preferably the fermentation product is a 1 -alcohol other than methanol and ethanol, such as e.g. butanol, decanol, dodecanol and higher 1 -alcohols or a derivative thereof. The cell according to the invention is preferably used to produce the fermentation product in a anoxic process as defined herein below.
In a third aspect, the invention relates to processes for the production of these compounds by the host cells of the invention. Thus, in this aspect the invention relates to a process for producing at least one fermentation product that is or is derived from an intermediate in the β-oxidation cycle with a carbon chain-length of at least C4, or wherein, more preferably, the fermentation product is selected from the group consisting of a fatty acid, a 1 -alcohol, a β-ketoacid, a β-ketoalcohol, a β-hydroxyacid, a 1,3-diol, a trans-Δ2- fatty acid, a trans-Δ2- fatty acid, an alkene and derivatives thereof. Most preferably, the fermentation product is a 1 -alcohol other than methanol and ethanol, such as e.g. butanol, decanol, dodecanol and higher 1 -alcohols or a derivative thereof. The process preferably, comprises the step of: a) fermenting a medium with a cell according to the invention, preferably under anoxic conditions, whereby the medium contains or is fed with a non- fatty acid carbon source and whereby the yeast cell ferments the non-fatty acid carbon source to the fermentation product. The yeast cell preferably is a (host) cell as herein defined above. The process preferably comprises a further step wherein the fermentation product is recovered. The process may be a batch process, a fed-batch process or a continuous process as are well known in the art.
In the process of the invention, the non-fatty acid carbon source preferably at least comprises a source of hexoses or multimers of hexoses that are assimilable by the cell, e.g. a yeast cell. Such assimilable hexoses or multimers thereof include e.g. glucose, fructose, galactose, mannose, maltose, saccharose, lactose and maltodextrines. In a preferred process the source of hexose comprises or consists of at least glucose. Preferably, the medium fermented by the cells of the invention comprises or is fed with (fractions of) hydrolyzed biomass comprising at least one at least a hexose such as glucose.
The term "biomass" is understood to mean the biodegradable fraction of products, waste and residues from biological origin from agriculture (including vegetal, such as crop residues, and animal substances), forestry (such as wood resources) and related industries including fisheries and aquaculture, as well as biodegradable fraction
of industrial and municipal waste, such as municipal solid waste or wastepaper. In a preferred embodiment, the biomass is plant biomass, more preferably a fermentable hexose/glucose/sugar-rich biomass, such as e.g. sugarcane, a starch-containing biomass, for example, wheat grain, or corn straw. Even more preferably, plant biomass is cereal grains, such as corn, wheat, barley or mixtures thereof. Another example of hydro lyzed biomass to be fermented in the processes of the invention is e.g. hydrolyzed cereal biomass. Methods for hydrolysis of biomass such as cereal are known in the art per se and include e.g. vapor and enzymes such as glucoamylases. Another example of hydrolyzed biomass to be fermented in the processes of the invention is e.g. hydrolyzed sugarcane biomass. Methods for hydrolysis of biomass such as sugarcane are also known in the art per se and include e.g. vapor.
In the process of the invention, the sources of glucose may be glucose as such (i.e. as monomeric sugars) or it may be in the form of any carbohydrate oligo- or polymer comprising glucose units, such as e.g. sugar cane, starch and the like. For release of glucose units from such carbohydrates, appropriate carbohydrases (such as glucanases, amylases, and the like) may be added to the fermentation medium or may be produced by the modified host cell. In the latter case the modified host cell may be genetically engineered to produce and excrete such carbohydrases. An additional advantage of using oligo- or polymeric sources of glucose is that it enables to maintain a low(er) concentration of free glucose during the fermentation, e.g. by using rate- limiting amounts of the carbohydrases preferably during the fermentation. In addition to a source of glucose as carbon source, the fermentation medium will further comprise the appropriate ingredients required for growth of the modified host cell. Compositions of fermentation media for growth of eukaryotic microorganisms such as yeasts are well known in the art.
The fermentation process may be an oxic (aerobic) or an anoxic (anaerobic) fermentation process. Preferably however, the process of the invention is an anoxic (anaerobic) fermentation process. An anaerobic fermentation process is herein defined as a fermentation process run in the absence of oxygen or in which substantially no oxygen is consumed, preferably less than 5, 2.5 or 1 mmol/L/h, more preferably 0 mmol/L/h is consumed (i.e. oxygen consumption is not detectable), and wherein organic molecules serve as both electron donor and electron acceptors. In the absence of oxygen, NADH produced in glycolysis and bio mass formation, cannot be oxidized
by oxidative phosphorylation. To solve this problem many microorganisms use pyruvate or one of its derivatives as an electron and hydrogen acceptor thereby regenerating NAD+. Thus, in a preferred anaerobic fermentation process, reduced fermentation products such as ethanol, glycerol as well as other fermentation products, such as e.g. the 1 -alcohols described herein, have to be produced in order to maintain a balanced NAD+ from NADH redox situation. Anaerobic processes of the invention are preferred over aerobic processes because anaerobic processes do not require investments and energy for aeration and in addition, anaerobic processes produce higher product yields than aerobic processes. The fermentation process is preferably run at a temperature that is optimal for the modified cells of the invention. Thus, for most yeasts cells, the fermentation process is performed at a temperature which is less than 42°C, preferably less than 38°C. For yeast cells, the fermentation process is preferably performed at a temperature which is lower than 35, 33, 30 or 28°C and at a temperature which is higher than 20, 22, or 25°C.
In a preferred fermentation process according to the invention the volumetric productivity of the fermentation product preferably is at least 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 5.0 or 10.0 g fermentation product per liter per hour. The yield of the fermentation product on glucose in the process preferably is at least 50, 60, 70, 80, 90, 95 or 98%. The yield is herein defined as a percentage of the theoretical maximum yield on glucose, which is for the following products in gram product per gram glucose:
1-butanol: 0.41, dodecanol: 0.34,.
In a preferred embodiment the fermentation process according to the invention is a two-stage process comprising a first oxic propagation phase, wherein biomass of the cell of the invention is produced, and a second anoxic production phase, wherein the biomass obtained in the first oxic propagation phase is used to inoculate, or for fermentation in, the second anoxic production phase. Preferably in this embodiment a cell according to the invention is used comprising a genetic modification that reduces or eliminates the production of the 1 -alcohol under oxic conditions as described above. The first oxic propagation phase may be a conventional (oxic) process for the production of yeast biomass as is generally known in the art of yeast production. The (yeast) biomass obtained in the first oxic process may optionally be dried and/or stored prior to use in the second anoxic production process. The two phases, i.e. the oxic propagation phase and the anoxic production phase, may be performed at different
locations. Thus, yeast biomass produced at a first yeast production location may be transported, optionally after drying and/or storage of the yeast biomass, to a second production location to inoculate a medium for the second anoxic production of the fermentation product such as the 1 -alcohol.
In this document and in its claims, the verb "to comprise" and its conjugations is used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded. In addition, reference to an element by the indefinite article "a" or "an" does not exclude the possibility that more than one of the element is present, unless the context clearly requires that there be one and only one of the elements. The indefinite article "a" or "an" thus usually means "at least one".
All patent and literature references cited in the present specification are hereby incorporated by reference in their entirety.
The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.
Description of the figures
Figure 1. A general pathway overview of a engineered yeast cell (e.g. S. cerevisiae) according to the invention wherein glucose is metabolized via pyruvate to acetyl-CoA to feed into a reversed β-oxidation cycle that is expressed in the cytosol of the yeast cell.
Figure 2. Physical map of plasmid pUG6 (Guldener et al, 1996, Nucleic Acids Res., 24:2519-2524)
Figure 3 : Physical map of plasmid pSH47 (Guldener et al, 1996, Nucleic Acids Res., 24:2519-2524)
Figure 4: Schematic depiction of expression cassette for expression of aldpA and ACSSE used for genomic integration into the S. cerevisiae FPS1 locus.
Figure 5 : Schematic depiction of expression cassette for expression of E. coli mhpF, used for genomic integration into the S. cerevisiae ALD6 locus
Figure 6: Schematic depiction of expression cassette for expression of aldpA and ACSSE used for genomic integration into the S. cerevisiae HO locus. Figure 7: Physical map of plasmid pMA-C12-l as constructed in Example 6.
Figure 8: Physical map of plasmid pMA-C4-l as constructed in Example 7.
Figure 9: Physical map of plasmid pMA-T7-C4 as constructed in Example 8.
Figure 10: Fermentation of strain CenPK 2a4 (Aadhl Afpsl Aald6::mhpF URA3) transformed with plasmids pMA-C4-l and pMA-T6-C4 in a 5L Labfors fermenter. Concentrations of cell dry weight (g/L), butanol ^g/L), ethanol (mg/L), acetic acid (mg/L) and glycerol (mg/L) are indicated over time.
Examples
Enzyme activity assays
Cell extracts for activity assays are prepared from exponentially growing aerobic or anaerobic batch cultures and analyzed for protein content as described by Abbot et al, (2009, Appl. Environ. Microbiol. 75 : 2320-2325).
NAD+-dependent acetaldehyde dehydrogenase (EC 1.2.1.10) activity is measured at 30°C by monitoring the oxidation of NADH at 340 nm. The reaction mixture (total volume 1 ml) contains 50 mM potassium phosphate buffer (pH 7.5), 0.15 mM NADH and cell extract. The reaction is started by addition of 0.5 mM acetyl-Coenzyme A.
The activity of pyruvate formate-lyase is estimated spectrophotometrically by recording the change in absorption at 340 nm at 35°C. The assay mixture of pyruvate formate-lyase contains 20 mM sodium pyruvate, 0.08 mM coenzyme A, 1 mM NAD, 6 mM sodium DL-malate, 2 mM dithiothreitol, 1.1 U of citrate synthase (pig heart, EC 4.1.3.7) per ml, 22 U of malate dehydrogenase (pig heart, EC 1.1.1.37) per ml, and cell- free extract in 100 mM potassium phosphate buffer (pH 7.6) (Takahashi et al, 1982, J. Bacteriol. 149: 1034-1040).
Thiolase activity is measured by monitoring the disappearance of acetoacetyl- CoA, corresponding to the thiolysis direction of the enzymatic reaction. The disappearance of acetoacetyl-CoA is monitored by the decrease in absorbance at 303 nm, which is the characteristic absorption band of an enolatecomplex formed by acetoacetyl-CoA with Mg2+. The reaction mixture contains 100 mM Tris-HCl, pH 8.0, 10 mM MgS04, 200 μΜ acetoacetyl-CoA, 200 μΜ CoA, and cell extract prepared as described above. A standard curve is constructed by measuring the absorbance of acetoacetyl-CoA at different concentrations with 10 mM Mg2+ (Shen et al, 201 1, Appl Environ Microbiol, 77:2905-15).
The hydroxyacyl-CoA dehydrogenase activity is measured by monitoring the decrease of absorption at 340 nm, corresponding to consumption of NADH. The reaction mixture contains 100 mM 3-(N-morpholino) propanesulfonic acid (MOPS), pH 7.0, 200 _M NADH, 200 μΜ acetoacetyl-CoA, and crude cell extract. The reaction is initiated by the addition of the cell extract. (Shen et al., 2011, supra).
The enoyl-CoA hydratase activity is measured by the decrease of absorption at
263 nm, corresponding to disruption of the α-β unsaturation of crotonyl-CoA. The assay mixture contains 100 mM Tris-HCl pH 7.6, 100 μΜ crotonyl-CoA, and the crude extract. The reaction is initiated by the addition of the cell extract. The standard curves for crotonyl-CoA and 3-hydroxybutyryl-CoA are constructed by measuring the absorbance of the two compounds at 263 nm at different concentrations. (Shen et al, 2011, supra).
The trans enoyl-CoA reductase activity for crotonyl-CoA is measured at 340 nm. The reaction mixture contains 100 mM potassium phosphate buffer, pH 6.2, 200 μΜ NADH, 200 μΜ crotonyl-CoA, and crude extract. The reaction is initiated by the addition of the extract. To detect the activity for butyryl-CoA, the reaction mixture contains 1 mM NAD+, 0.4 mM butyryl-CoA, and crude extract in 100 mM Tris HC1, pH 7.5. The absorbance is monitored at 340 nm at 30°C. The reaction is initiated by the addition of the extract.
The aldehyde and alcohol dehydrogenase activities of AdhE2 are measured by monitoring the decrease of absorbance at 340 nm corresponding to the consumption of NADH or NADPH. The reaction mixture contains 100 mM Tris-HCl, pH 7.5, 5 mM dithiothreitol (DTT), 300 μΜ NADH, and 1 mM butyryl-CoA for the butyraldehyde dehydrogenase (BYDH) reaction and 50 mM butyraldehyde for the butanol
dehydrogenase (BDH) reaction. The reaction is initiated by the addition of the extract. (Shen et al, 2011, supra).
NADH assay: A fluorescent NAD/NADH detection kit purchased from Cell Technology (Mountain View, CA) is used. Cells are harvested by centrifugation at 13,200 rpm at 4°C. The pellets are then resuspended with 0.2 ml of the NAD/NADH extraction buffer and 0.2 ml of the lysis buffer (provided). Lysis is allowed to proceed for 10 to 20 min at 60°C until the cell resuspension turns clear. The lysate is then centrifuged at 8,000 rpm for 5 min at 4°C. The supernatant is retrieved for subsequent NADH assays. For the measurement of intracellular NADH levels, the cell lysates are mixed with the enzyme and the fluorescent detection reagent provided in the kit. The reaction is allowed to proceed for 1 to 1.5 h at room temperature in the dark, and then readings are taken with excitation at 530 to 570 nm and emission at 590 to 600 nm.
Strain construction
The construction of the strains featured in the following examples is based on strain CEN.PK2-1C (MATa; ura3-52; trpl-289; leu2-3,112; his3A 1; MAL2-8C; SUC2). For further details on this strain see:
http://web.uni-frankfurt.de/fbl5/mikro/euroscarf/data/cen.html) Table 4: Overview of plasmids used for the strain construction (the plasmids are featured in the following Examples)
Ec, Escherichia coli; Td, Treponema denticola; Sc, Saccharomyces cerevisiae Clostridium acetobutylicum; Eg, Euglena gracilis; Cb, Clostridium beijerinckii. Table 5: Overview of basis strains for the strain construction (the construction of the strains is described in Examples 1 to 5).
I Name I Genotype I
CenPK MATa; ura3-52; trpl-289; leu2-3,112; his3A 1; MAL2-8C; SUC2
CenPK 2al CenPK Aald6::mhpF URA3
CenPK 2a2 CenPK Aadhl ::kanMX Aald6::mhpF URA3
CenPK 2a3 CenPK Afpsl ::kanMX Aald6::mhpF URA3
CenPK 2a4 CenPK Aadhl ::loxP Afpsl ::kanMX Aald6::mhpF URA3
CenPK 2a5 CenPK Aho: :aldpA acsSE URA3
CenPK 2a6 CenPK Aadhl ::kanMX Aho::aldPA acsSE URA3
CenPK 2a7 CenPK Afpsl ::kanMX Aho::aldPA acsSE URA3
CenPK 2a8 CenPK Aadhl : :kanMX Afps 1 : :aldPA acsSE URA3
Example 1 : Deletion of gene ADHI
For the deletion of the ADHI gene a deletion cassette is amplified from plasmid pUG6 (Guldener et al, 1996, Nucleic Acids Research, 24:2519-2524; Figure 2) via PCR with the following oligonucleotides:
ADHlcrelox fw:
5-ATG TCT ATC CCA GAA ACT CAA AAA GGT GTT ATC TTC TAC GCC AGC TGA AGC TTC GTA CGC-3' (SEQ ID NO: 66)
ADHlcrelox rev:
5'- TTA TTT AGA AGT GTC AAC AAC GTA TCT ACC AAC GAT TTG
AGC ATA GGC CAC TAG TGG ATC TG-3' (SEQ ID NO: 67)
The resulting 1.4 kbp fragment containing the KanMX marker gene (which provides resistance to geniticin in yeast) flanked by loxP sites (for recovery of the marker gene) and sequences homologous to the native ADHI gene locus (homologous to the first and last 40 bp of the coding region of ADHI; for sequence see: http://www.yeastgenome.org/cgi- bin/getSeq?querv=YOL086C&seqtvpe=ORF%20Genomic%20DNA&format=fasta is used to transform strain S. cerevisiae CEN.PK2-1C. After transformation with this construct via the lithium acetate method described by Gietz et al. (1992, Nucleic Acids Res., 20(6): 1425) the strain is cultivated on YE agar plates containing 200 μg/ml of geniticin for the selection of resistant cells (transformants carrying the deletion cassette instead of the adhl coding region).
Example 2: Deletion of gene FPS1
For the deletion of the FPS1 gene a deletion cassette is amplified from plasmid pUG6 (Guldener et al, 1996, supra; Figure 2) via PCR with the following oligonucleotides:
FPSlcrelox fw:
5'-ATG AGT AAT CCT CAA AAA GCT CTA AAC GAC TTT CTG TCC AGC CAG CTG AAG CTT CGT ACG C-3' (SEQ ID NO: 68)
FPSlcrelox rev:
5 '-TCA TGT TAC CTT CTT AGC ATT ACC ATA ATG CGA ATC TTC TGC
ATA GGC CAC TAG TGG ATC TG-3' (SEQ ID NO: 69)
The resulting 1.4 kbp fragment containing the KanMX marker gene (which provides resistance to geniticin in yeast) flanked by loxP sites (for recovery of the marker gene) and sequences homologous to the native FPSl gene locus (homologous to the first and last 40 bp of the coding region of FPSl; for sequence see http://www.yeastgenome.org/cgi- bin/getSeq?querv=YLL043W&seqtvpe=ORF%20Genomic%20DNA&format=fasta is used to transform strain S. cerevisiae CEN.PK2-1C. After transformation with this construct via the lithium acetate method described by Gietz et al. (1992, supra) the strain is cultivated on YE agar plates containing 200 μg/ml of geniticin for the selection of resistant cells (transformants carrying the deletion cassette instead of the fpsl coding region).
The sequential deletion of gene adhl and fpsl in one strain is accomplished by recovering the kanMX marker in the strain resulting from example 1 (adhl deletion strain) via the cre-recombinase procedure described by Guldener et al., (1996, supra) and transforming the resulting yeast strain with the fpsl deletion cassette (see above). The cre-recombinase procedure requires the transformation of the yeast strain with the plasmid pSH47 (see Figure 3), which carries the gene for the cre-recombinase. This enzyme is able to recombine the two loxP sites flanking the kanMX resistance gene. This recombination event leads to a loss of this marker gene leaving one loxP site at the target locus (in the present example locus adhl). To enable the loss of plasmid pSH47 the yeast strain is cultivated for at least 10 generations in WMVIII (Lang and Looman, 1995 Appl Microbiol Biotechnol, 44(1-2): 147-56) containing uracil. Colonies, which have lost the plasmid pSH47 are identified via counter selection on plates with 5- fluoroorotic acid and picked for further construction purposes.
Example 3: Deletion of the gene FPSl and expression of the P. aeruginosa aldpA and S. enterica acssrjgenes
The P. aeruginosa aldpA gene (codon optimized for yeast: SEQ ID NO: 75) and the S. enterica acssE gene are synthesized (codon optimized for yeast: SEQ ID NO: 76) at GenScript USA Inc. (www.genscript.com) in one cluster (gene cassette). The two genes are clustered according to Figure 4 with the URA3 marker gene for selection in yeast (the URA 3 coding region including 400 bp upstream and 200 bp downstream, for sequence see http ://www. yeastgenome.org/cgi-
flanked by marker rescue sequences (MR; for recovery of the URA3 marker via counter selection on plates containing 5-FOA; SEQ ID NO: 70) and flanking regions, which are homologous to the native FPS1 locus (the first and last 40 bp of the FPS1 coding region, for sequence see: http://www.yeastgenome.org/cgi- bin/getSeq?querv=YLL043W&seqtvpe=ORF%20Genomic%20DNA&format=fasta for the genomic integration of the gene cassette into the FPS1 locus . For the expression of the aldpA gene the ENOl promoter and ENOl terminator are used (600 bp upstream and 300 bp downstream of the ENOl coding region, for sequences see: http :/ www.yeastgenomc.org/cgi- bin/getSeq?querv=YGR254W&flankl= 100()&flankr= 1000& format fasta). while for expression of the acssE gene the TDH3 promoter and TDH3 terminator are used (600 bp upstream and 300 bp downstream of the TDH3 coding region, for sequences see: http://www.yeastgenome.org/cgi- bra/getSeq?query=YGRl 92C&flankl= 1 QQQ&flankr= 1000&format=fasta .
Strain CEN.PK2-1C and the strain resulting from Example 1 (adhl deletion strain) are used for transformation with this gene cassette (Figure 4).
After transformation of the corresponding yeast strains with the gene cassette via the lithium acetate method described by Gietz et al. (1992, supra) the strains are cultivated on WMVIII (Lang and Looman, 1995, supra) agar plates lacking uracil for the selection of uracil prototrophic strains (transformants carrying the expression cassette instead of the fpsl coding region in the genome). Example 4: Deletion of the gene ALD6 and expression of the E. coli mhpF gene
The E. coli mhpF gene is synthesized (codon optimized for yeast: SEQ ID NO: 74) at GenScript USA Inc. (www . enscript.com) in one cluster (gene cassette). The two genes are clustered according to Figure 5 with the URA3 marker gene for selection
in yeast (the URA3 coding region including 400 bp upstream and 200 bp downstream, for sequence see: http://www.yeastgenome.org/cgi-
flanked by marker rescue sequences (MR; for recovery of the URA3 marker via counter selection on plates containing 5-FOA; SEQ ID NO: 70) and flanking regions which are homologous to the native ALD6 locus (the first and last 40 bp of the ALD6 coding region, for sequence see: http://www.yeastgenome.org/cgi- bin getSeq?querv=YPL061W&seqtvpe=QRF%20Genomic%20DNA&format=fasta for the genomic integration of the gene cassette into the ALD6 locus. For the expression of the mhpF gene the ENOl promoter and ENOl terminator are used (600 bp upstream and 300 bp downstream of the ENOl coding region, for sequences see: http://www.yeastgenome.org/cgi- bin/getSeq?query=YGR254W&flankl= 1000&flankr= 1 OOO&format fasta).
Strain CEN.PK2-1C and the strains resulting from Examples 1 and 2 (adhl and fpsl deletion strains) are used for transformation with this gene cassette (Figure 5).
After transformation of the corresponding yeast strains with the gene cassette via the lithium acetate method described by Gietz et al. (1992, supra) the strains are cultivated on WMVIII (Lang and Looman, 1995, supra) agar plates lacking uracil for the selection of uracil prototrophic strains (transformants carrying the expression cassette instead of the ALD6 coding region in the genome).
Example 5: Expression of the genes P. aeruginosa aldpA and S. enterica acssgjn the HO locus
The P. aeruginosa aldpA gene (codon optimized for yeast: SEQ ID NO: 75) and the S. enterica acssE gene are synthesized (codon optimized for yeast: SEQ ID NO: 76) at GenScript USA Inc. (www. enscript.com) in one cluster (gene cassette). The two genes are clustered according to Figure 6 with the URA3 marker gene for selection in yeast (the URA3 coding region including 400 bp upstream and 200 bp downstream, for sequence see: http://www.yeastgenome.org/cgi-
flanked by marker rescue sequences (MR; for recovery of the URA3 marker via counter selection on plates containing 5-FOA; SEQ ID NO: 70) and flanking regions which are homologous to the native HO locus (the first and last 40 bp of the HO coding region,
for sequence see: http://www.yeastgenome.org/cgi- bin/getSeq?qiiery=YDL227C&seqtype=ORF%20Genomic%20DNA&format=fasta) for the genomic integration of the gene cassette into the HO locus. For the expression of the aldpA gene the ENOl promoter and ENOl terminator are used (600 bp upstream and 300 bp downstream of the ENOl coding region, for sequences see: http://www.yeastgenome.org/cgi-
while for expression of the acssE gene the TDH3 promoter and TDH3 terminator are used (600 bp upstream and 300 bp downstream of the TDH3 coding region, for sequences see: http://www.yeastgenome.org/cgi- bm/getSeq?query=YGRl 92C&flankl= 1000&flankr= 10Q0&format=fasta .
Strain CEN.PK2-1C and the strains resulting from example 1 and 2 (adhl and fpsl deletion strains) are used for transformation with this gene cassette (Figure 6).
After transformation of the corresponding yeast strains with the gene cassette via the lithium acetate method described by Gietz et al. (1992, supra) the strains are cultivated on WMVIII (Lang and Looman, 1995, supra) agar plates lacking uracil for the selection of uracil prototrophic strains (transformants carrying the expression cassette instead of the HO coding region in the genome). Example 6: Expression of genes for the production of long chain compounds (e.g. C12) (with plasmid pMA-C12-l and pMA-C12-2
The Ci2 gene cassette 1 is synthesized by GenScript USA Inc. (www. enscript.com) and cloned into plasmid pMA via the Kpnl restriction site resulting in plasmid pMA-C12-l; see Figure 7). The pMA vector comprises an ampicillin resistance gene and an origin of replication for replication in E. coli (for sequence of pMA see: SEQ ID NO: 71). The cassette contains in one cluster a CEN/ARS sequence (SEQ ID NO: 72) for autonomous replication and segregation in yeast, the LEU2 expression cassette for selection of positive transformants (the LEU2 coding region including 400 bp upstream and 200 bp downstream, for sequence see: http ://www.yeastgenome.org/cgi- bin/getSeq?query=YCLO 18 W&flankl= 1 OOO&flankr 1 OOO&format fasta) and codon optimized variants (codon optimized for S. cerevisiae) of the genes FadA (E. coli), FadB (E. coli) and Ter ( T. denticola). For the expression of the FadA gene a modified
(constitutive) version of the ADH1 promoter (SEQ ID NO: 77) and the TRP1 terminator are used (300 bp downstream of the TRP1 coding region, for sequences see: http://www.yeastgenome.org/cgi- bin/getSeq?querv=YDR007W&flankl= 1000&flankr= 10Q0&format=fasta , while for expression of the FadB gene the ENOl promoter and ENOl terminator are used (600 bp upstream and 300 bp downstream of the ENOl coding region, for sequences see: http ://www.yeastgenome.org/cgi-
expression of the Ter gene the TDH3 promoter and the TDH3 terminator are used (600 bp upstream and 300 bp downstream of the TDH3 coding region, for sequences see: http://www.yeastgenome.org/cgi-
The strains resulting from Examples 3, 4 and 5 are used for transformation with plasmid pMA-C 12-1.
The corresponding yeast strains are transformed with pMA-C12-l via the lithium acetate method described by Gietz et al. (1992, supra) the strains are cultivated on WMVIII (Lang and Looman, 1995, supra) agar plates lacking leucine for the selection of leucine prototrophic strains (transformants carrying the plasmid pMA-C12-l).
Another variant of Example 6 is the construction and transformation of plasmid pMA-C12-2 in the corresponding yeast strains. This plasmid is analogous to plasmid pMA-C12-l except that POT1 (S. cerevisiae), FOX2 (S. cerevisiae) genes (both without PTS) are used instead of FadA (E. coli) and FadB (E. coli). The gene Ter (T. denticola) is used on both plasmids. Example 7: Expression of genes for the production of short chain compounds (e.g. C4) (with plasmids pMA-C4-l and pMA-C4-2)
The C4 gene cassette 1 is synthesized by GenScript USA Inc. (www.genscript.com) and cloned into plasmid pMA via the restriction site Kpnl resulting in plasmid pMA-C4-l; see Figure 8). The pMA vector comprises an ampicillin resistance gene and an origin of replication for replication in E. coli (for sequence of pMA please see SEQ ID NO: 71). The cassette contains in one cluster a CEN/ARS sequence (SEQ ID NO: 72) for autonomous replication and segregation in yeast, the LEU2 expression cassette for selection of positive transformants (the LEU2
coding region including 400 bp upstream and 200 bp downstream, for sequence see: http://www.yeastgenome.org/cgi-
and codon optimized variants (codon optimized for S. cerevisiae) of the genes ERG10 (S. cerevisiae), Hbd (C. acetobutylicum), crt (C. acetobutylicum) and Ter (T. denticola). For the expression of the ERG10 gene a modified (constitutive) version of the ADH1 promoter (SEQ ID NO: 77) and the TRPl terminator are used (300 bp downstream of the TRP l coding region, for sequences see: htt : 7www.yeastgenomc.org/cgi-
while for expression of the Hbd gene the ENOl promoter and ENOl terminator are used (600 bp upstream and 300 bp downstream of the ENOl coding region, for sequences see: http://www.yeastgenome.org/cgi-
For the expression of the crt gene the TDH3 promoter and the TDH3 terminator are used (600 bp upstream and 300 bp downstream of the TDH3 coding region, for sequences see: http://www.yeastgenome.org/cgi- bin/getSeq?query=YGRl 92C&flanH= 1000&f1ankr= 1000&format=fasta ).
For expression of the Ter gene the ENOl promoter and ENOl terminator are used (600 bp upstream and 300 bp downstream of the ENOl coding region, for sequences see http://www.yeastgenome.org/cgi- bin getSeq?querv=YGR254W&flankl= 1 QOQ&flankr= 1000&format=fasta .
The strains resulting from Examples 3, 4 and 5 are used for transformation with plasmid pMA-C4-l .
The corresponding yeast strains are transformed with pMA-C4-l via the lithium acetate method described by Gietz et al. (1992, supra) the strains are cultivated on WMVIII (Lang and Looman, 1995, supra) agar plates lacking leucine for the selection of leucine prototrophic strains (transformants carrying the plasmid pMA-C4-l).
Another variant of Example 7 concerns the construction and transformation of plasmid pMA-C4-2 in the corresponding yeast strains. This plasmid is analogous to plasmid pMA-C4-l except that atoB (E. coli), Hbd (C. beijerinckii), crt (C. beijerinckii)) and Ter (E. gracilis) genes are used instead of ERG10 (S. cerevisiae), Hbd (C. acetobutylicum), crt (C. acetobutylicum) and Ter ( T. denticola).
Example 8: Expression of termination enzymes
Expression of genes encoding for enzymes converting intermediates of the reversed β-oxidation cycle into desired final compounds (termination enzymes) is performed using plasmids pMA-T4-C12, pMA-T5-C12, pMA-T6-C4 and pMA-T7-C4 (see Table 4 for plasmids).
Plasmids pMA-T4-C12 and pMA-T5-C12 are used in combination with plasmids pMA-C12-l and pMA-C12-l (see Example 6) for the production of long chain compounds (in particular C12) and plasmids pMA-T6-C4 and pMA-T7-C4 were used in combination with plasmids pMA-C4-l and pMA-C4-l (see Example 7) for production of short chain compounds (in particular C4).
Constructs for the expression of the genes E. gracilis FAR or E. coli yiaY or C. acetobutylicum adhE2 or E. coli mhpF+FucO are synthesized by GenScript USA Inc. (www.genscript.com) and cloned into plasmid pMA via the Kpnl restriction site resulting in plasmids pMA-T4-C12, pMA-T5-C12, pMA-T6-C4 and pMA-T7-C4 (see Figure 9 for pMA-T7-C4). The pMA vector comprises an ampicillin resistance gene and an origin of replication for replication in E. coli (for sequence of pMA see SEQ ID NO: 71). The cassettes contain in one cluster a CEN/ARS sequence (SEQ ID NO: 72) for autonomous replication and segregation in yeast, the HIS3 expression cassette for selection of positive transformants after transformation (the HIS3 coding region including 500 bp upstream and 200 bp downstream, for sequence see: http://www.yeastgenome.org/cgi-
and codon optimized variants (codon optimized for S. cerevisiae) of the genes E. gracilis FAR or E. coli yiaY or C. acetobutylicum adhE2 or E. coli mhpF+FucO. For the expression of each of the gene the ENOl promoter and ENOl terminator are used (600 bp upstream and 300 bp downstream of the ENOl coding region, for sequences see: http://www.yeastgenome.org/cgi- bin/getSeq?querv=YGR254W&flanld= 1000&flankr= 1 OQQ&format=fasta . For the simultaneous expression of the E. coli mhpF and FucO gene the ENOl promoter and ENOl terminator are used for mhpF while for the FucO gene the TDH3 promoter and the TDH3 terminator are used (600 bp upstream and 300 bp downstream of the TDH3 coding region, for sequences see: htt :/ www.yeastgenornc.org/cgi- bin/getSeq?querv=YGRl 92C&flankl= 1000&flankr= 1000&format=fasta .
The strains resulting from Examples 6 and 7 are used for transformation with plasmids pMA-T4-C12, pMA-T5-C12, pMA-T6-C4 and pMA-T7-C4.
The strains were transformed via the lithium acetate method described by Gietz et al. (1992, supra) and were cultivated on WMVIII (Lang and Looman, 1995, supra) agar plates lacking histidine for the selection of histidine prototrophic strains (trans formants carrying plasmids pMA-T4-C12 or pMA-T5-C12 or pMA-T6-C4 or pMA-T7-C4).
Example 10: Cultivation procedure for strain evaluation (growth and productivity) The standard cultivation procedure for the strains of the yeast Saccharomyces cerevisiae was:
1) Preculture: 20 ml of WMVIII medium in a 100 ml shaking flask were inoculated with 20 μΐ of the corresponding glycerol stock (strain) and cultivated for 48 h at 30°C and 150 rpm on a rotary shaker..
2) Main culture: 50 ml of WMVIII medium in an Erlenmeyer shaking flask were inoculated with 1 % (v/v) of the preculture and cultivated for 72 h at 30°C and 150 rpm on a rotary shaker. For anaerobic fermentations the Erlenmeyer shaking flask were provided with a water lock to maintain anaerobiosis.
Strains with the genetic background of CEN.PK2-1C are auxotrophic for leucine, histidine, uracil and tryptophan. Therefore the medium was supplemented with leucine (400 mg/L), histidine (100 mg/L), uracil (100 mg/L) and tryptophan (100 mg/L) where necessary (to establish selection pressure on plasmids, plasmid containing strains were cultivated in medium lacking the corresponding supplement).
Composition of WMVIII medium (for 1L); according to Lang and Looman, 1995: 50 g sucrose, 250 mg NH4H2P04, 2,8 g NH4C1, 250 mg MgCl2 x 6H20, 100 mg CaCl2 x 2H20, 2 g KH2P04, 550 mg MgS04 x 7H20, 75 mg meso-Inositol and 10 g Na-glutamate.
Weigh out substances above and fill up with 1 L of distilled water. After autoclaving add filter sterilized (0,22 μιη) trace elements, vitamins and amino acids: 1 ml 1000 x trace elements, 4 ml 250 x vitamin solution of stock solutions.
Trace elements: lOOOx concentrated: 1,75 g ZnS04 x 7H20; 0,5 g Fe2S04 x 7 H20; 0,1 g CuS04 x 5 H20; 0,1 g MnCl2 x 4 H20; 0,1 g NaMo04 x 2 H20, (for one liter).
Vitamin solution: 25 Ox concentrated: 2,5 g Nicotinic acid; 6,25 g Pyridoxine; 2,5 g Thiamine; 0,625 g Biotine; 12,5 g Ca-Pantothenate, (for one liter).
Filter sterilize (0,22 μιη) trace elements and vitamin solution.
Supplementation with leucine (400 mg/L), histidine (100 mg/L), uracil (100 mg/L) and tryptophan (100 mg/L) is carried out, if necessary (note: amino acid are prepared in stock solutions with a concentration of 20 mg/ml and filter sterilized).
Example 11 : Metabolite analysis (identification and quantification of n-alcohols and fatty acids)
Identification of n-alcohols was conducted through gas chromatography- mass spectroscopy (GC-MS) following a modification of the method reported by Atsumi (2008). The analysis was performed on an AGILENT(TM) 6890 GC/5973 MS (AGILENT TECHNOLOGIES,(TM) Palo Alto, CA) instrument with a HP-5ms capillary column (30 m x 0.25 mm x 0.25 μιη). For the determination of intra- and extracellular metabolites 2 ml of culture broth (supernatant and cells) were mixed with 0.8 g of glass beads for cell disruption. After vortexing for 10 min and subsequent centrifugation at 14.000 x g for 10 min, 1ml of supernatant was extracted with 500 μΐ of GC standard grade hexane (Fluka). 0.5 μΐ of the extracted sample was injected using a 20: 1 split at 250° C. The oven temperature was initially held at 75° C for 2 min and then raised with a gradient of 5° C/min to 280° C and held for 2 min. Helium (MATHESON TRI-GAS,(TM) Longmont, CO) was used as the carrier gas with a 14- lb/in2 inlet pressure. The injector and detector were maintained at 255° C.
The quantification of ethanol and butanol was conducted by high-performance liquid chromatography (HPLC). Samples (culture broth after cell disruption with glass beads) were analyzed with ion-exclusion HPLC using a SHIMADZU(TM) Prominence SIL 20 system (SHIMADZU SCIENTIFIC INSTRUMENTS, INC.,(TM) Columbia, MD) equipped with an HPX-87H organic acid column (BIO-RAD,(TM) Hercules, CA) with operating conditions to optimize peak separation (0.3 mL/min flow rate, 30 mM H2S04 mobile phase, column temperature 42° C).
Quantification of longer chain (C > 4) n-alcohols was conducted through gas chromatography (GC) in a VARIAN(TM) CP-3800 gas chromatograph (VARIAN ASSOCIATES, INC.,(TM) Palo Alto, CA) equipped with a flame ionization detector (GC- FID). Sample extraction procedure was as described above in section Metabolite
Identification. The separation of alcohol compounds was carried out using a VF-5ht column (15 m, 0.32 mm internal diameter, 0.10 μιη film thickness; VARIAN ASSOCIATES, INC. (TM) Palo Alto, CA). The oven temperature was initially held at 40° C for 1 min and then raised with a gradient of 30° C/min to 130° C and held for 4 min. The temperature was then raised with a gradient of 15° C/min to 230° C and held for 4 min. Helium (1 ml min-1, MATHESON TRI-GAS,(TM) Longmont, CO) was used as the carrier gas. The injector and detector were maintained at 250° C. A 0.5-μ1 sample was injected in splitless injection mode.
Quantification of glycerol: Cell free supernatants of sampled cell suspensions of 1 ml are analyzed for extracellular glycerol by centrifugation at 3500 x g for 5 min and subsequent enzymatic determination of the glycerol content of the supernatant using commercial glycerol analysis kits (Free Glycerol Determination Kit, Sigma- Aldrich).
Determination of cell dry mass: cell dry weight is determined by harvesting 3 x 6 ml of culture after the desired cultivation time. The culture is centrifuged at 3500 x g for 5 min. Afterwards, the cells are washed once with H20 and the pellet is weighted by a scale after vacuum-drying for 12 h at 80 °C in a cabinet desiccator and cooling to room temperature in a dehydrator.
Example 12: Fermentations
Tables 6A, 6B and 6C present the results of shake flask fermentations (Tables
6A and 6B present the results of aerobic fermentations and Table 6C those of anaerobic fermentations) as obtained with the various background strains as indicated, and transformed with plasmids as indicated. In particular Table 6 presents for each of the transformed strains the yields of biomass (cell dry weight) and product of interest (as indicated), as well as the yields of the by-products ethanol and glycerol, after 24 hours of cultivation. The strains were cultivated under the conditions described in Example 10.
Example 13: Fermentation in Labfors fermenter
Strain CenPK 2a4 (Aadhl Afpsl Aald6::mhpF URA3) transformed with plasmids pMA-C4-l and pMA-T6-C4 was cultured in a 5L Labfors fermenter. The strain was precultured in 20 ml of WMVIII medium supplemented with 100 mg/L tryptophan in a
100 ml shaking flask were inoculated with 20 μΐ of the corresponding glycerol stock (strain) and cultivated for 48 h at 30°C and 150 rpm on a rotary shaker.
For the main culture 2L of WMVIII medium supplemented with 100 mg/L tryptophan in a 5L Labfors fermenter was inoculated with 40 mL (2 % v/v) of preculture and cultivated for 216 h. For agitation the stirrer speed was kept at 250 rpm and for aeration 0.1 wm were applied.
Metabolites were detected as described in Example 11. The results are presented in Figure 10. Example 14: Effects of deletions οΐΑΡΗ3 and ADH5 genes
The ADH3 gene, the ADH5 gene, and both the ADH3 and ADH5 genes were inactivated by deleted in strain CenPK 2a4 (Aadhl Afpsl Aald6::mhpF URA3). The deleted strains were then transformed with transformed with plasmids pMA-C4-l and pMA-T6-C4 and tested in oxic shake flask fermentation as described in Examples 12. Metabolites were detected as described in Example 11. The results are presented in Table 7.
Deletion of the ADH3 gene leads to an increased yield of product (butanol) and to a decrease in the formation of ethanol by-product as compared to the strain that has only the ADHI gene deletion. The additional deletion of the ADH4 gene or the ADH5 gene, in a strain that already has ADHI- and ^DHJ-deletions, results in a further increase in the yield of product (butanol). However, the ethanol by-products formation is not influenced by these additional deletions.
Table 7
Table 6A
a see Table 5 for genotypes of the strains b see Table 4 for details of the plasmids
Table 6B
a see Table 5 for genotypes of the strains b see Table 4 for details of the plasmids
Table 6C
a see Table 5 for genotypes of the strains b see Table 4 for details of the plasmids
Claims
1. A eukaryotic microbial host cell comprising:
a) cytosolic expression of the enzymes of the fatty acid β-oxidation cycle under anoxic conditions in the absence of fatty acids and in the presence of a non-fatty acid carbon source;
b) a metabolic route for producing under anoxic conditions, acetyl-CoA from the non-fatty acid carbon source to feed into and drive the β-oxidation cycle in the biosynthetic direction;
c) expression of a termination enzyme to convert reaction intermediates of the β- oxidation cycle into a 1 -alcohol or a derivative thereof and,
d) a genetic modification in the S. cerevisiae ADH1 and ADH3 genes or orthologues thereof, that reduces or eliminates specific alcohol dehydrogenase activity in the host cell.
2. A cell according to claim 1, wherein the acetyl-CoA is produced in the cytosol from pyruvate by at least one of:
a) conversion of pyruvate to acetyl-CoA by decarboxylation of pyruvate to acetaldehyde by expression of pyruvate decarboxylase activity, conversion of acetaldehyde to acetate by expression of acetaldehyde dehydrogenase activity, preferably, a heterologous NAD+-dependent aldehyde dehydrogenase, and conversion of acetate to acetyl-CoA by expression of acetyl-CoA synthetase activity, preferably the acetyl-CoA synthetase is an heterologous ADP-forming acetyl-CoA synthetase (EC 6.2.1.13);
b) conversion of pyruvate to acetyl-CoA by decarboxylation of pyruvate to acetaldehyde by expression of pyruvate decarboxylase activity and by direct conversion of acetaldehyde to acetyl-CoA by expression of acetylating acetaldehyde dehydrogenase (E.C. 1.2.1.10) activity, whereby the host comprises a genetic modification that reduces or eliminates endogenous cytosolic acetaldehyde dehydrogenase activity;
c) direct conversion of pyruvate to acetyl-CoA and formate by expression of pyruvate formate lyase (EC 2.3.1.54) activity, whereby the host comprises a genetic modification that reduces or eliminates endogenous pyruvate
decarboxylase activity and whereby the cell comprises formate dehydrogenase activity; or,
d) direct conversion of pyruvate to acetyl-CoA by expression of pyruvate dehydrogenase (EC 1.2.4.1) activity, whereby the host comprises a genetic modification that reduces or eliminates endogenous pyruvate decarboxylase activity.
A cell according to claim 2, wherein:
a) in a) the cell expresses a heterologous NAD+-dependent aldehyde dehydrogenase comprising an amino acid sequence with at least 45% amino acid sequence identity to SEQ ID NO: 46, the cell expresses a heterologous ADP- forming acetyl-CoA synthetase comprising an amino acid sequence with at least 45% amino acid sequence identity to SEQ ID NO: 45, and the cell, optionally, comprises a genetic modification that increases cytosolic pyruvate decarboxylase activity;
b) in b) the cell expresses a heterologous acetylating NAD+-dependent acetaldehyde dehydrogenase comprising an amino acid sequence with at least 55% amino acid sequence identity to SEQ ID NO: 37, and whereby the cell comprises a genetic modification that reduces or eliminates expression of endogenous ALD6 gene or an orthologue thereof;
c) in c) the cell expresses a heterologous pyruvate formate lyase comprising an amino acid sequence with at least 50% amino acid sequence identity to SEQ ID NO: 39, the cell expresses a heterologous pyruvate formate lyase activating enzyme comprising an amino acid sequence with at least 45% amino acid sequence identity to SEQ ID NO: 41, and whereby the cell comprises a genetic modification that reduces or eliminates expression of at least the endogenous PDCl and PDC5 genes or orthologues thereof, and the cell, optionally, comprises a genetic modification that increases formate dehydrogenase activity; or,
d) in d) the cell expresses a heterologous NAD+-dependent acetyl-transferring pyruvate dehydrogenase and whereby the cell comprises a genetic modification that reduces or eliminates expression of at least the endogenous PDCl and PDC5 genes or orthologues thereof.
A cell according to any one of claims 1 - 3, wherein the cell comprises one or genetic modifications selected from the group consisting of:
a) a genetic modification that reduces or eliminates fatty acid synthesis;
b) a genetic modification that reduces or eliminates activity of the glyoxylate cycle;
c) a genetic modification that reduces or eliminates activity of the tricarboxylic acid cycle;
d) a genetic modification that reduces or eliminates transport of pyruvate into mitochondria;
e) a genetic modification that reduces or eliminates transport of acetyl-CoA into mitochondria;
f) a genetic modification that reduces or eliminates transport of glycerol; and, g) a genetic modification that reduces or eliminates NADH-dependent glycerol synthesis.
A cell according to claim 4, wherein in:
a) the genetic modification is a modification that reduces or eliminates the expression of one or more of the S. cerevisiae FASl, FAS2, ACCl, IN02, IN04 genes or orthologues thereof;
b) the genetic modification is a modification that reduces or eliminates the expression of one or more of S. cerevisiae CIT2, ICLl, MLSl, MDH3, HAP2, HAP3, HAP4 and HAP5 genes or orthologues thereof;
c) the genetic modification is a modification that reduces or eliminates the expression of one or more of the S. cerevisiae PDAI, PDBI, LATI, LPDI, and PDX1 genes or orthologues thereof;
d) the genetic modification is a modification that reduces or eliminates the expression of one or more of the S. cerevisiae MPC1, YIA6 and YEA6 genes or orthologues thereof;
e) the genetic modification is a modification that reduces or eliminates the expression of one or more of the S. cerevisiae YAT1, YAT2 and CRC1 genes or orthologues thereof;
f) the genetic modification is a modification that reduces or eliminates the expression of the S. cerevisiae FPS1 gene or an orthologue thereof; and, g) the genetic modification is a modification that reduces or eliminates the expression of one or more of the S. cerevisiae GPD1, GPD2, HOR2 and RHR2 genes or orthologues thereof.
6. A cell according to any one of claims 1 - 5, wherein the enzymes of the fatty acid β-oxidation cycle are expressed from promoters that are insensitive to catabolite repression and wherein the enzymes of the fatty acid β-oxidation cycle include:
a) a thiolase with a short chain-length specificity, whereby, preferably, the thiolase comprises an amino acid sequence with at least 45% amino acid sequence identity with at least one of SEQ ID NO's: 48, 49 and 50;
b) an enzyme with 3-hydroxybutyryl-CoA dehydrogenase activity, whereby, preferably, the 3-hydroxybutyryl-CoA dehydrogenase comprises an amino acid sequence with at least 45% amino acid sequence identity with at least one of SEQ
ID NO's: 53 and 54;
c) a crotonase, whereby, preferably, the crotonase comprises an amino acid sequence with at least 45% amino acid sequence identity with at least one of SEQ ID NO's: 56 and 57; and,
d) a NADH-dependent trans-2-enoyl-CoA reductase, whereby, preferably, the trans-2-enoyl-CoA reductase comprises an amino acid sequence with at least 45% amino acid sequence identity with at least one of SEQ ID NO's: 58 and 59.
7. A cell according to any one of claims 1 - 5, wherein the enzymes of the fatty acid β-oxidation cycle are expressed from promoters that are insensitive to catabolite repression and wherein the enzymes of the fatty acid β-oxidation cycle include:
a) at least one of a peroxisomal thiolase that lacks a functional peroxisomal targeting signal and a heterologous thiolase with a broad chain-length specificity, whereby, preferably, the thiolase comprises an amino acid sequence with at least 45%) amino acid sequence identity with at least one of SEQ ID NO's: 47 and 51 ; b) at least one of a peroxisomal enzyme with hydroxyacyl-CoA dehydrogenase and enoyl-CoA hydratase activities that lacks a functional peroxisomal targeting signal and a heterologous enzyme with hydroxyacyl-CoA dehydrogenase and
enoyl-CoA hydratase activities with a broad chain-length specificity, whereby, preferably, the enzyme with hydroxyacyl-CoA dehydrogenase and enoyl-CoA hydratase activities comprises an amino acid sequence with at least 45% amino acid sequence identity with at least one of SEQ ID NO's: 52 and 55; and, c) a NADH-dependent trans-2-enoyl-CoA reductase, whereby, preferably, the trans-2-enoyl-CoA reductase comprises an amino acid sequence with at least 45% amino acid sequence identity with SEQ ID NO: 58.
8. A cell according to claim 6 or 7, wherein the cell comprises, as an alternative for the thiolase with a short chain-length specificity, or in addition to the peroxisomal thiolase or the heterologous thiolase with a broad chain-length specificity:
a) expression of an enzyme with acetyl-CoA carboxylase activity, whereby preferably the acetyl-CoA carboxylase comprises an amino acid sequence with at least 45% amino acid sequence identity with at least one of SEQ ID NO's: 10 and 60; and,
b) expression of an enzyme with acetoacetyl-CoA synthase activity, which catalyses the decarboxylative condensation of acetyl-CoA and malonyl-CoA to form acetoacetyl-CoA, whereby preferably the acetoacetyl-CoA synthase comprises an amino acid sequence with at least 45% amino acid sequence identity with SEQ ID NO: 61.
9. A cell according to claim 6 or 8, wherein the cell is a cell for producing butanol, wherein the cell expresses termination enzymes that catalyze the conversion of butyryl- CoA via butaldehyde to butanol, whereby, preferably the enzymes are selected from: a) a NADH-dependent enzyme having both aldehyde and alcohol dehydrogenase, preferably comprising an amino acid sequence with at least 45% amino acid sequence identity with SEQ ID NO: 63; and,
b) a NADH-dependent aldehyde dehydrogenase, preferably comprising an amino acid sequence with at least 55% amino acid sequence identity with SEQ ID NO: 37, expressed together with a NADH-dependent alcohol dehydrogenase preferably comprising an amino acid sequence with at least 45% amino acid sequence identity with SEQ ID NO: 62.
10. A cell according to claim 7 or 8 wherein the cell is a cell for producing an alcohol with a chain-length greater than C6 and preferably including dodecanol, wherein the cell expresses termination enzymes having fatty acyl-CoA reductase activity, whereby, preferably the enzymes are selected from:
a) a NADH-dependent alcohol forming fatty acyl-CoA reductase, preferably comprising an amino acid sequence with at least 45% amino acid sequence identity with SEQ ID NO: 64; and,
b) an NADH-dependent alcohol dehydrogenase, preferably comprising an amino acid sequence with at least 45% amino acid sequence identity with SEQ ID NO: 65.
11. A cell according to any one of claims 1 - 10, wherein the cell comprises a genetic modification that reduces or eliminates the production of the 1 -alcohol under oxic conditions, and whereby, preferably, the genetic modification comprises that at least one enzymatic activity in the metabolic route from pyruvate to the 1 -alcohol is controlled by an anoxic promoter, more preferably the activity of at least one of pyruvate decarboxylase, thiolase and acetoacetyl-CoA synthase controlled by an anoxic promoter.
12. A cell according to any one of claims 1 - 11, wherein the cell is a fungal cell, preferably a yeast cell, more preferably the cell is a cell of a yeast genus selected from the group consisting of Saccharomyces, Kluyveromyces, Candida, Pichia, Schizosaccharomyces, Hansenula, Kloeckera, Schwanniomyces, Yarrowia, Cryptococcus, Debaromyces, Saccharomycecopsis, Saccharomycodes, Wickerhamia, Debayomyces, Hanseniaspora, Ogataea, Kuraishia, Komagataella, Metschnikowia, Williopsis, Nakazawaea, Torulaspora, Bullera, Rhodotorula, and Sporobolomyces, and preferably the cell is a cell of a yeast species selected from the group consisting of Saccharomyces cerevisiae, S. exiguus, S. bayanus, S. delbriickii, S. italicus, S. ellipsoideus, S. fermentati, S. kluyveri, S. krusei, S. lactis, S. marxianus, S. microellipsoides, S. montanus, S. norbensis, S. oleaceus, S. paradoxus, S. pastorianus, S. pretoriensis, S. rosei, S. rouxii, S. uvarum, S. ludwigii, Kluyveromyces lactis, K. marxianus, K. marxianus var. marxianus, K. thermotolerans, Candida utilis, C
tropicalis, C. albicans, C. lipolytica, C. versatilis, Pichia stipidis, P. pastoris and P. sorbitophila, Hansenula polymorpha and Schizosaccharomyces pombe.
13. Use of a cell according to any one of claims 1 - 12, for the production of a 1- alcohol or a derivative thereof.
14. A process for producing a 1-alcohol or a derivative thereof, whereby the process comprises the steps of:
a) fermenting a medium with a cell as defined in any one of claims 1 - 12 under anoxic conditions, whereby the medium contains or is fed with a non-fatty acid carbon source and whereby the yeast cell ferments the non-fatty acid carbon source to the 1-alcohol or derivative thereof; and optionally,
b) recovery of the 1-alcohol or derivative thereof,
wherein preferably the non- fatty acid carbon source comprises at least one of hexoses and multimers of hexoses that are assimilable by the cell, preferably the non-fatty acid carbon source comprises one or more of glucose, fructose, maltose, galactose, mannose, saccharose, lactose and maltodextrines.
15. A process according to claim 14, wherein prior to step a) a cell according to claim 11 is cultured under oxic conditions to produce biomass, whereby the biomass obtained under oxic conditions is used to inoculate the medium in step a), and whereby, optionally, prior to inoculation of the medium in step a) the biomass is at least one of dried, stored and transported to another location.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13382243.7 | 2013-06-26 | ||
EP13382243 | 2013-06-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014207105A1 true WO2014207105A1 (en) | 2014-12-31 |
Family
ID=48703383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2014/063517 WO2014207105A1 (en) | 2013-06-26 | 2014-06-26 | Yeast engineered for the production of 1-alcohols from sugars under anoxic conditions |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014207105A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016188813A1 (en) * | 2015-05-22 | 2016-12-01 | Dsm Ip Assets B.V. | Acetate consuming yeast cell |
CN110678545A (en) * | 2017-04-17 | 2020-01-10 | 丹尼斯科美国公司 | Selected acetyl-CoA synthases for reducing acetate production in yeast |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008080124A2 (en) * | 2006-12-21 | 2008-07-03 | Gevo, Inc. | Butanol production by metabolically engineered yeast |
WO2011156794A2 (en) * | 2010-06-11 | 2011-12-15 | The Regents Of The University Of California | Synthetic pathways for biofuel synthesis |
WO2013076144A2 (en) * | 2011-11-21 | 2013-05-30 | Metabolic Explorer | Microorganism strains for the production of 2,3-butanediol |
-
2014
- 2014-06-26 WO PCT/EP2014/063517 patent/WO2014207105A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008080124A2 (en) * | 2006-12-21 | 2008-07-03 | Gevo, Inc. | Butanol production by metabolically engineered yeast |
WO2011156794A2 (en) * | 2010-06-11 | 2011-12-15 | The Regents Of The University Of California | Synthetic pathways for biofuel synthesis |
WO2013076144A2 (en) * | 2011-11-21 | 2013-05-30 | Metabolic Explorer | Microorganism strains for the production of 2,3-butanediol |
Non-Patent Citations (2)
Title |
---|
ANASTASIA KRIVORUCHKO ET AL: "Improving biobutanol production in engineered Saccharomyces cerevisiae by manipulation of acetyl-CoA metabolism", JOURNAL OF INDUSTRIAL MICROBIOLOGY & BIOTECHNOLOGY, vol. 40, no. 9, 13 June 2013 (2013-06-13), pages 1051 - 1056, XP055087006, ISSN: 1367-5435, DOI: 10.1007/s10295-013-1296-0 * |
STEEN ERIC J ET AL: "Metabolic engineering of Saccharomyces cerevisiae for the production of n-butanol", MICROBIAL CELL FACTORIES, BIOMED CENTRAL, LONDON, NL, vol. 7, no. 1, 3 December 2008 (2008-12-03), pages 36, XP021049875, ISSN: 1475-2859, DOI: 10.1186/1475-2859-7-36 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016188813A1 (en) * | 2015-05-22 | 2016-12-01 | Dsm Ip Assets B.V. | Acetate consuming yeast cell |
EP3604506A1 (en) * | 2015-05-22 | 2020-02-05 | DSM IP Assets B.V. | Acetate consuming yeast cell |
US11319543B2 (en) | 2015-05-22 | 2022-05-03 | Dsm Ip Assets B.V. | Acetate consuming yeast cell |
US12012604B2 (en) | 2015-05-22 | 2024-06-18 | Danisco Us Inc. | Acetate consuming yeast cell |
CN110678545A (en) * | 2017-04-17 | 2020-01-10 | 丹尼斯科美国公司 | Selected acetyl-CoA synthases for reducing acetate production in yeast |
CN110678545B (en) * | 2017-04-17 | 2023-10-10 | 丹尼斯科美国公司 | Selected acetyl-CoA synthases for reducing acetate production in yeast |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20180179557A1 (en) | Yeast organism producing isobutanol at a high yield | |
EP2121949B1 (en) | Butanol production by metabolically engineered yeast | |
US8097440B1 (en) | Engineered microorganisms capable of producing target compounds under anaerobic conditions | |
US8232089B2 (en) | Cytosolic isobutanol pathway localization for the production of isobutanol | |
CA2710359C (en) | Yeast organism producing isobutanol at a high yield | |
US20120045809A1 (en) | Engineered Microorganisms for the Production of One or More Target Compounds | |
EP2446043A1 (en) | Yeast organisms for the production of isobutanol | |
WO2014207113A1 (en) | Yeasts engineered for the production of valuable chemicals from sugars | |
US20120190089A1 (en) | Engineered microogranisms capable of producing target compounds under anaerobic conditions | |
US20140080188A1 (en) | Yeast microorganisms with reduced 2,3-butanediol accumulation for improved production of fuels, chemicals, and amino acids | |
AU2013305714A1 (en) | Production of fermentation products | |
WO2014207087A1 (en) | Production of advanced fuels and of chemicals by yeasts on the basis of second generation feedstocks | |
WO2014207099A1 (en) | Anoxic biological production of fuels and of bulk chemicals from second generation feedstocks | |
WO2014207105A1 (en) | Yeast engineered for the production of 1-alcohols from sugars under anoxic conditions | |
US20140295512A1 (en) | Ketol-Acid Reductoisomerases With Improved Performance Properties | |
EP3274449B1 (en) | Modified 6-phosphofructo-1 -kinases, which enable frementative growth of recombinant yeast saccharomyces cerevisiae cells on pentose sugars | |
WO2014200994A1 (en) | Oxygen-tolerant coa-acetylating aldehyde dehydrogenase containing pathway for biofuel production | |
WO2013033097A1 (en) | Alteration of the nadh/nad+ ratio to increase flux through nadh-dependent pathways |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14744473 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14744473 Country of ref document: EP Kind code of ref document: A1 |